question,document,type,order,text,pmid
1061,0,1_title,0,Hirschsprung associated GDNF mutations do not prevent RET activation.  ,11973622
1061,0,2_abstract_sentence,0,Hirschsprung disease (HSCR) is a complex disorder characterised by aganglia of distal gastrointestinal tracts. ,11973622
1061,0,2_abstract_sentence,1,The highest proportion of both familial and sporadic cases is due to mutations of the RET proto-oncogene. ,11973622
1061,0,2_abstract_sentence,2,"Five germline mutations in the glial cell-line-derived neurotrophic factor (GDNF) gene, one of  the RET ligands, have been detected in HSCR patients. ",11973622
1061,0,2_abstract_sentence,3,Pedigrees analysis and the  observed association between these GDNF alterations and RET variants in the same  patients raised the question of whether the GDNF gene plays any causative/predisposing role in HSCR pathogenesis. ,11973622
1061,0,2_abstract_sentence,4,"In the present work, we have studied the ability of GDNF proteins, each bearing one of the reported mutations, to activate RET by performing a functional test in cultured neuroblastoma cells. ",11973622
1061,0,2_abstract_sentence,5," Consistently with the lack of genotype/phenotype correlation in human subjects, our results indicate absence of detectable alterations of mutant GDNF induced RET activation. ",11973622
1061,1,1_title,0,Grb2 binding to the different isoforms of Ret tyrosine kinase.  ,9764818
1061,1,2_abstract_sentence,0,The RET proto-oncogene encodes two isoforms of a receptor tyrosine kinase which plays a role in neural crest and kidney development. ,9764818
1061,1,2_abstract_sentence,1,Ret ligands have been recently identified as the neuron survival factor GDNF (Glial-Derived Neurotrophic Factor) and Neurturin. ,9764818
1061,1,2_abstract_sentence,2,"Somatic rearrangements of RET, designated RET/PTCs, have been frequently detected in papillary thyroid carcinomas. ",9764818
1061,1,2_abstract_sentence,3,"In addition, distinct germ-line mutations of RET gene have been associated with the  inherited cancer syndromes MEN (Multiple Endocrine Neoplasia) 2A, 2B and FMTC (Familial Medullar Thyroid Carcinomas) as well as with the congenital megacolon or Hirschsprung's disease, thus enlightening a significant role of this receptor  gene in diverse human pathologic conditions. ",9764818
1061,1,2_abstract_sentence,4,"In this study, by performing classical inhibition experiments using synthetic phosphopeptides and by site-directed mutagenesis of the putative docking site, we have determined that for Grb2 the latter is provided by the tyrosine 620 of Ret/ptc2 long isoform (corresponding to Tyr 1096 on proto-Ret). ",9764818
1061,1,2_abstract_sentence,5,"However, in intact cells, the interaction of Grb2 with the two short and long Ret isoforms expressed separately is of similar strength, thus suggesting that Ret short isoform interaction with Grb2 could be mediated not only by Shc but also by a molecule that binds preferentially to this isoform. ",9764818
1061,1,2_abstract_sentence,6,"This possibility is supported by the evidence that the mutant Ret/ptc2Y620F long isoform displays a weak coimmunoprecipitation  with Grb2 and that this mutant, lacking the docking site for Grb2 but owing all the others phosphotyrosines, surprisingly displays a reduced transforming activity compared to that of the two WTs oncogenes. ",9764818
1061,1,2_abstract_sentence,7,"We thus conclude that in intact cells both Ret isoforms bind to Grb2, although with different modalities. ",9764818
1061,1,2_abstract_sentence,8," In addition, the present results are in agreement with the possibility that different signal transduction pathways are associated with the two isoforms of Ret. ",9764818
1061,2,1_title,0,"Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors.  ",9284737
1061,2,2_abstract_sentence,0,Causative germline missense mutations in the RET proto-oncogene have been associated with over 92% of families with the inherited cancer syndrome multiple  endocrine neoplasia type 2 (MEN 2). ,9284737
1061,2,2_abstract_sentence,1,"MEN 2A is characterized primarily by medullary thyroid carcinoma (MTC) and pheochromocytoma, both tumors of neural crest origin. ",9284737
1061,2,2_abstract_sentence,2,"Parathyroid hyperplasia or adenoma is also seen in MEN 2A, but rarely in MEN 2B, which has additional stigmata, including a marfanoid habitus, mucosal neuromas, and ganglioneuromatosis of the gastrointestinal tract. ",9284737
1061,2,2_abstract_sentence,3,"In familial MTC, MTC is the only lesion present. ",9284737
1061,2,2_abstract_sentence,4,"Somatic RET mutations have also been identified in a subset of sporadic MTCs, pheochromocytomas, and rarely, small cell lung cancer, but not in sporadic parathyroid hyperplasias/adenomas or  other neuroendocrine tumors. ",9284737
1061,2,2_abstract_sentence,5,"Glial cell line-derived neurotrophic factor (GDNF) and its receptor molecule GDNFR-alpha, have recently been identified as members of the RET ligand binding complex. ",9284737
1061,2,2_abstract_sentence,6,"Therefore, the genes encoding both GDNF and GDNFR-alpha are excellent candidates for a role in the pathogenesis of those MEN  2 families and sporadic neuroendocrine tumors without RET mutations. ",9284737
1061,2,2_abstract_sentence,7,"No mutations were found in the coding region of GDNF in DNA samples from 9 RET mutation negative MEN 2 individuals (comprising 6 distinct families), 12 sporadic MTCs, 17 sporadic cases of parathyroid adenoma, and 10 small cell lung cancer cell lines. ",9284737
1061,2,2_abstract_sentence,8," Therefore, we find no evidence that mutation within the coding regions of GDNF plays a role in the genesis of MEN 2 and sporadic neuroendocrine tumors. ",9284737
1061,3,1_title,0,Molecular genetics of Hirschsprung disease: a model of multigenic neurocristopathy.  ,11324313
1061,3,2_abstract_sentence,0,"Hirschsprung's disease (HSCR, aganglionic megacolon) is a frequent congenital malformation regarded as a multigenic neurocristopathy. ",11324313
1061,3,2_abstract_sentence,1,"Three susceptibility genes have been recently identified in HSCR, namely the RET proto-oncogene, the endothelin B receptor (EDNRB) gene, and the endothelin 3 (EDN3) gene. ",11324313
1061,3,2_abstract_sentence,2,"RET gene mutations were found in significant proportions of familial (50%) and sporadic (15-20%) HSCR, while homozygosity for EDNRB or EDN3 mutations accounted for the rare HSCR-Waardenburg syndrome (WS) association. ",11324313
1061,3,2_abstract_sentence,3,"More recently, heterozygous EDNRB an EDN3 missense mutations have been reported in isolated HSCR patients. ",11324313
1061,3,2_abstract_sentence,4,Some of these results were obtained after the identification of mouse genes whose natural or site-directed mutations resulted in megacolon and coat color spotting. ,11324313
1061,3,2_abstract_sentence,5,There is also conclusive evidence for the involvement of other independent loci in HSCR. ,11324313
1061,3,2_abstract_sentence,6,"In particular, the recent identification of neurotrophic factors acting  as RET ligands (GDNF and Neurturin) provide additional candidate genes for HSCR. ",11324313
1061,3,2_abstract_sentence,7," The dissection of the genetic etiology of HSCR disease may then provide a unique  opportunity to distinguish between a polygenic and a genetically heterogeneous disease, thereby helping to understand other complex disorders and congenital malformations hitherto considered as multifactorial in origin. ",11324313
1061,3,2_abstract_sentence,8,"Finally, the study of the molecular bases of HSCR is also a step towards the understanding of developmental genetics of the enteric nervous system giving support to the role of the tyrosine kinase and endothelin-signaling pathways in the development of neural crest-derived enteric neurons in human. ",11324313
1061,4,1_title,0,The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression  through distinct mechanisms in medullary thyroid cancer cells.  ,17638907
1061,4,2_abstract_sentence,0,The RET kinase has emerged as a promising target for the therapy of medullary thyroid cancers (MTC) and of a subset of papillary thyroid cancers. ,17638907
1061,4,2_abstract_sentence,1,"NVP-AST487, a N,N'-diphenyl urea with an IC(50) of 0.88 mumol/L on RET kinase, inhibited RET autophosphorylation and activation of downstream effectors, and potently inhibited the growth of human thyroid cancer cell lines with activating mutations of RET but not of lines without RET mutations. ",17638907
1061,4,2_abstract_sentence,2,"NVP-AST487 induced a dose-dependent growth inhibition of xenografts of NIH3T3 cells expressing oncogenic RET, and of the MTC cell line TT in nude mice. ",17638907
1061,4,2_abstract_sentence,3,"MTCs secrete calcitonin, a useful indicator of tumor burden. ",17638907
1061,4,2_abstract_sentence,4,"Human plasma calcitonin levels derived from the TT cell xenografts were inhibited shortly after treatment, when tumor volume  was still unchanged, indicating that the effects of RET kinase inhibition on calcitonin secretion were temporally dissociated from its tumor-inhibitory properties. ",17638907
1061,4,2_abstract_sentence,5,"Accordingly, NVP-AST487 inhibited calcitonin gene expression in vitro in TT cells, in part, through decreased gene transcription. ",17638907
1061,4,2_abstract_sentence,6,These data point to a previously unknown physiologic role of RET signaling on calcitonin gene expression. ,17638907
1061,4,2_abstract_sentence,7,"Indeed, the RET ligands persephin and GDNF robustly stimulated calcitonin mRNA, which was blocked by pretreatment with NVP-AST487. ",17638907
1061,4,2_abstract_sentence,8,"Antagonists of RET kinase activity in patients with MTC may result in effects on plasma calcitonin that are either disproportionate or dissociated from the effects on tumor burden, because RET kinase mediates a physiologic pathway controlling calcitonin secretion. ",17638907
1061,4,2_abstract_sentence,9,The role of traditional tumor biomarkers may need to be reassessed as targeted therapies designed against oncoproteins with key roles in  pathogenesis are implemented. ,17638907
1061,5,1_title,0,From monogenic to polygenic: model of Hirschsprung disease.  ,9885824
1061,5,2_abstract_sentence,0,"Hirschsprung's disease (HSCR, aganglionic megacolon) is a frequent congenital malformation regarded as a multigenic neurocristopathy. ",9885824
1061,5,2_abstract_sentence,1,"Three susceptibility genes have been recently identified in HSCR, namely the RET proto-oncogene, the endothelin B receptor (EDNRB) gene, and the endothelin 3 (EDN3) gene. ",9885824
1061,5,2_abstract_sentence,2,"RET gene mutations were found in significant proportions of familial (50%) and sporadic (15-20%) HSCR, while homozygosity for EDNRB or EDN3 mutations accounted for the rare HSCR-Waardenburg syndrome (WS) association. ",9885824
1061,5,2_abstract_sentence,3,"More recently, heterozygous EDNRB and EDN3 missense mutations have been reported in isolated HSCR patients. ",9885824
1061,5,2_abstract_sentence,4,Some of these results were obtained after the identification of mouse genes whose natural or site-directed mutations resulted in megacolon and coat color spotting. ,9885824
1061,5,2_abstract_sentence,5,There is also conclusive evidence for the involvement of other independent loci in HSCR. ,9885824
1061,5,2_abstract_sentence,6,"In particular, the recent identification of neurotrophic factors acting  as RET ligands (GDNF and Neurturin) provide additional candidate genes for HSCR. ",9885824
1061,5,2_abstract_sentence,7," The dissection of the genetic etiology of HSCR disease may then provide a unique  opportunity to distinguish between a polygenic and a genetically heterogeneous disease, thereby helping to understand other complex disorders and congenital malformations hitherto considered as multifactorial in origin. ",9885824
1061,5,2_abstract_sentence,8,"Finally, the study of the molecular bases of HSCR is also a step towards the understanding of developmental genetics of the enteric nervous system giving support to the role of the tyrosine kinase and endothelin-signaling pathways in the development of neural crest-derived enteric neurons in human. ",9885824
1061,6,1_title,0,GDNF availability determines enteric neuron number by controlling precursor proliferation.  ,12668632
1061,6,2_abstract_sentence,0,"To clarify the role of Ret signaling components in enteric nervous system (ENS) development, we evaluated ENS anatomy and intestinal contractility in mice heterozygous for Ret, GFRalpha1 and Ret ligands. ",12668632
1061,6,2_abstract_sentence,1,These analyses demonstrate that  glial cell line-derived neurotrophic factor (GDNF) and neurturin are important for different aspects of ENS development. ,12668632
1061,6,2_abstract_sentence,2,"Neurturin is essential for maintaining  the size of mature enteric neurons and the extent of neuronal projections, but does not influence enteric neuron number. ",12668632
1061,6,2_abstract_sentence,3,GDNF availability determines enteric neuron number by controlling ENS precursor proliferation. ,12668632
1061,6,2_abstract_sentence,4,"However, we were unable to find evidence of programmed cell death in the wild type ENS by immunohistochemistry for activated caspase 3. ",12668632
1061,6,2_abstract_sentence,5,"In addition, enteric neuron number  is normal in Bax(-/-) and Bid(-/-) mice, suggesting that, in contrast to most of  the rest of the nervous system, programmed cell death is not important for determining enteric neuron numbers. ",12668632
1061,6,2_abstract_sentence,6,Only mild reductions in neuron size and neuronal fiber counts occur in Ret(+/-) and Gfra1(+/-) mice. ,12668632
1061,6,2_abstract_sentence,7,"All of these heterozygous mice, however, have striking problems with intestinal contractility  and neurotransmitter release, demonstrating that Ret signaling is critical for both ENS structure and function. ",12668632
1061,7,1_title,0,GDNF deficit in Hirschsprung's disease.  ,9473110
1061,7,2_abstract_sentence,0,"BACKGROUND/PURPOSE: In 1996, the glial cell line-derived neurotrophic factor (GDNF) was identified as one of the ligands of the RET transmembrane receptor. ",9473110
1061,7,2_abstract_sentence,1,"In the same year, GDNF mutations were found in association with RET protooncogene mutations in Hirschsprung patients. ",9473110
1061,7,2_abstract_sentence,2,Mutations in GDNF per se are thought neither  necessary nor sufficient to cause Hirschsprung's disease (HD). ,9473110
1061,7,2_abstract_sentence,3,"To date, our study group has identified GDNF mutations only in 2 of 98 cases of intestinal dysganglionosis. ",9473110
1061,7,2_abstract_sentence,4,The aim of our study was to investigate a possible expression deficit of GDNF in the enteric nervous system of Hirschsprung patients not mutated for the GDNF gene. ,9473110
1061,7,2_abstract_sentence,5,METHODS: We used rabbit polyclonal antibodies raised against a peptide corresponding to amino acids 186-205 mapping within the carboxy-terminal domain of human GDNF. ,9473110
1061,7,2_abstract_sentence,6,GDNF expression was studied immunohistochemically in surgical specimens from 30 HD cases (27 classic forms and 3 ultralong forms) and from 10 age-matched controls. ,9473110
1061,7,2_abstract_sentence,7,"Serial sections from the same full-thickness specimens were investigated with the following histochemical and immunohistochemical techniques: acetylcholinesterase, lactate dehydrogenase, succinic dehydrogenase, alpha-naphthyl-esterase, glial fibrillary acid protein, S-100 protein, and neuron-specific enolase. ",9473110
1061,7,2_abstract_sentence,8,RESULTS: A high level of GDNF expression was found in normal intestine and in Hirschsprung ganglionic segment. ,9473110
1061,7,2_abstract_sentence,9,Satellite elements of myenteric ganglia presented a strong immunoreactivity to GDNF. ,9473110
1061,7,2_abstract_sentence,10,"Conversely, the aganglionic segment  showed cholinergic hyperinnervation and hypertrophic trunks of nerve fibers in the muscular interstitium with complete absence of GDNF expression. ",9473110
1061,7,2_abstract_sentence,11,The small ganglia of the hypoganglionic segment showed a reduced GDNF immunoreactivity. ,9473110
1061,7,2_abstract_sentence,12,"CONCLUSIONS: GDNF, a distantly related member of the transforming growth factor-beta superfamily, is a potent neurotrophic and survival factor for neurons and enteric ganglion cells. ",9473110
1061,7,2_abstract_sentence,13,"Mutations of the GDNF gene or GDNF expression deficit interrupt the faithful GDNF signaling via Ret, contributing to HD pathogenesis. ",9473110
1061,8,1_title,0,Differential effects of glial cell line-derived neurotrophic factor and neurturin in RET/GFRalpha1-expressing cells.  ,16294336
1061,8,2_abstract_sentence,0,"The c-ret protooncogene, RET, encodes a receptor tyrosine kinase. ",16294336
1061,8,2_abstract_sentence,1,"RET is activated by members of the glial cell line-derived neurotrophic factor (GDNF) family of ligands, which include GDNF, neurturin, artemin, and persephin. ",16294336
1061,8,2_abstract_sentence,2,"The ligands bind RET through GDNF family receptor alpha, termed GFRalpha1-4. ",16294336
1061,8,2_abstract_sentence,3,"Despite  the importance of RET signaling in the development of the enteric nervous system  and the kidney, the differential signaling mechanisms between RET ligands are poorly established. ",16294336
1061,8,2_abstract_sentence,4,It has been suggested that signal specificity is achieved through binding of the ligand to its preferred GFRalpha. ,16294336
1061,8,2_abstract_sentence,5,"To compare the signaling profiles of GDNF and neurturin, we have identified a cell line, NG108-15, which endogenously expresses RET and GFRalpha1 but not GFRalpha2-4. ",16294336
1061,8,2_abstract_sentence,6,"Immunoblot data showed that GDNF caused a transient activation, whereas neurturin caused a sustained activation, of both p44/p42 MAP kinases and PLCgamma. ",16294336
1061,8,2_abstract_sentence,7,"Under serum starvation, NG108-15 cells differentiate and form neurites. ",16294336
1061,8,2_abstract_sentence,8,"Neurturin but not GDNF stimulated neurite outgrowth, which could be blocked by the selective PLC inhibitor U73122. ",16294336
1061,8,2_abstract_sentence,9,"On the other hand, GDNF but not neurturin promoted cell survival, and this could be blocked by the p44/p42 MAP kinase inhibitor PD98059. ",16294336
1061,8,2_abstract_sentence,10," Our findings not only show the differential signaling of GDNF and neurturin but also suggest that this can be achieved through binding to the same GFRalpha subtype, leading to distinct biological responses. ",16294336
1061,9,1_title,0,Genetics of Hirschsprung disease.  ,11106284
1061,9,2_abstract_sentence,0,"Hirschsprung disease (HSCR), or congenital intestinal aganglionosis, is a relatively common disorder of neural crest migration. ",11106284
1061,9,2_abstract_sentence,1,"It has a strong genetic basis, although simple Mendelian inheritance is rarely observed. ",11106284
1061,9,2_abstract_sentence,2,"Hirschsprung disease is associated with several other anomalies and syndromes, and animal models for these conditions exist. ",11106284
1061,9,2_abstract_sentence,3,Mutations in the RET gene are responsible for  approximately half of familial cases and a smaller fraction of sporadic cases. ,11106284
1061,9,2_abstract_sentence,4,"Mutations in genes that encode RET ligands (GDNF and NTN); components of another  signaling pathway (EDNRB, EDN3, ECE-1); and the transcription factor, SOX10, have been identified in HSCR patients. ",11106284
1061,9,2_abstract_sentence,5,A subset of these mutations is associated with  anomalies of pigmentation and/or hearing loss. ,11106284
1061,9,2_abstract_sentence,6,"For almost every HSCR gene, incomplete penetrance of the HSCR phenotype has been observed, probably due to genetic modifier loci. ",11106284
1061,9,2_abstract_sentence,7,"Thus, HSCR has become a model of a complex polygenic disorder in which the interplay of different genes is currently being elucidated. ",11106284
1061,10,1_title,0,A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor.  ,9192898
1061,10,2_abstract_sentence,0,Erratum in     Nature 1998 Mar 12;392(6672):210. ,9192898
1061,11,1_title,0,GDNF: a novel factor with therapeutic potential for neurodegenerative disorders.  ,10321971
1061,11,2_abstract_sentence,0,The identification of novel factors that promote neuronal survival could have profound effects on developing new therapeutics for neurodegenerative disorders. ,10321971
1061,11,2_abstract_sentence,1, Glial cell line-derived neurotrophic factor (GDNF) is a novel protein purified and cloned based on its marked ability to promote dopaminergic neuronal function. ,10321971
1061,11,2_abstract_sentence,2,"GDNF, now known to be the first identified member of a family of factors, signals through the previously known receptor tyrosine kinase, Ret. ",10321971
1061,11,2_abstract_sentence,3,"Unlike most ligands for receptor tyrosine kinases, GDNF does not bind and activate Ret directly, but  requires the presence of GPI-linked coreceptors. ",10321971
1061,11,2_abstract_sentence,4,There are several coreceptors with differing affinities for the GDNF family members. ,10321971
1061,11,2_abstract_sentence,5,The profile of coreceptors in a cell may determine which factor preferentially activates Ret. ,10321971
1061,11,2_abstract_sentence,6,"In vivo differences in localization of the GDNF family members, its coreceptors and Ret suggest this ligand/receptor interaction has extensive and multiple functions in  the CNS as well as in peripheral tissues. ",10321971
1061,11,2_abstract_sentence,7,GDNF promotes survival of several neuronal populations both in vitro and in vivo. ,10321971
1061,11,2_abstract_sentence,8,Dopaminergic neuronal survival and function are preserved by GDNF in vivo when challenged by the toxins MPTP and 6-hydroxydopamine. ,10321971
1061,11,2_abstract_sentence,9,"Furthermore, GDNF improves the symptoms of pharmacologically induced Parkinson's disease in monkeys. ",10321971
1061,11,2_abstract_sentence,10,Several motor neuron populations isolated in vitro are also rescued by GDNF. ,10321971
1061,11,2_abstract_sentence,11,"In vivo, GDNF protects these neurons from programmed cell death associated with development and death induced by neuronal transection. ",10321971
1061,11,2_abstract_sentence,12,These experiments suggest that GDNF may provide significant therapeutic opportunities in several neurodegenerative disorders. ,10321971
1061,12,1_title,0,Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.  ,10027003
1061,12,2_abstract_sentence,0,The ret proto-oncogene encodes a receptor tyrosine kinase whose ligands belong to the glial cell line-derived neurotrophic factor (GDNF) protein family. ,10027003
1061,12,2_abstract_sentence,1,Its germline mutations are responsible for the development of multiple endocrine neoplasia (MEN) types 2A and 2B and Hirschsprung's disease (HSCR). ,10027003
1061,12,2_abstract_sentence,2,MEN2A and MEN2B mutations result in the constitutive activation of Ret by different molecular mechanisms. ,10027003
1061,12,2_abstract_sentence,3,MEN2A mutations involve cysteine residues present in the Ret extracellular domain and induce disulfide-linked Ret dimerization on the cell surface. ,10027003
1061,12,2_abstract_sentence,4,"MEN2B mutations were identified in methionine 918 in the tyrosine kinase domain and activate Ret without dimerization, probably due to a conformational change of its catalytic core region. ",10027003
1061,12,2_abstract_sentence,5,"In contrast to MEN2 mutations, HSCR mutations represent loss of function mutations. ",10027003
1061,12,2_abstract_sentence,6,We found that most of HSCR mutations detected in the extracellular domain impair the Ret cell surface expression. ,10027003
1061,12,2_abstract_sentence,7,"More interestingly, ret mutations in cysteines 618 and 620 were reported in several families who developed both MEN2A and HSCR. ",10027003
1061,12,2_abstract_sentence,8,"It was suggested  that these mutations might have two biological effects on Ret function, leading to the development of different clinical phenotypes in the same patients. ",10027003
1061,13,1_title,0,Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease.  ,11409869
1061,13,2_abstract_sentence,0,The glial-cell-line-derived neurotrophic factor (GDNF) family receptors alpha (GFRalpha) are cell surface bound glycoproteins that mediate interactions of the  GDNF ligand family with the RET receptor. ,11409869
1061,13,2_abstract_sentence,1,These interactions are crucial to the development of the kidney and some peripheral nerve lineages. ,11409869
1061,13,2_abstract_sentence,2,"In humans, mutations of RET or RET ligands are associated with the congenital abnormality Hirschsprung disease (HSCR) in which nerves and ganglia of the hind gut are absent. ",11409869
1061,13,2_abstract_sentence,3,"As the GFRalpha family are required for normal activation of the RET receptor, they are also candidates for a role in HSCR. ",11409869
1061,13,2_abstract_sentence,4,"The GFRA2 gene, which is required for the development of the myenteric nerve plexus, is an excellent candidate gene for HSCR. ",11409869
1061,13,2_abstract_sentence,5,"In this study, we cloned the human GFRA2 locus, characterized the gene structure, and compared it with other GFRA family members. ",11409869
1061,13,2_abstract_sentence,6,We further investigated the GFRA2 gene for mutations in a panel of HSCR patients. ,11409869
1061,13,2_abstract_sentence,7,GFRA2 has nine coding exons that are similar in size and organization to those of other GFRA family genes. ,11409869
1061,13,2_abstract_sentence,8,"We identified six sequence variants of GFRA2, four of which did not affect the amino acid sequence of the GFRalpha-2 protein. ",11409869
1061,13,2_abstract_sentence,9,Two further changes that resulted in amino acid substitutions were found in exon 9 and were predicted to lie in the amino acid sequence encoding the glycosylphosphatidylinositol-linkage signal of GFRalpha-2. ,11409869
1061,13,2_abstract_sentence,10,There was no difference in frequency of any of the sequence variants between control and HSCR  populations. ,11409869
1061,13,2_abstract_sentence,11,Our data indicate that members of the GFRA gene family are closely related in intron/exon structure and in sequence. ,11409869
1061,13,2_abstract_sentence,12,We have not detected any correlation between sequence variants of GFRA2 and the HSCR phenotype. ,11409869
1061,14,1_title,0,Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalpha1 RET-specific agonists.  ,10652334
1061,14,2_abstract_sentence,0,"The glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) (GDNF, neurturin, artemin, and persephin) are critical regulators of neurodevelopment and support the survival of midbrain dopaminergic and spinal motor neurons in vitro and in animal disease models making them attractive therapeutic candidates for treatment of neurodegenerative diseases. ",10652334
1061,14,2_abstract_sentence,1,The GFLs signal through a multicomponent receptor complex comprised of a high affinity binding component (GDNF-family receptor alpha-component (GFRalpha1-GFRalpha4)) and the receptor tyrosine kinase RET. ,10652334
1061,14,2_abstract_sentence,2,"To begin characterization of GFL receptor specificity at the molecular level, we performed comprehensive homologue-scanning mutagenesis of GDNF, the prototypical member of the GFLs. ",10652334
1061,14,2_abstract_sentence,3,Replacing short segments of GDNF with the homologous segments from persephin (PSPN) (which cannot bind or activate GFRalpha1.RET or GFRalpha2.RET) identified sites along the second finger of GDNF critical for activating the GFRalpha1.RET and GFRalpha2.RET receptor complexes. ,10652334
1061,14,2_abstract_sentence,4,"Furthermore, introduction of these regions from GDNF, neurturin, or artemin into PSPN demonstrated that they are sufficient for activating GFRalpha1. ",10652334
1061,14,2_abstract_sentence,5,"RET, but additional determinants are required for interaction with the other GFRalphas. ",10652334
1061,14,2_abstract_sentence,6,This difference in the molecular basis of GFL-GFRalpha specificity allowed the production of GFRalpha1. ,10652334
1061,14,2_abstract_sentence,7,RET-specific agonists and provides a foundation for understanding of GFL-GFRalpha.RET signaling at the molecular level. ,10652334
1061,15,1_title,0,"Expression of RET and its ligand complexes, GDNF/GFRalpha-1 and NTN/GFRalpha-2, in medullary thyroid carcinomas.  ",10822229
1061,15,2_abstract_sentence,0,"OBJECTIVE: Mutations in the RET proto-oncogene are found in about one third of sporadic medullary thyroid carcinomas (MTCs), mostly affecting codon 918. ",10822229
1061,15,2_abstract_sentence,1,"Glial cell line derived neurotropic factor (GDNF) and its membrane-bound GDNF family receptor alpha (GFRalpha-1), as well as neurturin (NTN) and its membrane-bound receptor GFRalpha-2 form a complex with the RET product, a receptor tyrosine kinase, resulting in downstream signaling to the nucleus. ",10822229
1061,15,2_abstract_sentence,2,"DESIGN: To elucidate the role of these RET ligands in MTC tumorigenesis, their expression was determined in 15 MTC samples, one papillary thyroid carcinoma (PTC) and three normal thyroid tissue specimens. ",10822229
1061,15,2_abstract_sentence,3,"METHODS: The mRNA expression of RET, GDNF, GFRalpha-1, NTN and GFRalpha-2 was investigated by mRNA in situ hybridization, and confirmed by reverse transcription-PCR analysis. ",10822229
1061,15,2_abstract_sentence,4,RESULTS: None of the five genes was expressed in the normal thyroids or in the PTC. ,10822229
1061,15,2_abstract_sentence,5,"All MTCs showed expression of RET, 13 expressed GDNF, 12 expressed GFRalpha-1 and 9 expressed NTN and GFRalpha-2. ",10822229
1061,15,2_abstract_sentence,6,"In 7 of the tumors RET, GDNF and GFRalpha-1 were expressed at high levels, and in five of these seven tumors NTN and GFRalpha-2 genes were also expressed at high levels. ",10822229
1061,15,2_abstract_sentence,7,The high level of expression was preferentially seen in tumor cells adjacent to stroma and connective tissue. ,10822229
1061,15,2_abstract_sentence,8,All MTCs without expression of the RET ligands harbored the RET codon 918 mutation. ,10822229
1061,15,2_abstract_sentence,9,"CONCLUSIONS: The results suggest that this signaling pathway is important for MTC development, and that it may be activated by expression of the RET ligand complexes by the tumor cells themselves. ",10822229
1061,16,1_title,0,RET and GDNF gene scanning in Hirschsprung patients using two dual denaturing gel systems.  ,10790203
1061,16,2_abstract_sentence,0,Hirschsprung disease (HSCR) is a congenital disorder characterised by intestinal  obstruction due to an absence of intramural ganglia along variable lengths of the intestine. ,10790203
1061,16,2_abstract_sentence,1,RET is the major gene involved in HSCR. ,10790203
1061,16,2_abstract_sentence,2,"Mutations in the GDNF gene, and encoding one of the RET ligands, either alone or in combination with RET mutations, can also cause HSCR, as can mutations in four other genes (EDN3, EDNRB, ECE1, and SOX10). ",10790203
1061,16,2_abstract_sentence,3,"The rare mutations in the latter four genes, however, are more or less restricted to HSCR associated with specific phenotypes. ",10790203
1061,16,2_abstract_sentence,4,"We have  developed a novel comprehensive mutation detection system to analyse all but three amplicons of the RET and GDNF genes, based on denaturing gradient gel electrophoresis. ",10790203
1061,16,2_abstract_sentence,5,"We make use of two urea-formamide gradients on top of each other, allowing mutation detection over a broad range of melting temperatures. ",10790203
1061,16,2_abstract_sentence,6,For the three remaining (GC-rich) PCR fragments we use a combination of DGGE and  constant denaturing gel electrophoresis (CDGE). ,10790203
1061,16,2_abstract_sentence,7,"These two dual gel systems substantially facilitate mutation scanning of RET and GDNF, and may also serve as a model to develop mutation detection systems for other disease genes. ",10790203
1061,16,2_abstract_sentence,8,"In a screening of 95 HSCR patients, RET mutations were found in nine out of 17 familial cases (53%), all containing long segment HSCR. ",10790203
1061,16,2_abstract_sentence,9,"In 11 of 78 sporadic cases (14%), none had long segment HSCR. ",10790203
1061,16,2_abstract_sentence,10,"Only one GDNF mutation was found, in a sporadic case. ",10790203
1061,17,1_title,0,RET and neuroendocrine tumors.  ,15013219
1061,17,2_abstract_sentence,0,"Glial cell line-derived neurotrophic factor (GDNF), a ligand of RET tyrosine kinase, and its family ligands promote the survival and differentiation of a variety of neurons. ",15013219
1061,17,2_abstract_sentence,1,"Gene ablation studies have revealed that the GDNF-RET receptor system is essential for the development of kidney and peripheral neurons, including sympathetic, parasympathetic and enteric neurons. ",15013219
1061,17,2_abstract_sentence,2,"RET can activate various signaling pathways such as RAS/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/AKT, p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) pathways. ",15013219
1061,17,2_abstract_sentence,3,These signaling pathways are activated via binding of adaptor proteins to intracellular tyrosine  residues of RET phosphorylated by its own kinase activity. ,15013219
1061,17,2_abstract_sentence,4,The RET is profoundly  involved in the development of several human neuroendocrine diseases. ,15013219
1061,17,2_abstract_sentence,5,"The constitutive activation of the RET by somatic rearrangement with other partner genes or germ-line mutations causes a considerable population of human papillary  thyroid carcinomas or multiple endocrine neoplasia (MEN) type 2A and 2B, respectively, whereas the dysfunction of RET by germ-line missense and/or nonsense mutations causes Hirschsprung's disease. ",15013219
1061,17,2_abstract_sentence,6,Biological properties of mutant RET protein determine the disease phenotype. ,15013219
1061,17,2_abstract_sentence,7,"For example, the MEN 2B mutation alters the substrate specificity of RET tyrosine kinase and RET carrying the MEN  2B mutation hereby induces the different set of genes from that carrying the MEN  2A mutation. ",15013219
1061,17,2_abstract_sentence,8,"In this review, we describe the current knowledge about the molecular mechanism of RET activation in human neuroendocrine tumors as well as the physiological roles and signal transduction of RET tyrosine kinase. ",15013219
1061,18,1_title,0,c-Jun in Schwann cells promotes axonal regeneration and motoneuron survival via paracrine signaling.  ,22753894
1061,18,2_abstract_sentence,0,The AP-1 transcription factor c-Jun is a master regulator of the axonal response  in neurons. ,22753894
1061,18,2_abstract_sentence,1,c-Jun also functions as a negative regulator of myelination in Schwann cells (SCs) and is strongly reactivated in SCs upon axonal injury. ,22753894
1061,18,2_abstract_sentence,2,"We demonstrate here that, after injury, the absence of c-Jun specifically in SCs caused impaired axonal regeneration and severely increased neuronal cell death. ",22753894
1061,18,2_abstract_sentence,3,"c-Jun deficiency resulted in decreased expression of several neurotrophic factors, and GDNF and Artemin, both of which encode ligands for the Ret receptor  tyrosine kinase, were identified as novel direct c-Jun target genes. ",22753894
1061,18,2_abstract_sentence,4,"Genetic inactivation of Ret specifically in neurons resulted in regeneration defects without affecting motoneuron survival and, conversely, administration of recombinant GDNF and Artemin protein substantially ameliorated impaired regeneration caused by c-Jun deficiency. ",22753894
1061,18,2_abstract_sentence,5,"These results reveal an unexpected function for c-Jun in SCs in response to axonal injury, and identify paracrine Ret signaling as an important mediator of c-Jun function in SCs during regeneration. ",22753894
1061,19,1_title,0,Germline mutations of the RET ligand GDNF are not sufficient to cause Hirschsprung disease.  ,8896569
1061,19,2_abstract_sentence,0,"Hirschsprung disease (HSCR, aganglionic megacolon) is a common congenital malformation leading to bowel obstruction, with an incidence of 1/5,000 live births. ",8896569
1061,19,2_abstract_sentence,1,It is characterized by the absence of intrinsic ganglion cells in the myenteric and submucosal plexuses along variable lengths of the gastrointestinal  tract. ,8896569
1061,19,2_abstract_sentence,2,"As enteric neurons are derived from the vagal neural crest, HSCR is regarded as a neurocristopathy. ",8896569
1061,19,2_abstract_sentence,3,"On the basis of a skewed sex-ratio (M/F = 4/1) and a risk to relatives much higher than the incidence in the general population, HSCR has long been regarded as a sex-modified multifactorial disorder. ",8896569
1061,19,2_abstract_sentence,4,"Accordingly, segregation analysis suggested an incompletely penetrant dominant inheritance in HSCR families with aganglionosis extending beyond the sigmoid colon. ",8896569
1061,19,2_abstract_sentence,5,We and others have mapped a dominant gene for HSCR to chromosome 10q11.2 and have ascribed the disease to mutations in the RET proto-oncogene. ,8896569
1061,19,2_abstract_sentence,6,"However, the lack of genotype-phenotype correlation, the low penetrance and the sex-dependent effect of RET mutations supported the existence of one or more modifier gene(s) in familial HSCR. ",8896569
1061,19,2_abstract_sentence,7,"In addition, thus far, RET mutations only accounted for 50% and 15-20% of familial and sporadic HSCR patients, respectively. ",8896569
1061,19,2_abstract_sentence,8,RET encodes a tyrosine kinase receptor whose ligand was unknown. ,8896569
1061,19,2_abstract_sentence,9,"Recently, the Glial cell line-derived neurotrophic factor (GDNF) has been identified to be a ligand for RET. ",8896569
1061,19,2_abstract_sentence,10,"Moreover, Gdnf-/- knockout mutant mice display congenital intestinal aganglionosis and renal agenesis, a phenotype very similar  to the Ret-/- mouse. ",8896569
1061,19,2_abstract_sentence,11,These data prompted us to hypothesize that mutations of the  gene encoding GDNF could either cause or modulate the HSCR phenotype in some cases. ,8896569
1061,20,1_title,0,"Mutation of the RET ligand, neurturin, supports multigenic inheritance in Hirschsprung disease.  ",9700200
1061,20,2_abstract_sentence,0,Erratum in     Hum Mol Genet 1998 Oct;7(11):1831. ,9700200
1061,21,1_title,0,"Polymorphisms in the genes encoding the 4 RET ligands, GDNF, NTN, ARTN, PSPN, and susceptibility to Hirschsprung disease.  ",18970938
1061,21,2_abstract_sentence,0,"PURPOSE: Hirschsprung disease (HSCR) is a developmental disorder caused by a failure of neural crest cells to migrate, proliferate, and/or differentiate during the enteric nervous system development. ",18970938
1061,21,2_abstract_sentence,1,"It presents a multifactorial, nonmendelian pattern of inheritance, with several genes playing some role in its  pathogenesis. ",18970938
1061,21,2_abstract_sentence,2,"Its major susceptibility gene is the RET protooncogene, which encodes a receptor tyrosine kinase activating several key signaling pathways in the enteric nervous system development. ",18970938
1061,21,2_abstract_sentence,3,"Given the pivotal role of RET in HSCR, the genes encoding their ligands (GDNF, NRTN, ARTN, and PSPN) are also good candidates for the disease. ",18970938
1061,21,2_abstract_sentence,4,"METHODS: We have performed a case-control study using Taqman technology to evaluate 10 polymorphisms within these genes, as well as haplotypes comprising them, as susceptibility factors for HSCR. ",18970938
1061,21,2_abstract_sentence,5,RESULTS: No differences were found in the allelic frequencies of the variants or  in the haplotype distribution between patients and controls. ,18970938
1061,21,2_abstract_sentence,6,"In addition, no particular association was detected of the variants/haplotypes to any demographic/clinical parameters within the group of patients. ",18970938
1061,21,2_abstract_sentence,7,"CONCLUSION: These data would be consistent with the lack of association between these polymorphisms and HSCR, although they do not permit to completely discard a possible role of other variants within these genes in the disease. ",18970938
1061,21,2_abstract_sentence,8,"Moreover, because the gene-by-gene approach does not take into account the polygenic nature of HSCR disease, it would be interesting to investigate sets of variants in many  other different susceptibility loci described for HSCR, which may permit to consider possible interactions among susceptibility genes. ",18970938
235,0,1_title,0,Analysis of banana transcriptome and global gene expression profiles in banana roots in response to infection by race 1 and tropical race 4 of Fusarium oxysporum f. sp. cubense.  ,24304681
235,0,2_abstract_sentence,0,"BACKGROUND: Cavendish, the most widely grown banana cultivar, is relatively resistant to Race 1 of Fusarium oxysporum f. ",24304681
235,0,2_abstract_sentence,1,sp. ,24304681
235,0,2_abstract_sentence,2,cubense (Foc1) which caused widespread Panama disease during the first half of the 20th century but is susceptible to Tropical Race 4 of Foc (Foc TR4) which is threatening world banana production. ,24304681
235,0,2_abstract_sentence,3,The genome of the diploid species Musa acuminata which is the ancestor of a majority of triploid banana cultivars has recently been sequenced. ,24304681
235,0,2_abstract_sentence,4, Availability of banana transcriptomes will be highly useful for improving banana  genome annotation and for biological research. ,24304681
235,0,2_abstract_sentence,5,The knowledge of global gene expression patterns influenced by infection of different Foc races will help to understand the host responses to the infection. ,24304681
235,0,2_abstract_sentence,6,RESULTS: RNA samples from different organs of the Cavendish cultivar were pooled  for deep sequencing using the Illumina technology. ,24304681
235,0,2_abstract_sentence,7,Analysis of the banana transcriptome led to identification of over 842 genes that were not annotated by  the Musa genome project. ,24304681
235,0,2_abstract_sentence,8,A large number of simple nucleotide polymorphisms (SNPs) and short insertions and deletion (indels) were identified from the transcriptome data. ,24304681
235,0,2_abstract_sentence,9,GFP-expressing Foc1 and Foc TR4 were used to monitor the infection process. ,24304681
235,0,2_abstract_sentence,10,Both Foc1 and Foc TR4 were found to be able to invade banana roots and spread to  root vascular tissues in the first two days following inoculation. ,24304681
235,0,2_abstract_sentence,11,Digital gene expression (DGE) profiling analysis reveal that the infection by Foc1 and Foc TR4 caused very similar changes in the global gene expression profiles in the banana  roots during the first two days of infection. ,24304681
235,0,2_abstract_sentence,12,The Foc infection led to induction  of many well-known defense-related genes. ,24304681
235,0,2_abstract_sentence,13,Two genes encoding the ethylene biosynthetic enzyme ACC oxidase and several ethylene-responsive transcription factors (ERF) were among the strongly induced genes by both Foc1 and Foc TR4. ,24304681
235,0,2_abstract_sentence,14,CONCLUSIONS: Both Foc1 and Foc TR4 are able to spread into the vascular system of banana roots during the early infection process and their infection led to similar gene expression profiles in banana roots. ,24304681
235,0,2_abstract_sentence,15,The transcriptome profiling analysis indicates that the ethylene synthetic and signalling pathways were activated in response to the Foc infection. ,24304681
235,1,1_title,0,Fusarium Wilt of Banana Is Caused by Several Pathogens Referred to as Fusarium oxysporum f. sp. cubense.  ,18943184
235,2,1_title,0,"Effect of menadione sodium bisulfite, an inducer of plant defenses, on the dynamic of banana phytoalexin accumulation during pathogenesis.  ",12926878
235,2,2_abstract_sentence,0,"Using an authentic sample of 2-hydroxy-9-(p-hydroxyphenyl)-phenalen-1-one, a banana phenalenone-type phytoalexin, we studied its dynamic of accumulation during pathogenesis of banana plants (Musa acuminata (AAA), Grand Nain) inoculated with Fusarium oxysporum f.sp. ",12926878
235,2,2_abstract_sentence,1,"cubense (FOC), Race 4, the causal agent  of Panama disease. ",12926878
235,2,2_abstract_sentence,2,"The results obtained demonstrate that banana plants treated prior inoculation with menadione sodium bisulfite (MSB), an inducer of plant defenses, are capable of changing the dynamic of accumulation (higher amount and  speed of biosynthesis) of this banana phytoalexin, biosynthesized by the banana plant during pathogenesis. ",12926878
235,3,1_title,0,Induction of Defense-Related Enzymes in Banana Plants: Effect of Live and Dead Pathogenic Strain of Fusarium oxysporum f. sp. cubense.  ,25969777
235,3,2_abstract_sentence,0,"The aim of the present study was to scrutinize the response of banana (Grand Naine variety) plants when interacting with dead or live pathogen, Fusarium oxysporum f.sp. ",25969777
235,3,2_abstract_sentence,1,"cubense, a causative agent of Panama disease. ",25969777
235,3,2_abstract_sentence,2,"Response of plants  was evaluated in terms of induction of defense-related marker enzyme activity, namely, peroxidase (POX), polyphenol oxidase (PPO), Î²-1,3 glucanase, chitinase, and phenolics. ",25969777
235,3,2_abstract_sentence,3,Plant's interaction with live pathogen resulted in early induction of defense to restrain penetration as well as antimicrobial productions. ,25969777
235,3,2_abstract_sentence,4,"However, pathogen overcame the defense of plant and caused disease. ",25969777
235,3,2_abstract_sentence,5,Interaction with dead  pathogen resulted in escalating defense response in plants. ,25969777
235,3,2_abstract_sentence,6,Later on plants inoculated with dead pathogen showed resistance to even forced inoculation of live pathogen. ,25969777
235,3,2_abstract_sentence,7,Results obtained in the present study suggest that dead pathogen was able to mount defense response in plants and provide resistance to Panama disease upon subsequent exposure. ,25969777
235,3,2_abstract_sentence,8,"Therefore, preparation from dead pathogen could be a potential candidate as a biocontrol agent or plant vaccine to combat Panama  disease. ",25969777
235,4,1_title,0,Multiple evolutionary origins of the fungus causing Panama disease of banana: concordant evidence from nuclear and mitochondrial gene genealogies.  ,9482835
235,4,2_abstract_sentence,0,"Panama disease of banana, caused by the fungus Fusarium oxysporum f. ",9482835
235,4,2_abstract_sentence,1,sp. ,9482835
235,4,2_abstract_sentence,2,"cubense, is a serious constraint both to the commercial production of banana and cultivation for subsistence agriculture. ",9482835
235,4,2_abstract_sentence,3,Previous work has indicated that F. ,9482835
235,4,2_abstract_sentence,4,oxysporum f. ,9482835
235,4,2_abstract_sentence,5,sp. ,9482835
235,4,2_abstract_sentence,6,cubense consists of several clonal lineages that may be genetically distant. ,9482835
235,4,2_abstract_sentence,7,In this study we tested whether lineages of the Panama disease pathogen have a monophyletic origin by comparing DNA sequences of nuclear and mitochondrial genes. ,9482835
235,4,2_abstract_sentence,8,DNA sequences were obtained for translation elongation factor 1alpha and the mitochondrial small subunit ribosomal RNA genes for F. ,9482835
235,4,2_abstract_sentence,9,"oxysporum strains from banana, pathogenic strains from other hosts and putatively nonpathogenic isolates of F. ",9482835
235,4,2_abstract_sentence,10,oxysporum. ,9482835
235,4,2_abstract_sentence,11,Cladograms for the two genes were highly  concordant and a partition-homogeneity test indicated the two datasets could be combined. ,9482835
235,4,2_abstract_sentence,12,"The tree inferred from the combined dataset resolved five lineages corresponding to ""F. ",9482835
235,4,2_abstract_sentence,13,oxysporum f. ,9482835
235,4,2_abstract_sentence,14,sp. ,9482835
235,4,2_abstract_sentence,15,"cubense"" with a large dichotomy between two taxa represented by strains most commonly isolated from bananas with Panama disease. ",9482835
235,4,2_abstract_sentence,16,The results also demonstrate that the latter two taxa have significantly different chromosome numbers. ,9482835
235,4,2_abstract_sentence,17,F. ,9482835
235,4,2_abstract_sentence,18,oxysporum isolates collected as nonpathogenic or pathogenic to other hosts that have very similar or identical elongation factor 1alpha and mitochondrial small subunit genotypes as banana pathogens were shown to cause little or no disease on banana. ,9482835
235,4,2_abstract_sentence,19,"Taken together, these results indicate Panama disease of banana is caused by fungi with independent evolutionary origins. ",9482835
235,5,1_title,0,Development of a real-time fluorescence loop-mediated isothermal amplification assay for rapid and quantitative detection of Fusarium oxysporum f. sp. cubense tropical race 4 in soil.  ,24376590
235,5,2_abstract_sentence,0,Erratum in     PLoS One. ,24376590
235,5,2_abstract_sentence,1,2014;9(1). ,24376590
235,5,2_abstract_sentence,2,doi:10.1371/annotation/8a1fd6a3-754f-42e2-a906-9d224167344e. ,24376590
235,6,1_title,0,Control of Panama disease of banana by rotating and intercropping with Chinese chive (Allium tuberosum Rottler): role of plant volatiles.  ,23355016
235,6,2_abstract_sentence,0,Intercropping and rotating banana (Musa spp.) with Chinese chive (Allium tuberosum Rottler) has been used as an effective method to control Panama disease (Fusarium wilt) of banana in South China. ,23355016
235,6,2_abstract_sentence,1,"However, the underlying mechanism is unknown. ",23355016
235,6,2_abstract_sentence,2,"In this study, we used aqueous leachates and volatiles from Chinese chive to evaluate their antimicrobial activity on Fusarium oxysporum f. ",23355016
235,6,2_abstract_sentence,3,sp. ,23355016
235,6,2_abstract_sentence,4,"cubense race 4 (FOC), the causal agent of Panama disease in banana, and identified the antifungal compounds. ",23355016
235,6,2_abstract_sentence,5,"Both leaf and root leachates of Chinese chive displayed strong inhibition against FOC, but the concentrated leachates showed lower inhibition than the original leachates. ",23355016
235,6,2_abstract_sentence,6,In a sealed system volatiles emitted from the leaves and roots of Chinese chive inhibited mycelial growth of FOC. ,23355016
235,6,2_abstract_sentence,7,Volatile compounds emitted from the intact growing roots mimicking natural environment inhibited spore germination of FOC. ,23355016
235,6,2_abstract_sentence,8,"We identified five volatiles including 2-methyl-2-pentenal and four organosulfur compounds (dimethyl trisulfide, dimethyl disulfide, dipropyl disulfide, and dipropyl trisulfide) from the leaves and roots of Chinese chive. ",23355016
235,6,2_abstract_sentence,9,"All these compounds exhibited inhibitory effects on FOC, but 2-methyl-2-pentenal and dimethyl trisulfide showed stronger inhibition than the other three compounds. ",23355016
235,6,2_abstract_sentence,10,2-Methyl-2-pentenal at 50-100 Î¼l/l completely inhibited the mycelial growth of FOC. ,23355016
235,6,2_abstract_sentence,11,Our results demonstrate that antifungal volatiles released from Chinese chive help control Panama disease in banana. ,23355016
235,6,2_abstract_sentence,12,We conclude that intercropping and rotating banana with Chinese chive can control Panama disease and increase cropland biodiversity. ,23355016
1096,0,1_title,0,Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current.  ,23334259
1096,0,2_abstract_sentence,0,Comment in     Cardiovasc Res. ,23334259
1096,0,2_abstract_sentence,1,2013 May 1;98(2):326-7. ,23334259
1096,0,2_abstract_sentence,2,    Cardiovasc Res. ,23334259
1096,0,2_abstract_sentence,3,2013 May 1;98(2):327-8. ,23334259
1096,1,1_title,0,Multiple modes of ryanodine receptor 2 inhibition by flecainide.  ,25274603
1096,1,2_abstract_sentence,0,"Catecholaminergic polymorphic ventricular tachycardia (CPVT) causes sudden cardiac death due to mutations in cardiac ryanodine receptors (RyR2), calsequestrin, or calmodulin. ",25274603
1096,1,2_abstract_sentence,1,"Flecainide, a class I antiarrhythmic drug, inhibits Na(+) and RyR2 channels and prevents CPVT. ",25274603
1096,1,2_abstract_sentence,2,The purpose of this study is to identify inhibitory mechanisms of flecainide on RyR2. ,25274603
1096,1,2_abstract_sentence,3,"RyR2 were isolated from sheep heart, incorporated into lipid bilayers, and investigated by single-channel recording under various activating conditions, including the presence of cytoplasmic ATP (2 mM) and a range of cytoplasmic [Ca(2+)], [Mg(2+)], pH, and [caffeine]. ",25274603
1096,1,2_abstract_sentence,4,"Flecainide applied to either the cytoplasmic or luminal sides of the  membrane inhibited RyR2 by two distinct modes: 1) a fast block consisting of brief substate and closed events with a mean duration of â¼1 ms, and 2) a slow block consisting of closed events with a mean duration of â¼1 second. ",25274603
1096,1,2_abstract_sentence,5,Both inhibition modes were alleviated by increasing cytoplasmic pH from 7.4 to 9.5 but were unaffected by luminal pH. ,25274603
1096,1,2_abstract_sentence,6,"The slow block was potentiated in RyR2 channels that had relatively low open probability, whereas the fast block was unaffected by RyR2 activation. ",25274603
1096,1,2_abstract_sentence,7,"These results show that these two modes are independent mechanisms for RyR2 inhibition, both having a cytoplasmic site of action. ",25274603
1096,1,2_abstract_sentence,8,"The slow mode is a closed-channel block, whereas the fast mode blocks RyR2 in the open state. ",25274603
1096,1,2_abstract_sentence,9,"At diastolic cytoplasmic [Ca(2+)] (100 nM), flecainide possesses an additional inhibitory mechanism that reduces RyR2 burst duration. ",25274603
1096,1,2_abstract_sentence,10,"Hence, multiple modes of action underlie RyR2 inhibition by flecainide. ",25274603
1096,2,1_title,0,Arrhythmogenic effect of flecainide toxicity.  ,23558880
1096,2,2_abstract_sentence,0,Flecainide is a class 1C antiarrhythmic drug especially used for the management of supraventricular arrhythmia. ,23558880
1096,2,2_abstract_sentence,1,"In overdose cases, flecainide can induce life treating ventricular arrhythmias and cardiogenic shock. ",23558880
1096,2,2_abstract_sentence,2,"We report the case of a 72-year-old woman admitted to our intensive care unit for a regular monomorphic wide complex tachycardia (QRS duration 240 ms, right bundle branch block and superior axis morphology) without apparent P waves. ",23558880
1096,2,2_abstract_sentence,3,Clinical examination showed slight left congestive heart failure signs without cardiogenic shock. ,23558880
1096,2,2_abstract_sentence,4,An intravenous bolus of 10 mg adenosine 5'-triphosphate (ATP) was ineffective to stop the tachycardia. ,23558880
1096,2,2_abstract_sentence,5,The diagnosis of ventricular tachycardia induced by flecainide overdose was considered. ,23558880
1096,2,2_abstract_sentence,6,500 mL of intravenous 84â° sodium bicarbonate  was administrated. ,23558880
1096,2,2_abstract_sentence,7,The patient's QRS narrowed immediately and 12-lead ECG showed  sinus rhythm. ,23558880
1096,2,2_abstract_sentence,8,Blood samples confirmed the flecainide overdose and the clinical status progressively improved. ,23558880
1096,3,1_title,0,Flecainide-induced myoclonus.  ,24614665
1096,3,2_abstract_sentence,0,Flecainide is a class 1c antiarrhythmic that acts by blocking sodium channels to  reduce intracardiac conduction and is used mainly in the treatment of supraventricular arrhythmias. ,24614665
1096,3,2_abstract_sentence,1,"Dizziness, visual disturbances, headache, and nausea are commonly associated with flecainide, but severe central nervous system toxicity is rare. ",24614665
1096,3,2_abstract_sentence,2,"Here, we report the case of a 71-year-old woman with a history  of renal transplantation who developed severe myoclonus 24 hours after being started on flecainide, 100 mg 2 times a day, because of atrial fibrillation. ",24614665
1096,3,2_abstract_sentence,3,This symptom completely disappeared once the drug was removed. ,24614665
1096,3,2_abstract_sentence,4,Only 2 patients presenting with flecainide-induced myoclonus have been previously reported. ,24614665
1096,3,2_abstract_sentence,5,"Although the exact pathophysiologic explanation of this phenomenon remains unclear, it is well known that the susceptibility to severe flecainide toxicity is increased in patients with chronic kidney disease. ",24614665
1096,4,1_title,0,An unusual case of flecainide-induced QT prolongation leading to cardiac arrest.  ,24510469
1096,4,2_abstract_sentence,0,Flecainide is recommended as a first-line antiarrhythmic drug to maintain normal  sinus rhythm in patients with atrial fibrillation (AF) who have structurally normal hearts or hypertension without left ventricular hypertrophy. ,24510469
1096,4,2_abstract_sentence,1,Flecainide is a sodium channel blocker with minimal effects expected on ventricular repolarization. ,24510469
1096,4,2_abstract_sentence,2,We describe the case of a 32-year-old man with a structurally normal heart and persistent AF who was started on diltiazem and flecainide 50Â mg  twice/day approximately a year prior to presentation. ,24510469
1096,4,2_abstract_sentence,3,"Due to persistent and bothersome symptoms, his dose was increased to 150Â mg twice/day, which was associated with a progressive lengthening of his corrected QT interval. ",24510469
1096,4,2_abstract_sentence,4,"On the day of presentation, he underwent an exercise test as part of his job requirements. ",24510469
1096,4,2_abstract_sentence,5,"While running, he felt lightheaded and experienced a syncopal event and cardiac arrest. ",24510469
1096,4,2_abstract_sentence,6,An automated external defibrillator was available that displayed polymorphic ventricular tachycardia. ,24510469
1096,4,2_abstract_sentence,7,The patient was successfully resuscitated. ,24510469
1096,4,2_abstract_sentence,8,"Although rare, this case suggests that flecainide can induce QT prolongation leading to torsades de pointes. ",24510469
1096,4,2_abstract_sentence,9,Clinicians should be aware and consider periodic evaluations with electrocardiograms. ,24510469
1096,5,1_title,0,Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.  ,24917414
1096,5,2_abstract_sentence,0,"It remains unclear whether flecainide, a Class I antiarrhythmic drug, improves left ventricular pressure gradient (LVPG) or symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). ",24917414
1096,5,2_abstract_sentence,1,"Our study evaluated the long-term  efficacy of flecainide, compared to disopyramide, when administered orally, on LVPG and symptoms in obstructive HCM patients. ",24917414
1096,5,2_abstract_sentence,2,"Among 164 obstructive HCM patients, 15 were administered oral flecainide therapy and 33 administered oral disopyramide therapy. ",24917414
1096,5,2_abstract_sentence,3,LVPG declined from 79.8Â Â±Â 36.6 to 39.2Â Â±Â 36.7Â mmHg (pÂ =Â 0.003) after flecainide therapy and from 74.5Â Â±Â 26.4 to 31.4Â Â±Â 24.8Â mmHg (pÂ <Â 0.001) after disopyramide therapy. ,24917414
1096,5,2_abstract_sentence,4,"The percent reduction in LVPG was -47.9Â Â±Â 43.2Â % in patients treated with flecainide, comparable to the results for those treated with disopyramide (-57.1Â Â±Â 33.0Â %; pÂ =Â 0.425). ",24917414
1096,5,2_abstract_sentence,5,We found no significant differences in improvement in NYHA functional class between patients  treated with flecainide and those treated with disopyramide (pÂ =Â 0.331). ,24917414
1096,5,2_abstract_sentence,6,"Patients treated with flecainide exhibited no significant adverse side effects, and there  was no need for myectomy or alcohol septal ablation to reduce LVPG and symptoms. ",24917414
1096,5,2_abstract_sentence,7," Improvements in LVPG and symptoms were similar in patients treated with flecainide and patients treated with disopyramide, suggesting that flecainide is  a potentially useful alternative for symptomatic obstructive HCM patients, particularly those with disopyramide-induced vagolytic side effects, narrow angle glaucoma, or prostatic hyperplasia and pre-existing urination difficulties. ",24917414
1096,5,2_abstract_sentence,8,"Our data must be viewed with caution, however, in view of the small number of study patients. ",24917414
1096,5,2_abstract_sentence,9,Flecainide therapy will require further proof of safety before it can be routinely recommended in patients with symptomatic obstructive HCM. ,24917414
1096,6,1_title,0,Arrhythmogenic effects by local left ventricular stretch: effects of flecainide and streptomycin.  ,24858181
1096,6,2_abstract_sentence,0,Mechanical stretch has been shown to provoke arrhythmia. ,24858181
1096,6,2_abstract_sentence,1,"We wanted to analyze ventricular arrhythmia induced by local left ventricular stretch in order to find out, where arrhythmias originate and whether they can be prevented pharmacologically. ",24858181
1096,6,2_abstract_sentence,2,Isolated rabbit hearts (Langendorff technique) were submitted  to increased left ventricular stretch at the left wall by insertion of an additional intraventricular balloon and adjusting the end-diastolic pressure (EDP) to 25 mmHg for 10 min followed by 20 min recovery at normal EDP of 5-8 mmHg. ,24858181
1096,6,2_abstract_sentence,3,Activation and repolarization processes were investigated by ventricular 256 electrode epicardial mapping. ,24858181
1096,6,2_abstract_sentence,4,"The hearts were treated during the whole procedure either with vehicle, 0.5 Î¼M flecainide (sodium channel blocker) or 100  Î¼M streptomycin (here used as stretch-activated ion-channel blocker). ",24858181
1096,6,2_abstract_sentence,5,"In addition, we performed a series of experiments, in which we enhanced EDP to 30 mmHg (global stretch instead of local stretch) by inflating the left ventricular  pressure balloon (strain, 0.148âÂ±â0.034). ",24858181
1096,6,2_abstract_sentence,6,Each series was performed with nâ=â6. ,24858181
1096,6,2_abstract_sentence,7,"Stretch resulted in local strain of 25% at the left wall together with a local slowing of the activation process at the left wall, in a change in the activation pattern, and in ventricular arrhythmia. ",24858181
1096,6,2_abstract_sentence,8,Coronary flow was not affected. ,24858181
1096,6,2_abstract_sentence,9,Ventricular arrhythmias originated from the border between the stretched area and the non-stretched region. ,24858181
1096,6,2_abstract_sentence,10,Flecainide and streptomycin reduced the prolongation of the activation process at the stretched left wall and mitigated the difference in total activation time between left and front wall but only partially prevented arrhythmia. ,24858181
1096,6,2_abstract_sentence,11,"In the additional global stretch experiments relative coronary flow and the other parameters remained unchanged, in particular TAT. ",24858181
1096,6,2_abstract_sentence,12,"Thus, in contrast to the local stretch series, there was no difference in the change in TAT between left and front wall. ",24858181
1096,6,2_abstract_sentence,13,Only rare single ventricular extrasystoles (<1/min; originating from LV (front and left wall) i.e. ,24858181
1096,6,2_abstract_sentence,14,from within the stretched region)  were seen during stretch (but not at the beginning) and during recovery. ,24858181
1096,6,2_abstract_sentence,15,Local left ventricular stretch can elicit ventricular arrhythmias. ,24858181
1096,6,2_abstract_sentence,16,Local slowing of electrical activation seems involved so that the difference in total activation time of the stretched free left wall and the non-stretched increased. ,24858181
905,0,1_title,0,An infant with cytomegalovirus-induced subacute thyroiditis.  ,18422033
905,1,1_title,0,Viruses and thyroiditis: an update.  ,19138419
905,1,2_abstract_sentence,0,Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases This review examines the data related to the role of viruses in the development of thyroiditis. ,19138419
905,1,2_abstract_sentence,1,Our research has been focused on human data. ,19138419
905,1,2_abstract_sentence,2,"We have reviewed virological data for each type of thyroiditis at different levels of evidence; epidemiological data, serological data or research on circulating viruses, direct evidence of thyroid tissue infection. ",19138419
905,1,2_abstract_sentence,3,Interpretation of epidemiological and serological data must be  cautious as they don't prove that this pathogen is responsible for the disease. ,19138419
905,1,2_abstract_sentence,4,"However, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (HFV) and mumps in subacute thyroiditis, for retroviruses (HTLV-1, HFV, HIV and SV40) in Graves's disease and for HTLV-1, enterovirus, rubella, mumps virus, HSV, EBV and parvovirus in Hashimoto's thyroiditis. ",19138419
905,1,2_abstract_sentence,5,"However, it remains to determine whether they are responsible for thyroid diseases or whether they are just innocent bystanders. ",19138419
905,1,2_abstract_sentence,6,"Further studies are needed to clarify the relationship between viruses and thyroid diseases, in order to develop new strategies for prevention and/or treatment. ",19138419
905,2,1_title,0,Subacute thyroiditis in the course of novel H1N1 influenza infection.  ,20960165
905,2,2_abstract_sentence,0,To describe the first documented case of subacute (De Quervain) thyroiditis in the course of novel H1N1 influenza infection. ,20960165
905,2,2_abstract_sentence,1,"This is a case report of a patient  diagnosed at the General Hospital ""G. ",20960165
905,2,2_abstract_sentence,2,"Hatzikosta"" of Ioannina, Greece. ",20960165
905,2,2_abstract_sentence,3,"A 55-year-old previously healthy male developed an influenza-like syndrome that was accompanied by severe neck pain, palpitations, weight loss, and disproportionately increased erythrocyte sedimentation rate. ",20960165
905,2,2_abstract_sentence,4,Polymerase chain reaction assay of pharyngeal swabs confirmed the diagnosis of novel H1N1 influenza infection. ,20960165
905,2,2_abstract_sentence,5,Serum thyroid-stimulating hormone was suppressed to zero and levels of free thyroxine and particularly triiodothyronine were increased. ,20960165
905,2,2_abstract_sentence,6,Technetium-99m-pertechnetate scintigraphy showed diffuse and inhomogeneous very low technetium trapping. ,20960165
905,2,2_abstract_sentence,7,The patient was treated with non-steroidal anti-inflammatory drugs and thyroid function gradually normalized without evolving to a hypothyroid phase. ,20960165
905,2,2_abstract_sentence,8,This is the first case of subacute thyroiditis associated with novel H1N1 influenza infection. ,20960165
905,2,2_abstract_sentence,9,"Furthermore, this is the first case to definitely demonstrate active influenza infection of any type concurrent  with thyroiditis, and one of the very rare similar cases for any active viral disease etiologically implicated in the pathogenesis of subacute thyroiditis. ",20960165
905,3,1_title,0,Subacute thyroiditis associated with positive antibodies to the Epstein-Barr virus.  ,11109652
905,3,2_abstract_sentence,0,Subacute thyroiditis is an inflammatory disorder of the thyroid caused probably by viruses. ,11109652
905,3,2_abstract_sentence,1,"It is clinically characterized by the presence of anterior cervical pain and/or painful goiter, and rarely as fever of unknown origin or as prolonged fever syndrome. ",11109652
905,3,2_abstract_sentence,2,"We report a case of a 49-year-old female admitted to the hospital because of fever during last month, leukocytosis and accelerated erythrocyte sedimentation rate. ",11109652
905,3,2_abstract_sentence,3,"Following observation, slight tenderness over the thyroid gland and signs of hyperthyroidism occurred. ",11109652
905,3,2_abstract_sentence,4,"After the laboratory studies, low thyroidal radioactive iodine uptake and fine-needle aspiration cytology (FNAC) of thyroid, she was diagnosed of subacute thyroiditis with hyperthyroidism. ",11109652
905,3,2_abstract_sentence,5,We believe that the etiologic agent was the Epstein-Barr virus because heterophile and Epstein-Barr virus-specific antibodies were positive. ,11109652
905,3,2_abstract_sentence,6,The patient was treated with acetaminophen (1.500 mg/day) with prompt and complete resolution of the clinical and laboratory abnormalities. ,11109652
905,3,2_abstract_sentence,7,There has been no recurrence of the disease during a 1 year follow-up. ,11109652
905,4,1_title,0,Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan.  ,23227861
905,4,2_abstract_sentence,0,"BACKGROUND: Oral glucocorticoids are administered in moderate and severe cases of subacute thyroiditis (SAT), providing dramatic relief from pain and fever. ",23227861
905,4,2_abstract_sentence,1,"However, there have been no reports regarding the optimal dose of prednisolone (PSL) for treatment of SAT. ",23227861
905,4,2_abstract_sentence,2,"In this study, we used 15 mg/day of PSL as the initial dosage and tapered it by 5 mg every 2 weeks. ",23227861
905,4,2_abstract_sentence,3,We assessed the effectiveness of this treatment protocol. ,23227861
905,4,2_abstract_sentence,4,METHODS: We examined 384 consecutive and untreated patients with SAT who visited  our thyroid clinic between February 2005 and December 2008. ,23227861
905,4,2_abstract_sentence,5,"We excluded patients  who did not fit our protocol, and the final number of subjects was 219. ",23227861
905,4,2_abstract_sentence,6,"When patients complained of pain in their neck or C-reactive protein (CRP) was still high, physicians were able to extend the tapering of the dose of PSL or increase  it at 2-week intervals. ",23227861
905,4,2_abstract_sentence,7,The endpoint of the study was the duration of the PSL medication. ,23227861
905,4,2_abstract_sentence,8,We also compared the severity of thyrotoxicosis and rate of hypothyroidism after SAT between the short medication group (patients who recovered within 6 weeks) and long medication group (patients who recovered in 12 weeks or more). ,23227861
905,4,2_abstract_sentence,9,"RESULTS: The number of patients whose thyroiditis improved within 6 weeks and did not recur was 113 (51.6%), and 61 (27.9%) improved within 7 to 8 weeks and did not have a recurrence. ",23227861
905,4,2_abstract_sentence,10,The longest duration was 40 weeks. ,23227861
905,4,2_abstract_sentence,11,Seven patients (3.2%) needed increases in the dosage of PSL. ,23227861
905,4,2_abstract_sentence,12,Thyroid hormone (free thyroxine and free triiodothyronine) levels measured at the initial visit in the short medication group were significantly higher than those in the long medication group (p<0.05). ,23227861
905,4,2_abstract_sentence,13,"Serum CRP, male-to-female ratio, body weight, and age showed no differences between the two groups. ",23227861
905,4,2_abstract_sentence,14,There were no differences in the rate of hypothyroidism after SAT between the two groups (p=0.0632). ,23227861
905,4,2_abstract_sentence,15,"CONCLUSIONS: The treatment protocol that we employed had 15 mg/day of PSL as the  initial dosage for the treatment of SAT, with tapering by 5 mg every 2 weeks, and was effective and safe for Japanese patients. ",23227861
905,4,2_abstract_sentence,16,"However, 20% of patients with SAT needed longer than 8 weeks to recover from the inflammation. ",23227861
905,5,1_title,0,Subacute thyroiditis (de Quervain's) due to influenza A: presenting as fever of unknown origin (FUO).  ,22819125
905,5,2_abstract_sentence,0,Subacute (de Quervain's) thyroiditis is a rare but important cause of fever of unknown origin. ,22819125
905,5,2_abstract_sentence,1,"Most cases of subacute thyroiditis are caused by a variety of viruses, for example, Coxsackie, cytomegalovirus, Epstein-Barr virus, and adenovirus. ",22819125
905,5,2_abstract_sentence,2,Influenza immunization or infection may cause subacute thyroiditis. ,22819125
905,5,2_abstract_sentence,3,We present the first reported case of a fever of unknown origin due to seasonal influenza A in a 67-year-old woman. ,22819125
905,6,1_title,0,Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C.  ,19627727
905,6,2_abstract_sentence,0,Chronic hepatitis C virus infection may be associated with extrahepatic manifestations. ,19627727
905,6,2_abstract_sentence,1,Thyroid disease related to chronic hepatitis C virus infection has been associated with interferon-alpha treatment. ,19627727
905,6,2_abstract_sentence,2,"We present the case of a 40-year-old woman with chronic hepatitis C virus infection, who developed subacute thyroiditis during treatment with pegylated interferon-alpha plus ribavirin. ",19627727
905,7,1_title,0,Subacute thyroiditis following the H1N1 vaccine.  ,20671410
905,8,1_title,0,Can subacute thyroiditis be associated with acute hepatitis B virus infection?  ,22527824
905,9,1_title,0,The incidence of thyroid stimulating blocking antibodies during the hypothyroid phase in patients with subacute thyroiditis.  ,1856259
905,9,2_abstract_sentence,0,"The etiology of subacute (de Quervain's) thyroiditis (SAT) is uncertain, although it probably represents a nonspecific inflammatory response by the thyroid to a variety of viruses. ",1856259
905,9,2_abstract_sentence,1,It has been suggested that nonimmune processes are involved in SAT patients who have negative autoantibody titers. ,1856259
905,9,2_abstract_sentence,2,"The disease has a variable course; although it is self-limited in most cases, some patients develop transient hypothyroidism, and others do not during the recovery period. ",1856259
905,9,2_abstract_sentence,3,"The present study was performed to evaluate the occurrence of TSH receptor antibody (TRAb), measured by RRA (TSH binding inhibitor), TRAb measured by stimulation assay (thyroid-stimulating antibody), and TRAb measured by blocking assay [TSH-blocking antibody (TSH-BAb)] activity in 68 patients with SAT who had negative autoantibody titers. ",1856259
905,9,2_abstract_sentence,4,"The patients were divided into 2 groups: group I, 31 patients who developed hypothyroidism during the recovery period; and group II, 37 patients who remained euthyroid during recovery. ",1856259
905,9,2_abstract_sentence,5,"Positive immunoglobulin activity occurred in about 20% of group I patients during follow-up, but in only  3% of group II patients. ",1856259
905,9,2_abstract_sentence,6,"About 20% of group I patients developed positive TSH-BAb activity and were hypothyroid, requiring exogenous hormone therapy for 1.2-3.5 yr, whereas hypothyroidism was relatively transient in group I patients who had negative TSH-BAb activity (2-6 months). ",1856259
905,9,2_abstract_sentence,7,"Although increased TSH-BAb activity may account for hypothyroidism in some patients with SAT, the precise mechanism for the development of transient hypothyroidism in SAT remains enigmatic. ",1856259
905,10,1_title,0,Effects of human recombinant alpha and gamma and of highly purified natural beta  interferons on simian Spumavirinae prototype (simian foamy virus 1) multiplication in human cells.  ,1691523
905,10,2_abstract_sentence,0,"The present study demonstrates the inhibitory effect of human recombinant interferons (r-Hu-IFN) alpha and gamma, and that of highly purified natural human interferon beta on the replication of simian foamy virus type 1 (SFV1) in human AV3-cell cultures. ",1691523
905,10,2_abstract_sentence,1,All IFN led to strong inhibition of the SFV1 cytopathic effect. ,1691523
905,10,2_abstract_sentence,2,Electron microscopy showed a 70 to 95% decrease in viral particles. ,1691523
905,10,2_abstract_sentence,3,Significant inhibition of virus-associated reverse transcriptase activity was found in supernatant fluids of infected IFN-treated cultures. ,1691523
905,10,2_abstract_sentence,4,Metabolic labelling of the virus confirmed the inhibition of extracellular release of SFV1. ,1691523
905,10,2_abstract_sentence,5,PAGE analysis of immunoprecipitates indicated a reduction in viral-specific protein bands. ,1691523
905,10,2_abstract_sentence,6,"Altogether, these results indicate that the mechanism of inhibition of Spumavirinae infection by interferon differs from that described for the other Retroviridae, and particularly for types B, C and D viruses. ",1691523
905,10,2_abstract_sentence,7,Our data is of therapeutic interest since Spumavirinae have been linked to pathological processes such as de Quervain thyroiditis. ,1691523
905,11,1_title,0,Clinical characteristics of 852 patients with subacute thyroiditis before treatment.  ,18421188
905,11,2_abstract_sentence,0,OBJECTIVE: Subacute thyroiditis (SAT) is a transient inflammatory disease of the  thyroid. ,18421188
905,11,2_abstract_sentence,1,We evaluated the clinical characteristics based on laboratory and imaging studies in patients with SAT before treatment. ,18421188
905,11,2_abstract_sentence,2,PATIENTS: We reviewed the medical records of 852 patients (107 men and 745 women) with SAT who visited our thyroid clinic at Kuma Hospital from 1996 through 2004. ,18421188
905,11,2_abstract_sentence,3,"RESULTS: SAT developed most often in female patients aged 40 to 50 years, with significant seasonal clusters during summer to early autumn. ",18421188
905,11,2_abstract_sentence,4,"While the rates of any virus infections and diseases did not differ from those in the general population, recurrent episodes of SAT at intervals of 13.6+/-5.6 years accounted  for 1.6% of all cases. ",18421188
905,11,2_abstract_sentence,5,"At the onset of SAT, 28.2% of patients had temperatures greater than 38 degrees C and typical symptoms associated with thyrotoxicosis developed in more than 60% of patients. ",18421188
905,11,2_abstract_sentence,6,"Before treatment, most of the abnormal laboratory findings associated with thyrotoxicosis, inflammation, and liver dysfunction reached peak levels within 1 week after onset. ",18421188
905,11,2_abstract_sentence,7,Ultrasound examination showed that half of the patients with unilateral thyroid pain presented with bilateral hypoechogenic area in the thyroid and the rate of bilateral hypoechogenic area tended to increase 2 months after onset. ,18421188
905,11,2_abstract_sentence,8,CONCLUSION: Laboratory studies of thyroid dysfunction and inflammation related to SAT presented peak levels within 1 week after onset. ,18421188
905,12,1_title,0,Cellular composition of subacute thyroiditis. an immunohistochemical study of six cases.  ,12608662
905,12,2_abstract_sentence,0,"To clarify the cellular composition of subacute thyroiditis, histologic and immunohistochemical studies were performed. ",12608662
905,12,2_abstract_sentence,1,"Histologically, the lesion presented  a patchy distribution of non-caseous granulomas comprising colloid, small lymphocytes, neutrophils, macrophages with or without epithelioid features, and multinucleated giant cells of foreign body type. ",12608662
905,12,2_abstract_sentence,2,"In addition, numerous plasmacytoid monocytes were closely associated with the granulomas. ",12608662
905,12,2_abstract_sentence,3,"The giant cells were CD68+, thyroglobulin- and cytokeratin-. ",12608662
905,12,2_abstract_sentence,4,"Usually, small lymphocytes in  the granulomas are CD3+, CD8+, CD45RO+ cytotoxic T-cells. ",12608662
905,12,2_abstract_sentence,5,"In the non-granulomatous lesion, the follicles were often infiltrated by CD8+ T-lymphocytes, plasmacytoid monocytes and histiocytes, resulting in disrupted basement membrane and rupture of the follicles. ",12608662
905,12,2_abstract_sentence,6,Lymphoid follicles with or without active germinal centers were not observed. ,12608662
905,12,2_abstract_sentence,7,"Moreover, no residual follicular dendritic cell networks were detected by CD23 and CAN.42 immunostains. ",12608662
905,12,2_abstract_sentence,8,"In the interfollicular area, scattered plasma cells were observed among infiltrating cells. ",12608662
905,12,2_abstract_sentence,9,Neither human herpes virus 8 nor EBER-positive cells were detected in the six patients. ,12608662
905,12,2_abstract_sentence,10,The findings of our study suggest that cellular immune response may play an important role in the pathogenesis of subacute thyroiditis. ,12608662
905,13,1_title,0,Quick recovery of myocardium damage in a case of subacute thyroiditis.  ,22459018
905,13,2_abstract_sentence,0,We describe a case of quick recovery of myocardium damage in a 15-year-old adolescent with subacute thyroiditis. ,22459018
905,13,2_abstract_sentence,1,"After 1 week of admission, his cardiovascular status began to show signs of improvement accompanied by the recovery of electrocardiogram and indicators of myocardial damage. ",22459018
905,13,2_abstract_sentence,2,"We speculate that myocardium damage associated with subacute thyroiditis is a complication of  common virus, although we did not detect any abnormal virus antibody and deoxyribonucleic acid in the patient's serum. ",22459018
905,14,1_title,0,de Quervain thyroiditis in a young boy following hand-foot-mouth disease.  ,20886354
905,14,2_abstract_sentence,0,"de Quervain thyroiditis, also known as subacute thyroiditis, is a self-limited inflammatory disease of the thyroid gland. ",20886354
905,14,2_abstract_sentence,1,It is extremely rare in children. ,20886354
905,14,2_abstract_sentence,2,"The  hallmarks for diagnosis are painful thyroid enlargement, elevated inflammatory markers, and decreased uptake of the thyroid gland on thyroid scintigraphy. ",20886354
905,14,2_abstract_sentence,3,Viral infection has been proposed to be associated with de Quervain thyroiditis. ,20886354
905,14,2_abstract_sentence,4,Coxsackie virus has been reported to be one of the viruses associated with the disease. ,20886354
905,14,2_abstract_sentence,5,"To our knowledge, childhood de Quervain thyroiditis associated with hand-foot-mouth disease caused by coxsackie infection has never been reported. ",20886354
905,14,2_abstract_sentence,6,We report a 2.7-year-old boy who presented with typical features of de Quervain thyroiditis following hand-foot-mouth disease caused by coxsackie B4 infection. ,20886354
905,14,2_abstract_sentence,7,"He had a brief thyrotoxic phase initially, followed by transient hypothyroid phase and euthyroidism thereafter. ",20886354
905,14,2_abstract_sentence,8,"His thyroid scintigraphy showed a typical faint uptake at the diagnosis, and an improvement of the thyroid scan and uptake  was shown 8 weeks later. ",20886354
905,14,2_abstract_sentence,9,He was treated with prednisolone and nearly complete resolution was documented within 2 months. ,20886354
905,14,2_abstract_sentence,10,Careful evaluation of the patient led  to the correct diagnosis and appropriate management. ,20886354
905,15,1_title,0,Amyloid goiter presented as a subacute thyroiditis-like symptom in a patient with hypersensitivity vasculitis.  ,9790279
905,15,2_abstract_sentence,0,"We present a 25-year-old woman with amyloid goiter due to hypersensitivity vasculitis, who developed transient thyrotoxicosis resembling subacute thyroiditis. ",9790279
905,15,2_abstract_sentence,1,"She received prednisolone (20 mg/ day) for three years for hypersensitivity vasculitis, and was diagnosed as having secondary amyloidosis by biopsies of the stomach, rectum and kidneys. ",9790279
905,15,2_abstract_sentence,2,"She noticed neck swelling with severe right neck tenderness, palpitation, hyperhidrosis and weight loss. ",9790279
905,15,2_abstract_sentence,3,"An elastic firm diffuse goiter was palpable, and the upper pole of the right lobe was extremely tender. ",9790279
905,15,2_abstract_sentence,4,"Her serum free T4 and T3 levels were high, and the serum TSH was suppressed to subnormal. ",9790279
905,15,2_abstract_sentence,5,She was positive for serum C-reactive protein. ,9790279
905,15,2_abstract_sentence,6,Anti-thyroidal autoantibodies were all negative. ,9790279
905,15,2_abstract_sentence,7,Her thyrotoxicosis subsided spontaneously within one week. ,9790279
905,15,2_abstract_sentence,8,"Serum titers of antibodies to various viruses were unchanged during the clinical course for two weeks, but she was positive for HLA  B35. ",9790279
905,15,2_abstract_sentence,9,Examination of a needle-biopsy specimen of the thyroid gland showed extensive amyloid deposition and no evidence of subacute thyroiditis. ,9790279
905,15,2_abstract_sentence,10,We considered her transient thyrotoxicosis to be associated with amyloid goiter. ,9790279
905,15,2_abstract_sentence,11,"The clinical course of this case was similar to the subacute thyroiditis-like syndrome, first described by Ikenoue et al. ",9790279
905,15,2_abstract_sentence,12,"When patients with primary or secondary amyloidosis have symptoms and signs of subacute thyroiditis, but develop an unusual course, amyloid goiter should be considered. ",9790279
905,16,1_title,0,Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus.  ,10971829
905,16,2_abstract_sentence,0,"Autoimmune thyroiditis has been frequently reported during interferon monotherapy for hepatitis C, but there are few reports concerning subacute thyroiditis. ",10971829
905,16,2_abstract_sentence,1,"Recently, combination therapy of IFN plus ribavirin has become the preferred therapeutic schedule for chronic hepatitis C. ",10971829
905,16,2_abstract_sentence,2,"Similarly to interferon monotherapy, there are no reports concerning subacute thyroiditis during combination therapy. ",10971829
905,16,2_abstract_sentence,3,We described four episodes of subacute thyroiditis occurring in three patients during antiviral combination therapy. ,10971829
905,16,2_abstract_sentence,4,"All patients had symptoms compatible with hyperthyroidism, which could be misdiagnosed as IFN side-effects. ",10971829
905,16,2_abstract_sentence,5,The antiviral treatment was continued in all three patients and thyroid function  increased progressively with pharmacological treatment for hyperthyroidism. ,10971829
905,16,2_abstract_sentence,6,"We concluded that subacute thyroiditis may be a complication of combination antiviral therapy and should be investigated in patients presenting with compatible symptoms, in order to differentiate from IFN side-effects. ",10971829
905,17,1_title,0,Subacute thyroiditis.  ,4936649
905,18,1_title,0,Subacute thyroiditis presenting as pyrexia of unknown origin in a patient with human immunodeficiency virus infection.  ,10525005
905,19,1_title,0,Simultaneous occurrence of subacute thyroiditis and Graves' disease.  ,22136271
905,19,2_abstract_sentence,0,BACKGROUND: Rare cases of Graves' disease occurring years after subacute thyroiditis (SAT) have been reported. ,22136271
905,19,2_abstract_sentence,1,"Here, we present the first known case of simultaneous occurrence of Graves' disease and SAT. ",22136271
905,19,2_abstract_sentence,2,"PATIENT FINDINGS: A 41-year-old woman presented with 10 days of neck pain, dysphagia, and hyperthyroid symptoms. ",22136271
905,19,2_abstract_sentence,3,"Neck pain had initially started at the base of the right anterior neck and gradually spread to her upper chest, the left side of her neck, and bilateral ears. ",22136271
905,19,2_abstract_sentence,4,Physical examination revealed a heart rate of 110 beats/minute and a diffusely enlarged tender thyroid gland without evidence of orbitopathy. ,22136271
905,19,2_abstract_sentence,5,There was a resting tremor of the fingers and brisk deep tendon reflexes. ,22136271
905,19,2_abstract_sentence,6,"Laboratory values: thyrotropin<0.01âmcIU/mL (nL 0.39-5.33), free thyroxine 2.0âng/dL (nL 0.59-1.60), free T3 6.6âpg/mL (nL 2.3-4.2), thyroglobulin 20.1âng/mL (nL 2.0-35.0), thyroglobulin antibody 843âIU/mL (nL 0-80), thyroperoxidase antibody 130âIU/mL (nL 0-29), thyroid stimulating hormone receptor antibody 22.90âIU/L (nL<1.22), thyroid stimulating immunoglobulins 299 units (nL<140), erythrocyte sedimentation rate 120âmm/h (nL 0-20), and C-reactive protein 1.117âmg/dL (nL 0-0.5). ",22136271
905,19,2_abstract_sentence,7,"Human leukocyte antigen (HLA) typing revealed DRB1, DR8, B35, B39, DQB1, DQ4, and DQ5. ",22136271
905,19,2_abstract_sentence,8,A thyroid ultrasound showed an enlarged  heterogeneous gland with mild hypervascularity. ,22136271
905,19,2_abstract_sentence,9,Fine-needle aspiration (FNA) biopsies of both thyroid lobes revealed granulomatous thyroiditis. ,22136271
905,19,2_abstract_sentence,10,The thyroid scan showed a diffusely enlarged gland and heterogeneous trapping. ,22136271
905,19,2_abstract_sentence,11,There was a focal area of relatively increased radiotracer accumulation in the right upper pole. ,22136271
905,19,2_abstract_sentence,12,The 5-hour uptake ((123)I) was 6.6% (nL 4-15). ,22136271
905,19,2_abstract_sentence,13,The patient was symptomatically treated. ,22136271
905,19,2_abstract_sentence,14,"Over the next several weeks, she developed hypothyroidism requiring levothyroxine treatment. ",22136271
905,19,2_abstract_sentence,15,SUMMARY: This case illustrates a rare simultaneous occurrence of Graves' disease  and SAT. ,22136271
905,19,2_abstract_sentence,16,Previous case studies have shown that Graves' disease may develop months to years after an episode of SAT. ,22136271
905,19,2_abstract_sentence,17,A strong family history of autoimmune thyroid disorders was noted in this patient. ,22136271
905,19,2_abstract_sentence,18,Genetic predilection was also shown by HLA typing. ,22136271
905,19,2_abstract_sentence,19,"CONCLUSION: Although the occurrence of SAT with Graves' disease may be coincidental, SAT-induced autoimmune alteration may promote the development of Graves' disease in susceptible patients. ",22136271
905,19,2_abstract_sentence,20,"Genetically mediated mechanisms, as seen in this patient by HLA typing and a strong family history, may also be involved. ",22136271
905,20,1_title,0,Odynophagia after viral infection.  ,15332726
905,21,1_title,0,Atypical subacute thyroiditis caused by Epstein-Barr virus infection in a three-year-old girl.  ,16279854
905,21,2_abstract_sentence,0,Subacute thyroiditis is a rare disease in childhood and is considered postviral in origin. ,16279854
905,21,2_abstract_sentence,1,"Epstein-Barr virus (EBV) involvement has been suspected, but just once demonstrated in an adult female. ",16279854
905,21,2_abstract_sentence,2,We report a case of subacute thyroiditis during  infectious mononucleosis in a 3-year-old girl. ,16279854
905,21,2_abstract_sentence,3,"The diagnosis of infectious mononucleosis was supported, in addition to the typical clinical symptoms, by presence of EBV DNA both in plasma and leukocytes. ",16279854
905,21,2_abstract_sentence,4,"Subacute thyroiditis was diagnosed based on elevated thyroid hormone levels with thyrotropin (TSH) suppression, high inflammation markers and almost absent (99)TC uptake by thyroid. ",16279854
905,21,2_abstract_sentence,5,Moreover after 3 months from diagnosis thyroid function went back to normal as well as the (99)TC uptake. ,16279854
905,22,1_title,0,Failure in detection of Epstein-Barr virus and cytomegalovirus in specimen obtained by fine needle aspiration biopsy of thyroid in patients with subacute thyroiditis.  ,9915102
905,22,2_abstract_sentence,0,"To study the possible role of viral infection in the etiology of subacute thyroiditis (SAT), we measured serum virus-specific antibodies to measles, rubella, mumps, type I herpes, chicken pox, human parvovirus B19 and cytomegalovirus (CMV) in 10 patients with SAT during the course of illness. ",9915102
905,22,2_abstract_sentence,1,"In spite of the presence of IgG to each virus in more than 70% of patients, no significant changes in the IgG titers were observed except those to measles, rubella, chicken pox or CMV in only 10% of patients, respectively. ",9915102
905,22,2_abstract_sentence,2,Then we examined the presence of virus DNA in specimens of 9 patients with SAT obtained by fine-needle aspiration biopsy (FNAB) of the thyroid. ,9915102
905,22,2_abstract_sentence,3,DNA was amplified to detect that of Epstein-Barr virus and CMV by polymerase chain reaction. ,9915102
905,22,2_abstract_sentence,4,"However,  none of them were detected in all the specimens. ",9915102
905,22,2_abstract_sentence,5,"Whereas previous studies suggest the involvement of viral infection in the pathogenesis of SAT, we failed to demonstrate significant changes in serum antiviral antibody titers or to detect viral DNA in the specimens obtained by FNAB of the thyroid. ",9915102
905,22,2_abstract_sentence,6,Thus further studies  are clearly required to establish the definite role of viral infection in the pathogenesis of SAT. ,9915102
2763,0,1_title,0,The Oral Bacterial Communities of Children with Well-Controlled HIV Infection and without HIV Infection.  ,26146997
2763,0,2_abstract_sentence,0,The oral microbial community (microbiota) plays a critical role in human health and disease. ,26146997
2763,0,2_abstract_sentence,1,"Alterations in the oral microbiota may be associated with disorders  such as gingivitis, periodontitis, childhood caries, alveolar osteitis, oral candidiasis and endodontic infections. ",26146997
2763,0,2_abstract_sentence,2,"In the immunosuppressed population, the spectrum of potential oral disease is even broader, encompassing candidiasis, necrotizing gingivitis, parotid gland enlargement, Kaposi's sarcoma, oral warts and other diseases. ",26146997
2763,0,2_abstract_sentence,3,"Here, we used 454 pyrosequencing of bacterial 16S rRNA genes  to examine the oral microbiome of saliva, mucosal and tooth samples from HIV-positive and negative children. ",26146997
2763,0,2_abstract_sentence,4,Patient demographics and clinical characteristics were collected from a cross-section of patients undergoing routine dental care. ,26146997
2763,0,2_abstract_sentence,5,Multiple specimens from different sampling sites in the mouth were collected for each patient. ,26146997
2763,0,2_abstract_sentence,6,"The goal of the study was to observe the potential diversity of the oral microbiota among individual patients, sample locations, HIV status and various dental characteristics. ",26146997
2763,0,2_abstract_sentence,7,"We found that there were significant differences in the microbiome among the enrolled patients, and between sampling locations. ",26146997
2763,0,2_abstract_sentence,8,"The analysis was complicated by uneven enrollment in  the patient cohorts, with only five HIV-negative patients enrolled in the study and by the rapid improvement in the health of HIV-infected children between the time the study was conceived and completed. ",26146997
2763,0,2_abstract_sentence,9,The generally good oral health of the HIV-negative patients limited the number of dental plaque samples that could be collected. ,26146997
2763,0,2_abstract_sentence,10,"We did not identify significant differences between well-controlled HIV-positive patients and HIV-negative controls, suggesting that well-controlled  HIV-positive patients essentially harbor similar oral flora compared to patients  without HIV. ",26146997
2763,0,2_abstract_sentence,11,Nor were significant differences in the oral microbiota identified between different teeth or with different dental characteristics. ,26146997
2763,0,2_abstract_sentence,12,Additional studies are needed to better characterize the oral microbiome in children and those with poorly-controlled HIV infections. ,26146997
2895,0,1_title,0,Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes.  ,29127238
2895,0,2_abstract_sentence,0,Comment in     Am J Physiol Heart Circ Physiol. ,29127238
2895,0,2_abstract_sentence,1,2018 Apr 1;314(4):H772-H775. ,29127238
2895,1,1_title,0,Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis.  ,29274359
2895,1,2_abstract_sentence,0,Ferroptosis is a form of oxidative cell death and has become a chemotherapeutic target for cancer treatment. ,29274359
2895,1,2_abstract_sentence,1,"BAY 11-7085 (BAY), which is a well-known IÎºBÎ± inhibitor, suppressed viability in cancer cells via induction of ferroptotic death in an NF-ÎºB-independent manner. ",29274359
2895,1,2_abstract_sentence,2,"Reactive oxygen species scavenging, relief  of lipid peroxidation, replenishment of glutathione and thiol-containing agents,  as well as iron chelation, rescued BAY-induced cell death. ",29274359
2895,1,2_abstract_sentence,3,"BAY upregulated a variety of Nrf2 target genes related to redox regulation, particularly heme oxygenase-1 (HO-1). ",29274359
2895,1,2_abstract_sentence,4,Studies with specific inhibitors and shRNA interventions suggested that the hierarchy of induction is Nrf2-SLC7A11-HO-1. ,29274359
2895,1,2_abstract_sentence,5,"SLC7A11 inhibition by erastin, sulfasalazine, or shRNA interference sensitizes BAY-induced cell death. ",29274359
2895,1,2_abstract_sentence,6,Overexperession of SLC7A11 attenuated BAY-inhibited cell  viability. ,29274359
2895,1,2_abstract_sentence,7,The ferroptotic process induced by hHO-1 overexpression further indicated that HO-1 is a key mediator of BAY-induced ferroptosis that operates through cellular redox regulation and iron accumulation. ,29274359
2895,1,2_abstract_sentence,8,"BAY causes compartmentalization of HO-1 into the nucleus and mitochondrion, and followed mitochondrial dysfunctions, leading to lysosome targeting for mitophagy. ",29274359
2895,1,2_abstract_sentence,9,"In this  study, we first discovered that BAY induced ferroptosis via Nrf2-SLC7A11-HO-1 pathway and HO-1 is a key mediator by responding to the cellular redox status. ",29274359
2895,2,1_title,0,To eat or not to eat-the metabolic flavor of ferroptosis.  ,29175614
2895,2,2_abstract_sentence,0,"Ferroptosis is a newly defined iron-dependent, non-apoptotic mode of cell death with necrotic morphology. ",29175614
2895,2,2_abstract_sentence,1,"Distinctive from other death mechanisms, ferroptosis requires cellular iron and lipid peroxides, and is dictated by specific cellular  metabolic processes. ",29175614
2895,2,2_abstract_sentence,2,"Importantly, ferroptosis has been implicated in a plethora of human diseases. ",29175614
2895,2,2_abstract_sentence,3,This paper reviews the recent advances and outstanding questions of the field by focusing on the role of cellular metabolism in ferroptosis. ,29175614
2895,2,2_abstract_sentence,4,The relevance of ferroptosis to disease and therapy is also discussed. ,29175614
2895,3,1_title,0,Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells.  ,28515173
2895,3,2_abstract_sentence,0,Comment in     Am J Physiol Renal Physiol. ,28515173
2895,3,2_abstract_sentence,1,2017 Oct 1;313(4):F959-F960. ,28515173
2895,4,1_title,0,Ferroptosis: A Novel Anti-tumor Action for Cisplatin.  ,28494534
2895,4,2_abstract_sentence,0,"PURPOSE: Ferroptosis is a new mode of regulated cell death, which is completely distinct from other cell death modes based on morphological, biochemical, and genetic criteria. ",28494534
2895,4,2_abstract_sentence,1,"This study evaluated the therapeutic role of ferroptosis in classic chemotherapy drugs, including the underlying mechanism. ",28494534
2895,4,2_abstract_sentence,2,MATERIALS AND METHODS: Cell viabilitywas detected by using the methylthiazoltetrazlium dye uptake method. ,28494534
2895,4,2_abstract_sentence,3,"RNAiwas used to knockout iron-responsive element binding protein 2, and polymerase chain reaction, western blot was used to evaluate the efficiency. ",28494534
2895,4,2_abstract_sentence,4,Intracellular reduced glutathione level and glutathione peroxidases activitywere determined by related assay kit. ,28494534
2895,4,2_abstract_sentence,5,Intracellularreactive oxygen species levelswere determined by flowcytometry. ,28494534
2895,4,2_abstract_sentence,6,Electron microscopywas used to observe ultrastructure changes in cell. ,28494534
2895,4,2_abstract_sentence,7,"RESULTS: Among five chemotherapeutic drugs screened in this study, cisplatin was  found to be an inducer for both ferroptosis and apoptosis in A549 and HCT116 cells. ",28494534
2895,4,2_abstract_sentence,8,The depletion of reduced glutathione caused by cisplatin and the inactivation of glutathione peroxidase played the vital role in the underlying mechanism. ,28494534
2895,4,2_abstract_sentence,9,"Besides, combination therapy of cisplatin and erastin showed significant synergistic effect on their anti-tumor activity. ",28494534
2895,4,2_abstract_sentence,10,"CONCLUSION: Ferroptosis had great potential to become a new approach in anti-tumor therapies and make up for some classic drugs, which open up a new way  for their utility in clinic. ",28494534
960,0,1_title,0,Paternal origin of FGFR3 mutations in Muenke-type craniosynostosis.  ,15241680
960,0,2_abstract_sentence,0,"Muenke syndrome, also known as FGFR3-associated coronal synostosis, is defined molecularly by the presence of a heterozygous nucleotide transversion, c.749C>G,  encoding the amino acid substitution Pro250Arg, in the fibroblast growth factor receptor type 3 gene (FGFR3). ",15241680
960,0,2_abstract_sentence,1,"This frequently occurs as a new mutation, manifesting one of the highest documented rates for any transversion in the human genome. ",15241680
960,0,2_abstract_sentence,2,"To understand the biology of this mutation, we have investigated its parental origin, and the ages of the parents, in 19 families with de novo c.749C>G mutations. ",15241680
960,0,2_abstract_sentence,3,All ten informative cases originated from the paternal allele (95% confidence interval 74-100% paternal); the average paternal age at birth overall was 34.7 years. ,15241680
960,0,2_abstract_sentence,4,"An exclusive paternal origin of mutations, and increased  paternal age, were previously described for a different mutation (c.1138G>A) of the FGFR3 gene causing achondroplasia, as well as for mutations of the related FGFR2 gene causing Apert, Crouzon and Pfeiffer syndromes. ",15241680
960,0,2_abstract_sentence,5,We conclude that similar biological processes are likely to shape the occurrence of this c.749C>G  mutation as for other mutations of FGFR3 as well as FGFR2. ,15241680
960,1,1_title,0,Trigonocephaly in Muenke syndrome.  ,17036334
960,1,2_abstract_sentence,0,Saethre-Chotzen syndrome is caused by mutations in the TWIST gene on chromosome 7p21.2. ,17036334
960,1,2_abstract_sentence,1,"However, Muenke et al. ",17036334
960,1,2_abstract_sentence,2,[(1997); Am J Hum Genet 91: 555-564] described a new subgroup carrying the Pro250Arg mutation in the fibroblast growth factor receptor (FGFR) 3 gene on chromosome 4p16. ,17036334
960,1,2_abstract_sentence,3,Uni or bicoronal synostosis appears to be the main clinical finding in both syndromes. ,17036334
960,1,2_abstract_sentence,4,We observed trigonocephaly as a new manifestation in Muenke syndrome. ,17036334
960,1,2_abstract_sentence,5,"As a consequence we advise to routinely perform mutation analysis of the FGFR1, 2, and 3 genes in children with non-syndromic trigonocephaly. ",17036334
960,2,1_title,0,Significant phenotypic variability of Muenke syndrome in identical twins.  ,19449410
960,2,2_abstract_sentence,0,"Muenke syndrome (MS), also known as Muenke nonsyndromic coronal craniosynostosis, is an autosomal dominant condition which can be distinguished from the more common forms of acrocephalosyndactyly but presents a significant variable phenotype. ",19449410
960,2,2_abstract_sentence,1,We report on a set of identical twins with a de novo C749G mutation in the FGFR3 gene codon 250 after a pregnancy complicated by prenatal exposure to Nortriptyline. ,19449410
960,2,2_abstract_sentence,2,These patients illustrate the variable expressivity of MS in association with an identical gene mutation. ,19449410
960,3,1_title,0,Sudden infant death in a patient with FGFR3 P250R mutation.  ,17103449
960,3,2_abstract_sentence,0,"P250R mutation in the FGFR3 gene also known as Muenke syndrome is associated with coronal craniosynostosis, sensorineural deafness, craniofacial, and digital abnormalities. ",17103449
960,3,2_abstract_sentence,1,"We report a family with this mutation associated with sudden death in an affected newborn, most probably due to upper airway obstruction. ",17103449
960,4,1_title,0,A familial case of Muenke syndrome. Diverse expressivity of the FGFR3 Pro252Arg mutation--case report and review of the literature.  ,24168007
960,4,2_abstract_sentence,0,"Muenke is a fibroblast growth factor receptor 3 (FGFR-3)-associated syndrome, which was first described in late 1990 s. ",24168007
960,4,2_abstract_sentence,1,"Muenke syndrome is an autosomal dominant disorder characterized mainly by coronal suture craniosynostosis, hearing impairment and intellectual disability. ",24168007
960,4,2_abstract_sentence,2,The syndrome is defined molecularly by a unique point mutation c.749C > G in exon 7 of the FGFR3 gene which results to an amino acid substitution p.Pro250Arg of the protein product. ,24168007
960,4,2_abstract_sentence,3,"Despite the fact that the mutation rate at this nucleotide is one of the most frequently described in human genome, few Muenke familial case reports are published in current literature. ",24168007
960,4,2_abstract_sentence,4,We describe individuals among three generations  of a Greek family who are carriers of the same mutation. ,24168007
960,4,2_abstract_sentence,5,Medical record and physical examination of family members present a wide spectrum of clinical manifestations. ,24168007
960,4,2_abstract_sentence,6,"In particular, a 38-year-old woman and her father appear milder clinical findings regarding craniofacial characteristics compared to her uncle and newborn female child. ",24168007
960,4,2_abstract_sentence,7,This familial case illustrates the variable expressivity of Muenke syndrome in association with an identical gene mutation. ,24168007
960,5,1_title,0,Clinical and molecular diagnosis of the skeletal dysplasias associated with mutations in the gene encoding Fibroblast Growth Factor Receptor 3 (FGFR3) in Portugal.  ,19215249
960,5,2_abstract_sentence,0,"Mutations in the gene that encodes Fibroblast Growth Factor Receptor 3 (FGFR3) are associated with Achondroplasia (MIM 100800), Hypochondroplasia (MIM 146000),  Muenke Syndrome (MIM 602849), Thanatophoric Dysplasia (MIM 187600, MIM 187601) and Lacrimo-Auriculo-Dento-Digital Syndrome (MIM 149730).Here we report a clinical and molecular study in a large cohort of 125 Portuguese patients with these skeletal disorders. ",19215249
960,5,2_abstract_sentence,1,The identification of the P250R mutation allowed the confirmation of the Muenke Syndrome in 9 out of the 52 cases referred. ,19215249
960,5,2_abstract_sentence,2,Two known  mutations were found in the Thanatophoric Dysplasia referred cases. ,19215249
960,5,2_abstract_sentence,3,No mutations  were identified in the LADD syndrome patient. ,19215249
960,5,2_abstract_sentence,4,"In Achondroplasia and Hypochondroplasia, genetic heterogeneity was present amongst the 70 clinically diagnosed patients with 5 different mutations identified. ",19215249
960,5,2_abstract_sentence,5,"As in other studies, complex phenotypic heterogeneity amongst patients carrying the same gene defect was observed. ",19215249
960,5,2_abstract_sentence,6,"In several cases, the new amino acids encoded, as a consequence of  mutations, were related to the severity of patients' phenotype. ",19215249
960,5,2_abstract_sentence,7,The presence of 10 misdiagnosed cases emphasizes the importance of performing mutation analysis of the hotspot regions responsible for both dysplasias (Ach and Hch). ,19215249
960,5,2_abstract_sentence,8,"For patients with an unquestionable clinical diagnosis, lacking the most common mutations, a complete screening of FGFR3 is necessary. ",19215249
960,6,1_title,0,Craniofacial morphology in Muenke syndrome.  ,17414289
960,6,2_abstract_sentence,0,The purpose of this study was to test whether the severity of the cranial phenotype in Muenke syndrome infants with unicoronal synostosis is greater than in infants with nonsyndromic unicoronal synostosis. ,17414289
960,6,2_abstract_sentence,1,A total of 23 infants were included in the study. ,17414289
960,6,2_abstract_sentence,2,All infants included in the study had a computed tomography (CT)-verified synostosis of the coronal suture. ,17414289
960,6,2_abstract_sentence,3,"The patients were either placed into the ""Muenke"" group (n=11) or the ""non-Muenke"" control group (n=12) on the basis of a test for the P250R mutation in the FGFR3 gene. ",17414289
960,6,2_abstract_sentence,4,"On the basis of CT scans, a three-dimensional surface model corresponding to bone was created for each individual. ",17414289
960,6,2_abstract_sentence,5,"The sutures were inspected for synostosis, and the degree of synostosis was assessed. ",17414289
960,6,2_abstract_sentence,6,Increased digital markings were recorded for both groups. ,17414289
960,6,2_abstract_sentence,7,"Craniofacial morphology was assessed quantitatively using bony landmarks and recording of the midsagittal surface of the calvaria, cranial base, and maxillary complex. ",17414289
960,6,2_abstract_sentence,8,Increased digital markings were more severe posteriorly in Muenke patients than in non-Muenke patients. ,17414289
960,6,2_abstract_sentence,9,The Muenke patients with unilateral  coronal synostosis showed a somewhat more severe asymmetry in the anterior part of the skull than the non-Muenke patients. ,17414289
960,6,2_abstract_sentence,10,The study indicates differences with regard to severity of increased digital markings and craniofacial asymmetry between the infants with Muenke syndrome and the infants with nonsyndromic unilateral coronal synostosis. ,17414289
960,7,1_title,0,"Muenke syndrome mutation, FgfR3PÂ²â´â´R, causes TMJ defects.  ",22622662
960,7,2_abstract_sentence,0,Muenke syndrome is characterized by various craniofacial deformities and is caused by an autosomal-dominant activating mutation in fibroblast growth factor receptor 3 (FGFR3(P250R) ). ,22622662
960,7,2_abstract_sentence,1,"Here, using mice carrying a corresponding mutation (FgfR3(P244R) ), we determined whether the mutation affects temporomandibular joint (TMJ) development and growth. ",22622662
960,7,2_abstract_sentence,2,In situ hybridization showed that FgfR3 was expressed in condylar chondroprogenitors and maturing chondrocytes that also expressed the Indian hedgehog (Ihh) receptor and transcriptional target Patched 1(Ptch1). ,22622662
960,7,2_abstract_sentence,3,"In FgfR3(P244R) mutants, the condyles displayed reduced levels of Ihh expression, H4C-positive proliferating chondroprogenitors, and collagen type II-  and type X-expressing chondrocytes. ",22622662
960,7,2_abstract_sentence,4,Primary bone spongiosa formation was also disturbed and was accompanied by increased osteoclastic activity and reduced trabecular bone formation. ,22622662
960,7,2_abstract_sentence,5,Treatment of wild-type condylar explants with recombinant FGF2/FGF9 decreased Ptch1 and PTHrP expression in superficial/polymorphic layers and proliferation in chondroprogenitors. ,22622662
960,7,2_abstract_sentence,6,"We also observed early degenerative changes of condylar articular cartilage, abnormal development of the articular eminence/glenoid fossa in the TMJ, and fusion of the articular disc. ",22622662
960,7,2_abstract_sentence,7,"Analysis of our data indicates that the activating FgfR3(P244R) mutation disturbs TMJ developmental processes, likely by reducing hedgehog signaling and endochondral ossification. ",22622662
960,7,2_abstract_sentence,8,We suggest that a balance between FGF and hedgehog signaling pathways is critical for the integrity of TMJ development  and for the maintenance of cellular organization. ,22622662
960,8,1_title,0,Scalp fibroblasts have a shared expression profile in monogenic craniosynostosis.  ,19755431
960,8,2_abstract_sentence,0,"BACKGROUND: Craniosynostosis can be caused by both genetic and environmental factors, the relative contributions of which vary between patients. ",19755431
960,8,2_abstract_sentence,1,"Genetic testing identifies a pathogenic mutation or chromosomal abnormality in â¼ 21% of cases, but it is likely that further causative mutations remain to be discovered. ",19755431
960,8,2_abstract_sentence,2,OBJECTIVE: To identify a shared signature of genetically determined craniosynostosis by comparing the expression patterns in three monogenic syndromes with a control group of patients with non-syndromic sagittal synostosis. ,19755431
960,8,2_abstract_sentence,3,"METHODS: Fibroblasts from 10 individuals each with Apert syndrome (FGFR2 substitution S252W), Muenke syndrome (FGFR3 substitution P250R), Saethre-Chotzen  syndrome (various mutations in TWIST1) and non-syndromic sagittal synostosis (no  mutation detected) were cultured. ",19755431
960,8,2_abstract_sentence,4,"The relative expression of â¼ 47,000 transcripts was quantified on Affymetrix arrays. ",19755431
960,8,2_abstract_sentence,5,"RESULTS: 435, 45 and 46 transcripts were identified in the Apert, Muenke and Saethre-Chotzen groups, respectively, that differed significantly from the controls. ",19755431
960,8,2_abstract_sentence,6,"Forty-six of these transcripts were shared between two or more syndromes and, in all but one instance, showed the same direction of altered expression level compared with controls. ",19755431
960,8,2_abstract_sentence,7,Pathway analysis showed over-representation of the shared transcripts in core modules involving cell-to-cell communication and signal transduction. ,19755431
960,8,2_abstract_sentence,8,"Individual samples from the Apert syndrome cases could be reliably distinguished from non-syndromic samples based on the gene expression profile, but this was not possible for samples from  patients with Muenke and Saethre-Chotzen syndromes. ",19755431
960,8,2_abstract_sentence,9,CONCLUSIONS: Common modules of altered gene expression shared by genetically distinct forms of craniosynostosis were identified. ,19755431
960,8,2_abstract_sentence,10,"Although the expression profiles cannot currently be used to classify individual patients, this may be overcome by using more sensitive assays and sampling additional tissues. ",19755431
960,9,1_title,0,Medial temporal lobe dysgenesis in Muenke syndrome and hypochondroplasia.  ,12794698
960,9,2_abstract_sentence,0,Hypochondroplasia (HCH) and Muenke syndrome (MS) are caused by mutations on FGFR3 gene. ,12794698
960,9,2_abstract_sentence,1,FGFR3 is known to play a role in controlling nervous system development. ,12794698
960,9,2_abstract_sentence,2,"We describe the clinical and neuroradiological findings of the first two patients, to our knowledge, affected by HCH and MS, respectively, in whom bilateral dysgenesis of the medial temporal lobe structures has been observed. ",12794698
960,9,2_abstract_sentence,3,In both patients diagnosis was confirmed by molecular analysis. ,12794698
960,9,2_abstract_sentence,4,They were mentally normal and showed similarities in early-onset temporal lobe-related seizures. ,12794698
960,9,2_abstract_sentence,5,In both patients EEG recorded bilateral temporal region discharges. ,12794698
960,9,2_abstract_sentence,6,"MRI detected temporal lobe anomalies with inadequate differentiation between white and gray matter, defective gyri, and abnormally shaped hippocampus. ",12794698
960,10,1_title,0,Additional phenotypic features of Muenke syndrome in 2 Dutch families.  ,21403557
960,10,2_abstract_sentence,0,"In about 30% of the patients with syndromal craniosynostosis, a genetic mutation  can be traced. ",21403557
960,10,2_abstract_sentence,1,"For the purpose of adequate genetic counseling and treatment of these patients, the full spectrum of clinical findings for each specific mutation needs to be appreciated. ",21403557
960,10,2_abstract_sentence,2,The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes. ,21403557
960,10,2_abstract_sentence,3,A number of studies on the relationship  between genotype and phenotype concerning this specific mutation have been published. ,21403557
960,10,2_abstract_sentence,4,Two Dutch families with Muenke syndrome were screened for the reported characteristics of this syndrome and for additional features. ,21403557
960,10,2_abstract_sentence,5,"New phenotypical findings were hypoplasia of the frontal sinus, ptosis of the upper eyelids, dysplastic elbow joints with restricted elbow motion, and mild cutaneous syndactyly. ",21403557
960,10,2_abstract_sentence,6,"Incidentally, polydactyly, severe ankylosis of the elbow, fusion of cervical vertebrae, and epilepsy were found. ",21403557
960,10,2_abstract_sentence,7,Upper eyelid ptosis is thought to be pathognomonic for Saethre-Chotzen syndrome but was also observed in our series of patients with Muenke syndrome. ,21403557
960,10,2_abstract_sentence,8,"Because Muenke and Saethre-Chotzen syndrome can have similar phenotypes, DNA analysis is needed to distinguish between these syndromes, even when a syndrome diagnosis is already made in a family member. ",21403557
960,11,1_title,0,A Korean family with the Muenke syndrome.  ,20592905
960,11,2_abstract_sentence,0,"The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. ",20592905
960,11,2_abstract_sentence,1,"The birth prevalence is approximately one in 10,000 live births, accounting for 8-10% of patients with coronal synostosis. ",20592905
960,11,2_abstract_sentence,2,"Although MS is  a relatively common diagnosis in patients with craniosynostosis syndromes, with autosomal dominant inheritance, there has been no report of MS, in an affected Korean family with typical cephalo-facial morphology that has been confirmed by molecular studies. ",20592905
960,11,2_abstract_sentence,3,"Here, we report a familial case of MS in a female patient with a Pro250Arg mutation in exon 7 (IgII-IGIII linker domain) of the FGFR3 gene. ",20592905
960,11,2_abstract_sentence,4,"This patient had mild midfacial hypoplasia, hypertelorism, downslanting palpebral fissures, a beak shaped nose, plagio-brachycephaly, and mild neurodevelopmental delay. ",20592905
960,11,2_abstract_sentence,5,"The same mutation was confirmed in the patient's mother, two of the mother's sisters and the maternal grandfather. ",20592905
960,11,2_abstract_sentence,6,The severity of the cephalo-facial anomalies was variable among these family members. ,20592905
960,12,1_title,0,Muenke syndrome (FGFR3-related craniosynostosis): expansion of the phenotype and  review of the literature.  ,18000976
960,12,2_abstract_sentence,0,"Muenke syndrome is an autosomal dominant disorder characterized by coronal suture craniosynostosis, hearing loss, developmental delay, carpal and tarsal fusions, and the presence of the Pro250Arg mutation in the FGFR3 gene. ",18000976
960,12,2_abstract_sentence,1,Reduced penetrance  and variable expressivity contribute to the wide spectrum of clinical findings in Muenke syndrome. ,18000976
960,12,2_abstract_sentence,2,"To better define the clinical features of this syndrome, we initiated a study of the natural history of Muenke syndrome. ",18000976
960,12,2_abstract_sentence,3,"To date, we have conducted a standardized evaluation of nine patients with a confirmed Pro250Arg mutation in FGFR3. ",18000976
960,12,2_abstract_sentence,4,We reviewed audiograms from an additional 13 patients with Muenke syndrome. ,18000976
960,12,2_abstract_sentence,5,"A majority of the patients (95%) demonstrated a mild-to-moderate, low frequency sensorineural hearing loss. ",18000976
960,12,2_abstract_sentence,6,This pattern of hearing loss was not previously recognized as characteristic of Muenke syndrome. ,18000976
960,12,2_abstract_sentence,7, We also report on feeding and swallowing difficulties in children with Muenke syndrome. ,18000976
960,12,2_abstract_sentence,8,"Combining 312 reported cases of Muenke syndrome with data from the nine NIH patients, we found that females with the Pro250Arg mutation were significantly more likely to be reported with craniosynostosis than males (P < 0.01). ",18000976
960,12,2_abstract_sentence,9,"Based on our findings, we propose that the clinical management should include audiometric and developmental assessment in addition to standard clinical care and appropriate genetic counseling. ",18000976
960,13,1_title,0,Muenke syndrome.  ,14963686
960,13,2_abstract_sentence,0,BACKGROUND: Muenke syndrome is a genetically determined craniosynostosis that involves one or both coronal sutures. ,14963686
960,13,2_abstract_sentence,1,"In some patients it is associated with skeletal abnormalities such as thimble-like middle phalanges, coned epiphysis, and/or neurological impairment, namely sensorineural hearing loss or mental retardation. ",14963686
960,13,2_abstract_sentence,2,"In spite of a variable phenotype, Muenke syndrome has been related to a unique mutation on the FGFR3 gene, Pro 250 to Arg, which is characteristic of this disease. ",14963686
960,13,2_abstract_sentence,3,"Because of the incomplete penetrance of this anomaly, the suspicion of Muenke syndrome must be raised in any child with uni- or bilateral coronal craniosynostosis, and the genetic analysis propounded even in the absence of extracranial features. ",14963686
960,13,2_abstract_sentence,4,ILLUSTRATIVE CASES: We report the cases of two sisters who presented with Muenke  syndrome and whose affected mother did not have any form of craniosynostosis. ,14963686
960,14,1_title,0,Epilepsy in Muenke syndrome: FGFR3-related craniosynostosis.  ,23044018
960,14,2_abstract_sentence,0,"Epilepsy, a neurologic disorder characterized by the predisposition to recurrent  unprovoked seizures, is reported in more than 300 genetic syndromes. ",23044018
960,14,2_abstract_sentence,1,"Muenke syndrome is an autosomal-dominant craniosynostosis syndrome characterized by unilateral or bilateral coronal craniosynostosis, hearing loss, intellectual disability, and relatively subtle limb findings such as carpal bone fusion and tarsal bone fusion. ",23044018
960,14,2_abstract_sentence,2,Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. ,23044018
960,14,2_abstract_sentence,3,"Epilepsy rarely occurs in individuals with Muenke syndrome, and little detail is reported on types of epilepsy, patient characteristics, and long-term outcomes. ",23044018
960,14,2_abstract_sentence,4,We present seven patients with Muenke syndrome and seizures. ,23044018
960,14,2_abstract_sentence,5,"A review of 789 published cases of Muenke syndrome, with a focus on epilepsy and intracranial anomalies in Muenke syndrome, revealed epilepsy in six patients, with intracranial anomalies in five. ",23044018
960,14,2_abstract_sentence,6,"The occurrence of epilepsy in Muenke syndrome within our cohort of 58 patients, of whom seven manifested epilepsy, and the intracranial anomalies and epilepsy reported in the literature, suggest that patients with Muenke syndrome may be at  risk for epilepsy and intracranial anomalies. ",23044018
960,14,2_abstract_sentence,7,"Furthermore, the impact of Muenke syndrome on the central nervous system may be greater than previously thought. ",23044018
960,15,1_title,0,"Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome.  ",19086028
960,15,2_abstract_sentence,0,"Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of  craniosynostosis in humans. ",19086028
960,15,2_abstract_sentence,1,We have used gene targeting to introduce the Muenke syndrome mutation (equivalent to P244R) into the murine Fgfr3 gene. ,19086028
960,15,2_abstract_sentence,2,A rounded skull and shortened snout (often skewed) with dental malocclusion was observed in a minority of heterozygotes and many homozygotes. ,19086028
960,15,2_abstract_sentence,3,"Development of this incompletely penetrant skull phenotype was dependent on genetic background and sex, with males more often affected. ",19086028
960,15,2_abstract_sentence,4,"However, these cranial abnormalities were rarely attributable to craniosynostosis, which was only present in 2/364 mutants; more commonly, we found fusion of the premaxillary and/or zygomatic sutures. ",19086028
960,15,2_abstract_sentence,5,We also found decreased cortical thickness and bone mineral densities in long bones. ,19086028
960,15,2_abstract_sentence,6,"We conclude that although both cranial and long bone development is variably affected by the murine Fgfr3(P244R) mutation, coronal craniosynostosis is not reliably reproduced. ",19086028
960,16,1_title,0,"Talocalcaneal coalition in Muenke syndrome: report of a patient, review of the literature in FGFR-related craniosynostoses, and consideration of mechanism.  ",23378035
960,16,2_abstract_sentence,0,Muenke syndrome is an autosomal dominant craniosynostosis syndrome resulting from a defining point mutation in the Fibroblast Growth Factor Receptor3 (FGFR3) gene. ,23378035
960,16,2_abstract_sentence,1,"Muenke syndrome is characterized by coronal craniosynostosis (bilateral more often than unilateral), hearing loss, developmental delay, and carpal and/or tarsal bone coalition. ",23378035
960,16,2_abstract_sentence,2,Tarsal coalition is a distinct feature of Muenke syndrome  and has been reported since the initial description of the disorder in the 1990s. ,23378035
960,16,2_abstract_sentence,3,"Although talocalcaneal coalition is the most common tarsal coalition in the general population, it has never previously been reported in a patient with Muenke syndrome. ",23378035
960,16,2_abstract_sentence,4,We present a 7-year-old female patient with Muenke syndrome and  symptomatic talocalcaneal coalition. ,23378035
960,16,2_abstract_sentence,5,"She presented at the age of 7 with limping,  tenderness and pain in her right foot following a fall and strain of her right foot. ",23378035
960,16,2_abstract_sentence,6,"She was treated with ibuprofen, shoe inserts, a CAM walker boot, and stretching exercises without much improvement in symptoms. ",23378035
960,16,2_abstract_sentence,7,A computed tomography  (CT) scan revealed bilateral talocalcaneal coalitions involving the middle facet. ,23378035
960,16,2_abstract_sentence,8,"She underwent resection of the talocalcaneal coalitions, remaining pain-free post-operatively with an improvement in her range of motion, gait, and mobility. ",23378035
960,16,2_abstract_sentence,9, This report expands the phenotype of tarsal coalition in Muenke syndrome to include talocalcaneal coalition. ,23378035
960,16,2_abstract_sentence,10,"A literature review revealed a high incidence of tarsal coalition in all FGFR related craniosynostosis syndromes when compared to  the general population, a difference that is statistically significant. ",23378035
960,16,2_abstract_sentence,11,The most  common articulation involved in all syndromic craniosynostoses associated with FGFR mutations is the calcaneocuboid articulation. ,23378035
144,0,1_title,0,COUGER--co-factors associated with uniquely-bound genomic regions.  ,24861628
144,0,2_abstract_sentence,0,Most transcription factors (TFs) belong to protein families that share a common DNA binding domain and have very similar DNA binding preferences. ,24861628
144,0,2_abstract_sentence,1,"However, many paralogous TFs (i.e. ",24861628
144,0,2_abstract_sentence,2,members of the same TF family) perform different regulatory  functions and interact with different genomic regions in the cell. ,24861628
144,0,2_abstract_sentence,3,A potential mechanism for achieving this differential in vivo specificity is through interactions with protein co-factors. ,24861628
144,0,2_abstract_sentence,4,Computational tools for studying the genomic binding profiles of paralogous TFs and identifying their putative co-factors are currently lacking. ,24861628
144,0,2_abstract_sentence,5,"Here, we present an interactive web implementation of COUGER, a classification-based framework for identifying protein co-factors that might provide specificity to paralogous TFs. ",24861628
144,0,2_abstract_sentence,6,"COUGER takes as input two sets of genomic regions bound by paralogous TFs, and it identifies a small set of putative co-factors that best distinguish the two sets of sequences. ",24861628
144,0,2_abstract_sentence,7,"To achieve this task, COUGER uses a classification approach, with features that reflect the DNA-binding specificities of the putative co-factors. ",24861628
144,0,2_abstract_sentence,8,"The identified  co-factors are presented in a user-friendly output page, together with information that allows the user to understand and to explore the contributions of individual co-factor features. ",24861628
144,0,2_abstract_sentence,9,COUGER can be run as a stand-alone tool or through a web interface: http://couger.oit.duke.edu. ,24861628
129,0,1_title,0,Predictors of outcome in prolonged posttraumatic disorders of consciousness and assessment of medication effects: A multicenter study.  ,15759228
129,0,2_abstract_sentence,0,OBJECTIVES: To develop predictive models of recovery from the vegetative state (VS) and minimally conscious state (MCS) after traumatic brain injury (TBI) and to gather preliminary evidence on the impact of various psychotropic medications  on the recovery process to support future randomized controlled trials. ,15759228
129,0,2_abstract_sentence,1,"Design Longitudinal observational cohort design, in which demographic information, injury and acute care history, neuroimaging data, and an initial Disability Rating Scale (DRS) score were collected at the time of study enrollment. ",15759228
129,0,2_abstract_sentence,2,"Weekly follow-up data, consisting of DRS score, current psychoactive medications, and medical complications, were gathered until discharge from inpatient rehabilitation. ",15759228
129,0,2_abstract_sentence,3,SETTING: Seven acute inpatient rehabilitation facilities in the United States and Europe with specialized programs for treating patients in the VS and MCS. ,15759228
129,0,2_abstract_sentence,4,PARTICIPANTS: People with TBI (N=124) who were in the VS or MCS 4 to 16 weeks after injury. ,15759228
129,0,2_abstract_sentence,5,INTERVENTIONS: Not applicable. ,15759228
129,0,2_abstract_sentence,6,MAIN OUTCOME MEASURES: DRS score at 16 weeks after injury and time until commands were first followed (among those participants demonstrating no command following  at study enrollment). ,15759228
129,0,2_abstract_sentence,7,"Results DRS score at enrollment, time between injury and enrollment, and rate of DRS change during the first 2 weeks of poststudy observation were all highly predictive of both outcomes. ",15759228
129,0,2_abstract_sentence,8,No variables related to  injury characteristics or lesions on neuroimaging were significant predictors. ,15759228
129,0,2_abstract_sentence,9,"Of the psychoactive medications, amantadine hydrochloride was associated with greater recovery and dantrolene sodium was associated with less recovery, in terms of the DRS score at 16 weeks but not the time until commands were followed. ",15759228
129,0,2_abstract_sentence,10,"More detailed analysis of the timing of functional improvement, with respect to the initiation of amantadine provided suggestive, but not definitive, evidence of the drug's causal role. ",15759228
129,0,2_abstract_sentence,11,"CONCLUSIONS: These findings show the feasibility of improving outcome prediction  from the VS and MCS using readily available clinical variables and provide suggestive evidence for the effects of amantadine and dantrolene, but these results require confirmation through randomized controlled trials. ",15759228
129,1,1_title,0,Amantadine sulfate (PK-Merz) in the treatment of ischemic stroke: a clinical-experimental study.  ,19894299
129,2,1_title,0,Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique.  ,20129511
129,2,2_abstract_sentence,0,OBJECTIVE: To evaluate the pharmacokinetics of amantadine in children with impaired consciousness from acquired brain injury. ,20129511
129,2,2_abstract_sentence,1,"DESIGN: Randomized, double-blind, placebo-controlled, crossover study with sparse sampling for pharmacokinetics. ",20129511
129,2,2_abstract_sentence,2,SETTING: Tertiary care pediatric hospital. ,20129511
129,2,2_abstract_sentence,3,"PARTICIPANTS: Children, ages 6-18 years, with impaired consciousness 5-10 weeks after acquired brain injury. ",20129511
129,2,2_abstract_sentence,4,METHODS: Subjects received amantadine for 3 weeks. ,20129511
129,2,2_abstract_sentence,5,Subjects were randomized to placebo or amantadine 4 mg/kg/day for 7 days followed by 6 mg/kg/day for 14 days. ,20129511
129,2,2_abstract_sentence,6,Crossover was after a 7-day washout period. ,20129511
129,2,2_abstract_sentence,7,MAIN OUTCOME MEASURES: The Coma/Near-Coma Scale and Coma Recovery Scale-Revised were done 3 times per week to evaluate arousal and consciousness. ,20129511
129,2,2_abstract_sentence,8,Plasma concentrations of amantadine were determined for pharmacokinetic parameter estimation and evaluation of the exposure-response relationship. ,20129511
129,2,2_abstract_sentence,9,Adverse events were monitored. ,20129511
129,2,2_abstract_sentence,10,"RESULTS: Nine subjects met the final inclusion and exclusion criteria, 7 of whom  agreed to participate. ",20129511
129,2,2_abstract_sentence,11,Five subjects completed both arms of the study. ,20129511
129,2,2_abstract_sentence,12,Amantadine total body clearance was 0.17 L/h/kg with a half-life of 13.9 hours. ,20129511
129,2,2_abstract_sentence,13,Higher exposure of amantadine (average concentration of amantadine during 6 mg/kg/day >  1.5 mg/L) may be associated with better recovery of consciousness. ,20129511
129,2,2_abstract_sentence,14,CONCLUSIONS: Amantadine was well-tolerated in children with acquired brain injury and demonstrates pharmacokinetics similar to those reported for healthy young adults. ,20129511
129,2,2_abstract_sentence,15,"Based on the preliminary data, higher dosing may be considered in the setting of brain injury. ",20129511
129,3,1_title,0,Use of amantadine sulfate (PK-MERZ) during emergence from coma: results of a multicenter study.  ,18540467
129,4,1_title,0,Awakenings and awareness recovery in disorders of consciousness: is there a role  for drugs?  ,20658796
129,4,2_abstract_sentence,0,"Disorders of consciousness (DOC) include coma, vegetative state (VS) and minimally conscious state (MCS). ",20658796
129,4,2_abstract_sentence,1,"Coma is a condition of unarousability with a complete absence of wakefulness and awareness, whereas VS is characterized by a lack of awareness despite a preserved wakefulness. ",20658796
129,4,2_abstract_sentence,2,Patients in coma are unconscious because they lack both wakefulness and awareness. ,20658796
129,4,2_abstract_sentence,3,"Patients in a VS are unconscious because, although they are wakeful, they lack awareness. ",20658796
129,4,2_abstract_sentence,4,Patients in a MCS show minimal but definite behavioural evidence of self and environmental awareness. ,20658796
129,4,2_abstract_sentence,5,Coma results from diffuse bilateral hemispheric lesions or selective damage to the ascending reticular system (which is functionally connected to the  cerebral cortex by intralaminar thalamic nuclei). ,20658796
129,4,2_abstract_sentence,6,VS is a syndrome that is considered to be the result of a disconnection of different cortical networks rather than a dysfunction of a single area or a global reduction in cortical metabolism. ,20658796
129,4,2_abstract_sentence,7,"As revealed by functional imaging studies, clinical recovery is often associated with a functional restoration of cortico-thalamo-cortical connections. ",20658796
129,4,2_abstract_sentence,8,"Depending on the amount of network restored, patients may regain full consciousness or remain in a MCS. ",20658796
129,4,2_abstract_sentence,9,Molecular and neural mediators may indirectly contribute to the above restoration processes owing to their role in the phenomenon of neural synaptic plasticity. ,20658796
129,4,2_abstract_sentence,10,"Therefore, there is growing interest in the possible effects of drugs that act at the level of the CNS in promoting emergence from DOC. ",20658796
129,4,2_abstract_sentence,11,"Sporadic cases of dramatic recovery from DOC after the administration of various pharmacological agents, such as baclofen, zolpidem and  amantadine, have been recently supported by intriguing scientific observations. ",20658796
129,4,2_abstract_sentence,12,"Analysis of the reported cases of recovery, with particular attention paid to the condition of the patients and to the association of their improvement with the start of drug administration, suggests that these treatments might have promoted  the clinical improvement of some patients. ",20658796
129,4,2_abstract_sentence,13,"These drugs are from various and diverging classes, but can be grouped into two main categories, CNS stimulants and CNS depressants. ",20658796
129,4,2_abstract_sentence,14,"Some of these treatments seem to directly encourage a consciousness restoration, while others play a more determinant role in improving cognitive domains, especially in patients with residual cognitive impairment, than in the field of consciousness. ",20658796
129,4,2_abstract_sentence,15,"Given the great interest recently generated in the scientific community by the increasing number of papers addressing this issue, further investigation of the above treatments, with particular attention paid to their mechanisms of action, the neurotransmitters involved and their effects on cortico-thalamo-cortical circuitry, is needed. ",20658796
129,5,1_title,0,Placebo-controlled trial of amantadine for severe traumatic brain injury.  ,22375973
129,5,2_abstract_sentence,0,Comment in     N Engl J Med. ,22375973
129,5,2_abstract_sentence,1,2012 Jun 21;366(25):2427; author reply 2427-8. ,22375973
129,5,2_abstract_sentence,2,    N Engl J Med. ,22375973
129,5,2_abstract_sentence,3,2012 Jun 21;366(25):2427; author reply 2427-8. ,22375973
129,6,1_title,0,Vegetative state and minimally conscious state: a review of the therapeutic interventions.  ,20460949
129,6,2_abstract_sentence,0,"BACKGROUND/AIMS: The purpose of the present article is a systematic review of the proposed medical or surgical treatments in patients in chronic vegetative state (VS) or minimally conscious state (MCS), as well as of their mechanisms of action and limitations. ",20460949
129,6,2_abstract_sentence,1,"METHODS: For this review, we have agreed to include patients in VS or MCS having  persisted for over 6 months in posttraumatic cases, and over 3 months in nontraumatic cases, before the time of intervention. ",20460949
129,6,2_abstract_sentence,2,"Searches were independently  conducted by 2 investigators between May 2009 and September 2009 in the following databases: Medline, Web of Science and the Cochrane Library. ",20460949
129,6,2_abstract_sentence,3,The electronic search was complemented by cross-checking the references of all relevant articles. ,20460949
129,6,2_abstract_sentence,4,"Overall, 16 papers were eligible for this systematic review. ",20460949
129,6,2_abstract_sentence,5,"RESULTS: According to the 16 eligible studies, medical management by dopaminergic agents (levodopa, amantadine), zolpidem and median nerve stimulation, or surgical management by deep brain stimulation, extradural cortical stimulation, spinal cord stimulation and intrathecal baclofen have shown to improve the level of consciousness in certain cases. ",20460949
129,6,2_abstract_sentence,6,"CONCLUSION: The treatments proposed for disorders of consciousness have not yet gained the level of 'evidence-based treatments'; moreover, the studies to date have led to inconclusiveness. ",20460949
129,6,2_abstract_sentence,7,The published therapeutic responses must be substantiated by further clinical studies of sound methodology. ,20460949
129,7,1_title,0,Pharmacological modulation of the state of awareness in patients with disorders of consciousness: an overview.  ,24025054
129,7,2_abstract_sentence,0,The neurobiological approach to consciousness moves from the assumption that all  phenomenal experiences are based on neuronal activity in the brain. ,24025054
129,7,2_abstract_sentence,1,Consciousness has two main components: wakefulness and awareness. ,24025054
129,7,2_abstract_sentence,2,"While it may be relatively easy to determine the neuronal correlates of wakefulness, it is not the same for  awareness, of which the neural correlates are poorly understood. ",24025054
129,7,2_abstract_sentence,3,Knowledge of the circuitry and the neurochemistry of the sleep/wake condition is necessary but not sufficient to understand the circuitry and neurochemistry of consciousness. ,24025054
129,7,2_abstract_sentence,4,"Disorders of consciousness (DOCs) include coma, vegetative state and minimally conscious state. ",24025054
129,7,2_abstract_sentence,5,The study of DOCs and of the electrophysiological changes underlying general anaesthesia-induced loss of consciousness may help in understanding the neuronal correlates of consciousness. ,24025054
129,7,2_abstract_sentence,6,"In turn, the understanding of the neural bases of consciousness may help in designing interventions aimed at restoring consciousness in DOC patients. ",24025054
129,7,2_abstract_sentence,7,"Sporadic cases of recovery from a DOC have been reported after the administration of various pharmacological agents (baclofen, zolpidem, amantadine etc.). ",24025054
129,7,2_abstract_sentence,8,"This review provides an overview of such drugs, which are from various and diverging classes  but can be grouped into two main categories: CNS stimulants and CNS depressants. ",24025054
129,7,2_abstract_sentence,9," The available data seem to suggest an awakening effect obtained with CNS depressants rather than stimulants, the latter being more effective at improving  functional cognitive and behavioral recovery in patients who have spontaneously regained an appreciable level of consciousness. ",24025054
129,7,2_abstract_sentence,10,"There is a need for more rigorous systematic trials and further investigation of the above treatments, with particular attention paid to their mechanisms of action and the neurotransmitters involved. ",24025054
129,8,1_title,0,"Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness.  ",24025057
129,8,2_abstract_sentence,0,Survivors of severe brain injuries may end up in a state of 'wakeful unresponsiveness' or in a minimally conscious state. ,24025057
129,8,2_abstract_sentence,1,Pharmacological treatments of patients with disorders of consciousness aim to improve arousal levels and recovery of consciousness. ,24025057
129,8,2_abstract_sentence,2,"We here provide a systematic overview of the therapeutic effects of amantadine, apomorphine and zolpidem in patients recovering from coma. ",24025057
129,8,2_abstract_sentence,3,"Evidence from clinical trials using these commonly prescribed pharmacological agents suggests positive changes of the patients' neurological status, leading sometimes to dramatic improvements. ",24025057
129,8,2_abstract_sentence,4,These findings are discussed in the context of current hypotheses of these agents' therapeutic mechanisms on cerebral function. ,24025057
129,8,2_abstract_sentence,5,"In order to improve our understanding of the underlying pathophysiological mechanisms of these drugs, we suggest combining sensitive and specific behavioral tools with neuroimaging and electrophysiological measures in large randomized, double-blind, placebo-controlled experimental designs. ",24025057
129,8,2_abstract_sentence,6,"We conclude that the pharmacokinetics and pharmacodynamics of amantadine, apomorphine and zolpidem need further exploration to determine which treatment would provide a better neurological outcome regarding the patient's etiology, diagnosis, time since injury and overall condition. ",24025057
129,9,1_title,0,Disorders of consciousness and pharmaceuticals that act on oxygen based amino acid and monoamine neurotransmitter pathways of the brain.  ,24025056
129,9,2_abstract_sentence,0,Oxygen based neurotransmitters in the synapses of the brain are proposed to play  an important role in the generation of consciousness. ,24025056
129,9,2_abstract_sentence,1,"They include the amino acids glutamate and GABA which use Krebs cycle precursors for their synthesis, and the monoamines dopamine, noradrenalin, adrenalin and serotonin, which are derived from tyrosine and tryptophan. ",24025056
129,9,2_abstract_sentence,2,"During ischemia after an acute brain injury, a GABA surge often initiates brain suppression. ",24025056
129,9,2_abstract_sentence,3,"It has been proposed that with chronic ischemia, a secondary, possibly epigenetic response occurs when neurotransmitters deplete, a glucose and oxygen saving mechanism termed neurodormancy that may invoke alternative long term low energy metabolic pathways in the brain, encountered in Disorders of Consciousness. ",24025056
129,9,2_abstract_sentence,4,Some medications can reverse Disorders of Consciousness in some patients. ,24025056
129,9,2_abstract_sentence,5,Virtually all of them act on neurotransmitter systems that use oxygen as a building block or as an energy source within the brain. ,24025056
129,9,2_abstract_sentence,6,"Pharmaceuticals that act in the oxygen based amino acid  systems of the brain include the GABAergic medications zolpidem and baclofen, while those that act in the monoamine axes include the dopaminergic medications L Dopa, amantadine, bromocriptine, apomorphine and methylphenidate, and the noradrenergic and serotonergic medications desipramine, amitriptyline, protriptyline and fluoxetine. ",24025056
129,9,2_abstract_sentence,7,"Another group are the cholinesterase inhibitors, responsible for increasing acetylcholine, which is synthesized from the Krebs cycle initiator, acetyl CoA. ",24025056
129,9,2_abstract_sentence,8,It appears that pharmaceuticals that are active in the oxygen based neurotransmitter pathways of the brain are successful to arouse  to consciousness patients that suffer from its disorders. ,24025056
129,9,2_abstract_sentence,9,Research needs to be supported as foundation to understand the biochemical mechanisms that are involved in consciousness disorders and to explore further the pharmacological treatment possibilities for these devastating neurological conditions. ,24025056
129,10,1_title,0,Effects of amantadine in children with impaired consciousness caused by acquired  brain injury: a pilot study.  ,19404190
129,10,2_abstract_sentence,0,"OBJECTIVE: To conduct a pilot study of amantadine in children with impaired consciousness caused by acquired brain injury, to establish design feasibility, and to assess the effect on level of arousal and consciousness. ",19404190
129,10,2_abstract_sentence,1,"DESIGN: Randomized, double-blind, placebo-controlled crossover trial. ",19404190
129,10,2_abstract_sentence,2,"Seven subjects (mean age, 12.7 yrs) with an acquired brain injury (mean duration, 6 wks) were randomized to receive either 3 wks of placebo or amantadine, followed by a 1-wk washout period and then 3 wks of the other agent. ",19404190
129,10,2_abstract_sentence,3,"Main outcome measures were the Coma/Near-Coma Scale and Coma Recovery Scale-Revised, each done three times per week. ",19404190
129,10,2_abstract_sentence,4,Subjective evaluations of change in arousal and consciousness by  the parent and physician were done weekly. ,19404190
129,10,2_abstract_sentence,5,RESULTS: Five subjects completed the study. ,19404190
129,10,2_abstract_sentence,6,"There was no significant difference in the slopes of recovery during either arm for the Coma/Near-Coma Scale (P = 0.24) or the Coma Recovery Scale-Revised (P = 0.28), although improvements in consciousness were noted by the physician during weeks when amantadine was given  (P = 0.02). ",19404190
129,10,2_abstract_sentence,7,CONCLUSIONS: This study suggests that amantadine facilitates recovery of consciousness in pediatric acquired brain injury and provides important information necessary to design future more definitive studies. ,19404190
129,11,1_title,0,Review of awakening agents.  ,15825541
129,11,2_abstract_sentence,0,Brain injuries are a serious burden of illness to Canada and the US. ,15825541
129,11,2_abstract_sentence,1,"Advances in  managing head trauma have allowed more patients to emerge from decreased levels of consciousness and helped them cope with neurocognitive, neurobehavioural, and  neuropsychiatric deficits. ",15825541
129,11,2_abstract_sentence,2,"In this article, we review the current (1986-2002) evidence surrounding the pharmacological management of arousal states and the aforementioned neurological sequelae of head injury in either acute or chronic conditions. ",15825541
129,11,2_abstract_sentence,3,"This article will review the evidence for the use of psychostimulants (methylphenidate), antidepressants (amitriptyline, selective serotonin reuptake inhibitors, and buproprion), Parkinson's medications (amantadine, bromocriptine,  carbidopa/levodopa), anticonvulsants (valproic acid), modafinil (Provigil), lactate, hyperbaric oxygen chamber, electroconvulsive therapy, and transmagnetic  stimulation, in patients following a head injury. ",15825541
129,11,2_abstract_sentence,4,"The review did not include all  anticonvulsants, neuroleptics, beta-blockers, benzodiazepines, azospirones or cognitive enhancers. ",15825541
129,11,2_abstract_sentence,5,"Unfortunately, the quality of the evidence is generally poor, and sometimes conflicting, which in turn results in indecisive guidelines for treating patients. ",15825541
129,11,2_abstract_sentence,6,"Accepting the inherent flaws in the evidence we feel that  this paper may serve as a stepping-stone for future researchers to improve data gathering that targets neurocognitive, neurobehavioural and neuropsychiatric symptoms following a head injury. ",15825541
2797,0,1_title,0,"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.  ",29104121
2797,0,2_abstract_sentence,0,"BACKGROUND & AIMS: Vesatolimod (GS-9620) is an oral agonist of toll-like receptor 7, an activator of innate and adaptive immune responses. ",29104121
2797,0,2_abstract_sentence,1,Herein the safety and efficacy of vesatolimod is assessed after once-weekly treatment in patients with  chronic hepatitis B (CHB) infection suppressed on oral antiviral treatment. ,29104121
2797,0,2_abstract_sentence,2,"METHODS: In a phase II, double-blind, randomized, placebo (PBO)-controlled study, 162 patients stratified by hepatitis B surface antigen (HBsAg) levels and serum hepatitis B e antigen (HBeAg) status were randomized 1:3:3:3 to once-weekly oral  PBO or vesatolimod (1-, 2-, or 4-mg doses) for 4, 8 or 12â¯weeks per cohort. ",29104121
2797,0,2_abstract_sentence,3,Efficacy was assessed by change in baseline HBsAg (log10 IU/ml) at the primary endpoint (Week 24). ,29104121
2797,0,2_abstract_sentence,4,Safety assessments included adverse events (AE) and laboratory abnormality monitoring. ,29104121
2797,0,2_abstract_sentence,5,Pharmacodynamic assessments included peripheral cytokine level quantification and interferon-stimulated gene (ISG) mRNA expression evaluation. ,29104121
2797,0,2_abstract_sentence,6,RESULTS: The majority of patients were male (76%) and HBeAg-negative (79%) at baseline. ,29104121
2797,0,2_abstract_sentence,7,Most (41-80%) experienced â¥1 AE during the study with the majority of AEs mild or moderate in severity. ,29104121
2797,0,2_abstract_sentence,8,"No significant declines in HBsAg were observed  at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48). ",29104121
2797,0,2_abstract_sentence,9,"ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels; no patient demonstrated significant serum interferon alpha (IFNÎ±) expression at any timepoint evaluated. ",29104121
2797,0,2_abstract_sentence,10,Multivariate analyses showed that â¥2-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex. ,29104121
2797,0,2_abstract_sentence,11,"CONCLUSIONS: Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNÎ± expression or related symptoms. ",29104121
2797,0,2_abstract_sentence,12,"However, no significant HBsAg declines were observed. ",29104121
2797,0,2_abstract_sentence,13,"LAY SUMMARY: In a phase II study, vesatolimod, an oral, once-weekly, experimental immune-activating drug for the treatment of hepatitis B virus (HBV), is safe and  well-tolerated in chronic HBV patients who are virally suppressed on oral antiviral treatment. ",29104121
2797,0,2_abstract_sentence,14,"Despite demonstrating on-target biomarker responses in patients, no significant declines in hepatitis B surface antigen were observed. ",29104121
2797,0,2_abstract_sentence,15,Clinical Trial Number: GS-US-283-1059; NCT 02166047. ,29104121
2556,0,1_title,0,RIblast: an ultrafast RNA-RNA interaction prediction system based on a seed-and-extension approach.  ,28459942
2556,0,2_abstract_sentence,0,Motivation: LncRNAs play important roles in various biological processes. ,28459942
2556,0,2_abstract_sentence,1,"Although more than 58â000 human lncRNA genes have been discovered, most known lncRNAs are still poorly characterized. ",28459942
2556,0,2_abstract_sentence,2,One approach to understanding the functions of lncRNAs is the detection of the interacting RNA target of each lncRNA. ,28459942
2556,0,2_abstract_sentence,3,"Because experimental detections of comprehensive lncRNA-RNA interactions  are difficult, computational prediction of lncRNA-RNA interactions is an indispensable technique. ",28459942
2556,0,2_abstract_sentence,4,"However, the high computational costs of existing RNA-RNA interaction prediction tools prevent their application to large-scale lncRNA datasets. ",28459942
2556,0,2_abstract_sentence,5,"Results: Here, we present 'RIblast', an ultrafast RNA-RNA interaction prediction  method based on the seed-and-extension approach. ",28459942
2556,0,2_abstract_sentence,6,RIblast discovers seed regions using suffix arrays and subsequently extends seed regions based on an RNA secondary structure energy model. ,28459942
2556,0,2_abstract_sentence,7,"Computational experiments indicate that RIblast achieves a level of prediction accuracy similar to those of existing programs, but at speeds over 64 times faster than existing programs. ",28459942
2556,0,2_abstract_sentence,8,Availability and implementation: The source code of RIblast is freely available at https://github.com/fukunagatsu/RIblast . ,28459942
2556,0,2_abstract_sentence,9,Contact: t.fukunaga@kurenai.waseda.jp or mhamada@waseda.jp. ,28459942
2556,0,2_abstract_sentence,10,Supplementary information: Supplementary data are available at Bioinformatics online. ,28459942
1202,0,1_title,0,Standards of care for Duchenne muscular dystrophy: brief TREAT-NMD recommendations.  ,20225016
1202,1,1_title,0,The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases.  ,24148153
1202,1,2_abstract_sentence,0,BACKGROUND: Rare diseases pose many research challenges specific to their scarcity. ,24148153
1202,1,2_abstract_sentence,1,Advances in potential therapies have made it more important than ever to be able to adequately identify not only patients with particular genotypes (via patient registries) but also the medical professionals who provide care for  them at particular specialist centres of expertise and who may be competent to participate in trials. ,24148153
1202,1,2_abstract_sentence,2,Work within the neuromuscular field provides an example of how this may be achieved. ,24148153
1202,1,2_abstract_sentence,3,"METHODS: This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies. ",24148153
1202,1,2_abstract_sentence,4,"RESULTS: 285 CTSR-registered centres, reporting 35,495 neuromuscular patients, are described alongside an analysis of their provision for DMD. ",24148153
1202,1,2_abstract_sentence,5,"Site characteristics vary by country: the average number of DMD patients seen per site in the United States (96) is more than in Germany (25), and paediatric/adult breakdown is also markedly distinct. ",24148153
1202,1,2_abstract_sentence,6,"Over 70% of sites have previous trial experience, with a majority including a Clinical Trials Unit. ",24148153
1202,1,2_abstract_sentence,7,Most sites also have MLPA diagnostic capability and access to a range of medical specialists. ,24148153
1202,1,2_abstract_sentence,8,"However, in the three countries reporting most sites (US, the UK and Germany), few had access to all core DMD specialists internally. ",24148153
1202,1,2_abstract_sentence,9,Over 60% of sites did not  report any form of transition arrangement. ,24148153
1202,1,2_abstract_sentence,10,"CONCLUSIONS: Registries of care and trial sites have significant utility for research into rare conditions such as neuromuscular diseases, demonstrated by the significant engagement by industry and other researchers with the CTSR. ",24148153
1202,1,2_abstract_sentence,11,We suggest that this approach may be applicable to other fields needing to identify  centres of expertise with the potential to carry out clinical research and engage in clinical trials. ,24148153
1202,1,2_abstract_sentence,12,"Such registries also lend themselves to the developing context of European Reference Networks (ERNs), which seek to build networks of centres of expertise which fit specific criteria, and which may themselves aid the sustainability of such registries. ",24148153
1202,1,2_abstract_sentence,13,This is particularly the case given the utility of registries such as the CTSR in enabling networks of best-practice care centres. ,24148153
1202,2,1_title,0,"The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia.  ",23913485
1202,2,2_abstract_sentence,0,"Duchenne muscular dystrophy (DMD) is an X-linked genetic disease, caused by the absence of the dystrophin protein. ",23913485
1202,2,2_abstract_sentence,1,"Although many novel therapies are under development for DMD, there is currently no cure and affected individuals are often confined to a wheelchair by their teens and die in their twenties/thirties. ",23913485
1202,2,2_abstract_sentence,2,"DMD is a rare disease (prevalenceÂ <5/10,000). ",23913485
1202,2,2_abstract_sentence,3,"Even the largest countries do not have enough affected patients to rigorously assess novel therapies, unravel genetic complexities, and determine patient outcomes. ",23913485
1202,2,2_abstract_sentence,4,TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients. ,23913485
1202,2,2_abstract_sentence,5,The harmonized implementation of national and ultimately global patient registries has been central to the success of TREAT-NMD. ,23913485
1202,2,2_abstract_sentence,6,"For the DMD registries within TREAT-NMD, individual countries have chosen to collect patient information in the form of standardized  patient registries to increase the overall patient population on which clinical outcomes and new technologies can be assessed. ",23913485
1202,2,2_abstract_sentence,7,"The registries comprise more than  13,500 patients from 31 different countries. ",23913485
1202,2,2_abstract_sentence,8,"Here, we describe how the TREAT-NMD  national patient registries for DMD were established. ",23913485
1202,2,2_abstract_sentence,9,"We look at their continued  growth and assess how successful they have been at fostering collaboration between academia, patient organizations, and industry. ",23913485
1202,3,1_title,0,Infrastructure for new drug development to treat muscular dystrophy: current status of patient registration (remudy).  ,22068481
1202,3,2_abstract_sentence,0,"Clinical trials for new therapeutic strategies are now being planned for Duchenne and Becker muscular dystrophies (DMD/BMD); however, many challenges exist in the  planning and conduction of a clinical trial for rare diseases. ",22068481
1202,3,2_abstract_sentence,1,"The epidemiological data, total number of patients, natural history, and clinical outcome measures are unclear. ",22068481
1202,3,2_abstract_sentence,2,Adequate numbers of patients are needed to achieve  significant results in clinical trials. ,22068481
1202,3,2_abstract_sentence,3,"As solutions to these problems, patient registries are an important infrastructure worldwide, especially in the case of rare diseases such as DMD/BMD. ",22068481
1202,3,2_abstract_sentence,4,"In Europe, TREAT-NMD, a clinical research network  for neuromuscular disorders, developeda global database for dystrophinopathy patients. ",22068481
1202,3,2_abstract_sentence,5,We developed a national registry of Japanese DMD/BMD patients in collaboration with TREAT-NMD. ,22068481
1202,3,2_abstract_sentence,6,The database includes clinical and molecular genetic data as well as all required items for the TREAT-NMD global patient registry. ,22068481
1202,3,2_abstract_sentence,7,"As of July 2011, 750 patients were registered in the database. ",22068481
1202,3,2_abstract_sentence,8,"The purpose of this registry is the effective recruitment of eligible patients for clinical trials, and it may also provide timely information to individual patients about upcoming trials. ",22068481
1202,3,2_abstract_sentence,9,"This registry data also provides more detailed knowledge about natural history, epidemiology, and clinical care. ",22068481
1202,3,2_abstract_sentence,10,"In recent years, drug development has become dramatically globalized, and global clinical trials (GCTs) are being conducted in Japan. ",22068481
1202,3,2_abstract_sentence,11,"It is appropriate, particularly with  regard to orphan diseases, to include Japanese patients in GCTs to increase evidence for evaluation, because such large-scale trials would be difficult to conduct solely within Japan. ",22068481
1202,3,2_abstract_sentence,12,"GCTs enable the synchronization of clinical drug development in Japan with that in Western countries, minimizing drug approval delays. ",22068481
1300,0,1_title,0,Late onset spinal motor neuronopathy is caused by mutation in CHCHD10.  ,25428574
1300,0,2_abstract_sentence,0,Comment in     Ann Neurol. ,25428574
1300,0,2_abstract_sentence,1,2015 Nov;78(5):831. ,25428574
1300,0,2_abstract_sentence,2,    Ann Neurol. ,25428574
1300,0,2_abstract_sentence,3,2015 Nov;78(5):831-2. ,25428574
1300,1,1_title,0,A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement.  ,24934289
1300,1,2_abstract_sentence,0,Comment in     Brain. ,24934289
1300,1,2_abstract_sentence,1,2014 Dec;137(Pt 12):e309. ,24934289
1300,1,2_abstract_sentence,2,    Brain. ,24934289
1300,1,2_abstract_sentence,3,2014 Dec;137(Pt 12):e310. ,24934289
1300,1,2_abstract_sentence,4,    Brain. ,24934289
1300,1,2_abstract_sentence,5,2014 Dec;137(Pt 12):e312. ,24934289
1300,1,2_abstract_sentence,6,    Brain. ,24934289
1300,1,2_abstract_sentence,7,2014 Dec;137(Pt 12):e311. ,24934289
1300,1,2_abstract_sentence,8,    Brain. ,24934289
1300,1,2_abstract_sentence,9,2014 Dec;137(Pt 12):e313. ,24934289
1300,1,2_abstract_sentence,10,    Brain. ,24934289
1300,1,2_abstract_sentence,11,2014 Dec;137(Pt 12):e314. ,24934289
1300,1,2_abstract_sentence,12,    Brain. ,24934289
1300,1,2_abstract_sentence,13,2015 Aug;138(Pt 8):e372. ,24934289
1300,1,2_abstract_sentence,14,    Brain. ,24934289
1300,1,2_abstract_sentence,15,2015 Aug;138(Pt 8):e373. ,24934289
1300,1,2_abstract_sentence,16,    Brain. ,24934289
1300,1,2_abstract_sentence,17,2015 Sep;138(Pt 9):e377. ,24934289
1300,1,2_abstract_sentence,18,    Brain. ,24934289
1300,1,2_abstract_sentence,19,2015 Sep;138(Pt 9):e376. ,24934289
1300,1,2_abstract_sentence,20,    Brain. ,24934289
1300,1,2_abstract_sentence,21,2015 Sep;138(Pt 9):e380. ,24934289
1300,1,2_abstract_sentence,22,    Brain. ,24934289
1300,1,2_abstract_sentence,23,2015 Oct;138(Pt 10):e386. ,24934289
1300,1,2_abstract_sentence,24,    Brain. ,24934289
1300,1,2_abstract_sentence,25,2015 Oct;138(Pt 10):e385. ,24934289
1300,1,2_abstract_sentence,26,    Brain. ,24934289
1300,1,2_abstract_sentence,27,2016 Feb;139(Pt 2):e8. ,24934289
1300,1,2_abstract_sentence,28,    Brain. ,24934289
1300,1,2_abstract_sentence,29,2016 Apr;139(Pt 4):e22. ,24934289
1300,1,2_abstract_sentence,30,    Brain. ,24934289
1300,1,2_abstract_sentence,31,2016 Apr;139(Pt 4):e21. ,24934289
1300,2,1_title,0,Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy.  ,25193783
1300,2,2_abstract_sentence,0,Mitochondrial myopathies belong to a larger group of systemic diseases caused by  morphological or biochemical abnormalities of mitochondria. ,25193783
1300,2,2_abstract_sentence,1,Mitochondrial disorders can be caused by mutations in either the mitochondrial or nuclear genome. ,25193783
1300,2,2_abstract_sentence,2,Only 5% of all mitochondrial disorders are autosomal dominant. ,25193783
1300,2,2_abstract_sentence,3,We analyzed DNA from members of the previously reported Puerto Rican kindred with an autosomal dominant mitochondrial myopathy (Heimann-Patterson et al. ,25193783
1300,2,2_abstract_sentence,4,1997). ,25193783
1300,2,2_abstract_sentence,5,Linkage analysis suggested a putative locus on the pericentric region of the long arm of chromosome 22 (22q11). ,25193783
1300,2,2_abstract_sentence,6,"Using the tools of integrative genomics, we established chromosome 22 open reading frame 16 (C22orf16) (later designated as CHCHD10) as the only high-scoring mitochondrial candidate gene in our minimal candidate region. ",25193783
1300,2,2_abstract_sentence,7,Sequence analysis revealed a double-missense mutation (R15S and G58R) in cis in CHCHD10 which encodes a coiled coil-helix-coiled coil-helix protein of unknown function. ,25193783
1300,2,2_abstract_sentence,8,"These two mutations completely co-segregated with the disease phenotype and were absent in 1,481 Caucasian and 80 Hispanic (including 32 Puerto Rican) controls. ",25193783
1300,2,2_abstract_sentence,9,Expression profiling showed that CHCHD10 is enriched in skeletal muscle. ,25193783
1300,2,2_abstract_sentence,10,Mitochondrial localization of the CHCHD10 protein was confirmed using immunofluorescence in cells expressing either wild-type or mutant CHCHD10. ,25193783
1300,2,2_abstract_sentence,11,"We found that the expression of the G58R, but not the R15S, mutation induced mitochondrial fragmentation. ",25193783
1300,2,2_abstract_sentence,12,"Our findings identify a novel gene  causing mitochondrial myopathy, thereby expanding the spectrum of mitochondrial myopathies caused by nuclear genes. ",25193783
1300,2,2_abstract_sentence,13,Our findings also suggest a role for CHCHD10  in the morphologic remodeling of the mitochondria. ,25193783
1300,3,1_title,0,Screening of CHCHD10 in a French cohort confirms the involvement of this gene in  frontotemporal dementia with amyotrophic lateral sclerosis patients.  ,25155093
1300,3,2_abstract_sentence,0,"Mutations in the CHCHD10 gene have been recently identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with  amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment. ",25155093
1300,3,2_abstract_sentence,1,CHCHD10 encodes a protein located in the mitochondrial intermembrane  space and is likely involved in mitochondrial genome stability and maintenance of cristae junctions. ,25155093
1300,3,2_abstract_sentence,2,"However, the exact contribution of CHCHD10 in FTD and ALS diseases spectrum remains unknown. ",25155093
1300,3,2_abstract_sentence,3,"In this study, we evaluated the frequency of CHCHD10 mutations in 115 patients with FTD and FTD-ALS phenotypes. ",25155093
1300,3,2_abstract_sentence,4,"We identified  2 heterozygous variants in 3 unrelated probands presenting FTD and ALS, characterized by early and predominant bulbar symptoms. ",25155093
1300,3,2_abstract_sentence,5,This study demonstrates the implication of CHCHD10 in FTD and ALS spectrum. ,25155093
1300,3,2_abstract_sentence,6,"Although the frequency of mutations is low in this series (2.6%), our work suggests that CHCHD10 mutations  should be searched particularly when bulbar symptoms are present at onset. ",25155093
1278,0,1_title,0,De novo genesis of enhancers in vertebrates.  ,22069375
1278,0,2_abstract_sentence,0,Evolutionary innovation relies partially on changes in gene regulation. ,22069375
1278,0,2_abstract_sentence,1,"While a growing body of evidence demonstrates that such innovation is generated by functional changes or translocation of regulatory elements via mobile genetic elements, the de novo generation of enhancers from non-regulatory/non-mobile sequences has, to our knowledge, not previously been demonstrated. ",22069375
1278,0,2_abstract_sentence,2,Here we show evidence for the de novo genesis of enhancers in vertebrates. ,22069375
1278,0,2_abstract_sentence,3,"For this, we took advantage of the massive gene loss following the last whole genome duplication in teleosts to systematically identify regions that have lost their coding capacity  but retain sequence conservation with mammals. ",22069375
1278,0,2_abstract_sentence,4,We found that these regions show enhancer activity while the orthologous coding regions have no regulatory activity. ,22069375
1278,0,2_abstract_sentence,5,These results demonstrate that these enhancers have been de novo generated in fish. ,22069375
1278,0,2_abstract_sentence,6,"By revealing that minor changes in non-regulatory sequences are sufficient to generate new enhancers, our study highlights an important playground for creating new regulatory variability and evolutionary innovation. ",22069375
357,0,1_title,0,The mechanism of DNA replication termination in vertebrates.  ,26322582
357,0,2_abstract_sentence,0,Eukaryotic DNA replication terminates when replisomes from adjacent replication origins converge. ,26322582
357,0,2_abstract_sentence,1,"Termination involves local completion of DNA synthesis, decatenation of daughter molecules and replisome disassembly. ",26322582
357,0,2_abstract_sentence,2,Termination has been difficult to study because termination events are generally asynchronous and sequence nonspecific. ,26322582
357,0,2_abstract_sentence,3,"To overcome these challenges, we paused converging replisomes with a site-specific barrier in Xenopus egg extracts. ",26322582
357,0,2_abstract_sentence,4,"Upon removal of  the barrier, forks underwent synchronous and site-specific termination, allowing  mechanistic dissection of this process. ",26322582
357,0,2_abstract_sentence,5,"We show that DNA synthesis does not slow  detectably as forks approach each other, and that leading strands pass each other unhindered before undergoing ligation to downstream lagging strands. ",26322582
357,0,2_abstract_sentence,6,"Dissociation of the replicative CMG helicase (comprising CDC45, MCM2-7 and GINS) occurs only after the final ligation step, and is not required for completion of DNA synthesis, strongly suggesting that converging CMGs pass one another and dissociate from double-stranded DNA. ",26322582
357,0,2_abstract_sentence,7,This termination mechanism allows rapid completion of DNA synthesis while avoiding premature replisome disassembly. ,26322582
2962,0,1_title,0,TNFÎ± and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.  ,29472271
2962,0,2_abstract_sentence,0,The cGAS-STING cytosolic DNA sensing pathway may play an integral role in the initiation of antitumor immune responses. ,29472271
2962,0,2_abstract_sentence,1,"Studies evaluating the immunogenicity of various cyclic dinucleotide (CDN) STING agonists administered by intratumoral  (i.t.) injection showed potent induction of inflammation, tumor necrosis, and, in some cases, durable tumor-specific adaptive immunity. ",29472271
2962,0,2_abstract_sentence,2,"However, the specific immune mechanisms underlying these responses remain incompletely defined. ",29472271
2962,0,2_abstract_sentence,3,The majority of these studies have focused on the effect of CDNs on immune cells but  have not conclusively interrogated the role of stromal cells in the acute rejection of the CDN-injected tumor. ,29472271
2962,0,2_abstract_sentence,4,"Here, we revealed a mechanism of STING agonist-mediated tumor response that relied on both stromal and immune cells to achieve tumor regression and clearance. ",29472271
2962,0,2_abstract_sentence,5,"Using knockout and bone marrow chimeric mice, we showed that although bone marrow-derived TNFÎ± was necessary for CDN-induced necrosis, STING signaling in radioresistant stromal cells was also essential for CDN-mediated tumor rejection. ",29472271
2962,0,2_abstract_sentence,6,These results provide evidence for crosstalk between stromal and hematopoietic cells during CDN-mediated tumor collapse after i.t. ,29472271
2962,0,2_abstract_sentence,7,administration. ,29472271
2962,0,2_abstract_sentence,8,These mechanistic insights may prove critical in the clinical development of STING agonists. ,29472271
2962,0,2_abstract_sentence,9,Cancer Immunol Res; 6(4); 422-33. ,29472271
2962,0,2_abstract_sentence,10, Â©2018 AACR. ,29472271
2962,1,1_title,0,A robust microparticle platform for a STING-targeted adjuvant that enhances both  humoral and cellular immunity during vaccination.  ,29170142
2962,1,2_abstract_sentence,0,"Most FDA-approved adjuvants for infectious agents boost humoral but not cellular  immunity, and have poorly-understood mechanisms. ",29170142
2962,1,2_abstract_sentence,1,"Stimulator of interferon genes (STING, also known as MITA, MPYS, or ERIS) is an exciting adjuvant target due to  its role in cyclic dinucleotide (CDN)-driven anti-viral immunity; however, a major hindrance is STING's cytosolic localization which requires intracellular delivery of its agonists. ",29170142
2962,1,2_abstract_sentence,2,"As a result, STING agonists administered in a soluble form have elicited suboptimal immune responses. ",29170142
2962,1,2_abstract_sentence,3,"Delivery of STING agonists via particle platforms has proven a more successful strategy, but the opportunity for improved formulations and bioactivity remains. ",29170142
2962,1,2_abstract_sentence,4,"In this study we evaluated the adjuvant activity of the potent STING agonist, CDN 3'3'-cGAMP (cGAMP), encapsulated in acid-sensitive acetalated dextran (Ace-DEX) polymeric microparticles (MPs) which passively target antigen-presenting cells for intracellular release. ",29170142
2962,1,2_abstract_sentence,5,This formulation was superior to all particle delivery systems evaluated and maintained its bioactivity following a sterilizing dose of  gamma irradiation. ,29170142
2962,1,2_abstract_sentence,6,"Compared to soluble cGAMP, the Ace-DEX cGAMP MPs enhanced type-I interferon responses nearly 1000-fold in vitro and 50-fold in vivo, caused up to a 104-fold boost in antibody titers, increased Th1-associated responses, and expanded germinal center B cells and memory T cells. ",29170142
2962,1,2_abstract_sentence,7,"Furthermore, the encapsulated cGAMP elicited no observable toxicity in animals and achieved protective immunity against a lethal influenza challenge seven months post-immunization when using CDN adjuvant doses up to 100-fold lower than previous reports. ",29170142
2962,1,2_abstract_sentence,8,"For these reasons, Ace-DEX MP-encapsulated cGAMP represents a potent vaccine adjuvant of humoral and cellular immunity. ",29170142
2962,2,1_title,0,Identification of Î±-Mangostin as an Agonist of Human STING.  ,30079976
2962,2,2_abstract_sentence,0,"The xanthone derivate 5',6'-dimethylxanthenone-4-acetic acid (DMXAA, also known as ASA404 or vadimezan) is a potent agonist of murine STING (stimulator of interferon genes), but cannot activate human STING. ",30079976
2962,2,2_abstract_sentence,1,"Herein we report that Î±-mangostin, which bears the xanthone skeleton, is an agonist of human STING, but activates murine STING to a lesser extent. ",30079976
2962,2,2_abstract_sentence,2,"Biochemical and cell-based assays indicate that Î±-mangostin binds to and activates human STING, leading to activation of the downstream interferon regulatory factor (IRF) pathway and production of typeâI interferons. ",30079976
2962,2,2_abstract_sentence,3,"Furthermore, our studies show that Î±-mangostin  has the potential to repolarize human monocyte-derived M2 macrophages to the M1 phenotype. ",30079976
2962,2,2_abstract_sentence,4,The agonist effect of Î±-mangostin in the STING pathway might account for its antitumor and antiviral activities. ,30079976
2962,3,1_title,0,Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.  ,29127039
2962,3,2_abstract_sentence,0,Therapeutic cancer vaccines require adjuvants leading to robust type I interferon and proinflammatory cytokine responses in the tumor microenvironment to induce an anti-tumor response. ,29127039
2962,3,2_abstract_sentence,1,"Cyclic dinucleotides (CDNs), a potent Stimulator of Interferon Receptor (STING) agonist, are currently in phase I trials. ",29127039
2962,3,2_abstract_sentence,2,"However, their efficacy may be limited to micromolar concentrations due to the cytosolic residence of STING in the ER membrane. ",29127039
2962,3,2_abstract_sentence,3,"Here we utilized biodegradable, poly(beta-amino ester) (PBAE) nanoparticles to deliver CDNs to the cytosol leading to robust immune response at >100-fold lower extracellular CDN concentrations in vitro. ",29127039
2962,3,2_abstract_sentence,4,The leading CDN PBAE nanoparticle formulation induced a  log-fold improvement in potency in treating established B16 melanoma tumors in vivo when combined with PD-1 blocking antibody in comparison to free CDN without  nanoparticles. ,29127039
2962,3,2_abstract_sentence,5,This nanoparticle-mediated cytosolic delivery method for STING agonists synergizes with checkpoint inhibitors and has strong potential for enhanced cancer immunotherapy. ,29127039
2962,4,1_title,0,Activation of Stimulator of Interferon Genes (STING) and SjÃ¶gren Syndrome.  ,29505322
2962,4,2_abstract_sentence,0,"SjÃ¶gren syndrome (SS), a chronic autoimmune disorder causing dry mouth, adversely affects the overall oral health in patients. ",29505322
2962,4,2_abstract_sentence,1,Activation of innate immune responses and excessive production of type I interferons (IFNs) play a critical role in the pathogenesis of this disorder. ,29505322
2962,4,2_abstract_sentence,2,Recognition of nucleic acids by cytosolic nucleic acid sensors is a major trigger for the induction of type I IFNs. ,29505322
2962,4,2_abstract_sentence,3,"Upon activation, cytosolic DNA sensors can interact with the stimulator of  interferon genes (STING) protein, and activation of STING causes increased expression of type I IFNs. ",29505322
2962,4,2_abstract_sentence,4,The role of STING activation in SS is not known. ,29505322
2962,4,2_abstract_sentence,5,"In this study, to investigate whether the cytosolic DNA sensing pathway influences SS development, female C57BL/6 mice were injected with a STING agonist, dimethylxanthenone-4-acetic acid (DMXAA). ",29505322
2962,4,2_abstract_sentence,6,Salivary glands (SGs) were studied for  gene expression and inflammatory cell infiltration. ,29505322
2962,4,2_abstract_sentence,7,SG function was evaluated by  measuring pilocarpine-induced salivation. ,29505322
2962,4,2_abstract_sentence,8,Sera were analyzed for cytokines and autoantibodies. ,29505322
2962,4,2_abstract_sentence,9,Primary SG cells were used to study the expression and activation of STING. ,29505322
2962,4,2_abstract_sentence,10,"Our data show that systemic DMXAA treatment rapidly induced the expression of Ifnb1, Il6, and Tnfa in the SGs, and these cytokines were also elevated in circulation. ",29505322
2962,4,2_abstract_sentence,11,"In contrast, increased Ifng gene expression was dominantly detected in the SGs. ",29505322
2962,4,2_abstract_sentence,12,"The type I innate lymphoid cells present within the SGs were the major source of IFN-Î³, and their numbers increased significantly within 3 d of treatment. ",29505322
2962,4,2_abstract_sentence,13,STING expression in SGs was mainly observed in ductal and interstitial cells. ,29505322
2962,4,2_abstract_sentence,14,"In primary SG cells, DMXAA activated STING and induced IFN-Î² production. ",29505322
2962,4,2_abstract_sentence,15,"The DMXAA-treated mice developed autoantibodies, sialoadenitis, and glandular hypofunction. ",29505322
2962,4,2_abstract_sentence,16,Our study demonstrates that activation of the STING pathway holds the potential to initiate SS. ,29505322
2962,4,2_abstract_sentence,17,"Thus, apart from viral infections, conditions that cause cellular perturbations and accumulation of host DNA within  the cytosol should also be considered as possible triggers for SS. ",29505322
2516,0,1_title,0,Pain-mediated affect regulation is reduced after dialectical behavior therapy in  borderline personality disorder: a longitudinal fMRI study.  ,28119507
2516,0,2_abstract_sentence,0,"Borderline Personality Disorder (BPD) is characterized by affective instability,  but self-injurious behavior appears to have an emotion-regulating effect. ",28119507
2516,0,2_abstract_sentence,1,"We investigated whether pain-mediated affect regulation can be altered at the neural level by residential Dialectical Behavior Therapy (DBT), providing adaptive emotion regulation techniques. ",28119507
2516,0,2_abstract_sentence,2,"Likewise, we investigated whether pain thresholds  or the appraisal of pain change after psychotherapy. ",28119507
2516,0,2_abstract_sentence,3,"We investigated 28 patients  with BPD undergoing DBT (self-referral), 15 patients with treatment as usual and  23 healthy control subjects at two time points 12 weeks apart. ",28119507
2516,0,2_abstract_sentence,4,We conducted an fMRI experiment eliciting negative emotions with picture stimuli and induced heat pain to investigate the role of pain in emotion regulation. ,28119507
2516,0,2_abstract_sentence,5,"Additionally, we assessed heat and cold pain thresholds.At first measurement, patients with BPD showed amygdala deactivation in response to painful stimulation, as well as altered connectivity between left amygdala and dorsal anterior cingulate cortex. ",28119507
2516,0,2_abstract_sentence,6," These effects were reduced after DBT, as compared with patients with treatment as usual. ",28119507
2516,0,2_abstract_sentence,7,Pain thresholds did not differ between the patient groups. ,28119507
2516,0,2_abstract_sentence,8,"We replicated the role of pain as a means of affect regulation in BPD, indicated by increased amygdala coupling. ",28119507
2516,0,2_abstract_sentence,9,"For the first time, we could demonstrate that pain-mediated affect regulation can be changed by DBT. ",28119507
2516,1,1_title,0,Influence and Change of Self-Directedness in Dialectical Behavior Therapy.  ,27399588
2516,1,2_abstract_sentence,0,Objective Investigate influence and change of self-directedness (SD) in Dialectical-Behavior Therapy (DBT) for 26 female outpatients with borderline personality disorder (BPS). ,27399588
2516,1,2_abstract_sentence,1,Method Variance analyses are used to evaluate psychopathology and interpersonal problems in 2 subgroups (low vs. ,27399588
2516,1,2_abstract_sentence,2,high SD) with  questionnaires at 3 measuring times over the period of 1 year. ,27399588
2516,1,2_abstract_sentence,3,"Results Low SD was associated with higher psychopathology, more interpersonal problems and lower symptomreduction. ",27399588
2516,1,2_abstract_sentence,4,Over time of intervention the SD of all patients improved significantly. ,27399588
2516,1,2_abstract_sentence,5,Conclusion DBT strengthens the SD of patients with BPD. ,27399588
2516,1,2_abstract_sentence,6,"A screening of SD before intervention, and systematic support should be considered. ",27399588
2516,2,1_title,0,Exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - A pilot study.  ,27897326
2516,2,2_abstract_sentence,0,"OBJECTIVES: Borderline personality disorder (BPD) is characterized by emotional instability, interpersonal dysfunction, and other features that typically develop before a background of insecure attachment and traumatic experiences. ",27897326
2516,2,2_abstract_sentence,1,"Dialectical behaviour therapy (DBT) has proven highly effective in reducing self-harm and improving emotion regulation, whereby problems concerning social cognition, which are also characteristic of BPD, may need additional approaches such as mentalization-based treatment (MBT). ",27897326
2516,2,2_abstract_sentence,2,"METHODS: Here, we examined, in a pilot study, the effectiveness of MBT given adjunct to DBT, compared to DBT alone, in an inpatient sample with BPD, whereby mentalization was measured using a novel cartoon-based task. ",27897326
2516,2,2_abstract_sentence,3,RESULTS: Both treatments were highly effective in reducing symptom severity. ,27897326
2516,2,2_abstract_sentence,4,The  combination of DBT and MBT was superior in reducing fearful attachment and in improving affective mentalizing. ,27897326
2516,2,2_abstract_sentence,5,"CONCLUSIONS: Mentalization-based treatment in combination with DBT may improve certain aspects of social cognitive skills and attachment security, as compared to DBT alone, although the exact mechanisms that led to these changes need to be  studied further. ",27897326
2516,2,2_abstract_sentence,6,PRACTITIONER POINTS: Clinical implications Dialectical behaviour therapy (DBT) can usefully be combined with mentalization-based treatment (MBT). ,27897326
2516,2,2_abstract_sentence,7,The combination of DBT and MBT reduces self-harm more than DBT alone. ,27897326
2516,2,2_abstract_sentence,8,DBT plus MBT may lead to a reduction in fearful attachment and improvement of affective mentalizing. ,27897326
2516,2,2_abstract_sentence,9,Short-term combinations of evidence-based borderline treatments may  enrich psychiatric inpatient care. ,27897326
2516,2,2_abstract_sentence,10,"Therefore, such approaches deserve further research. ",27897326
2516,2,2_abstract_sentence,11,Limitations The treatment condition was therapeutically more intense than the control condition. ,27897326
2516,2,2_abstract_sentence,12,The study lacked a follow-up assessment. ,27897326
2516,2,2_abstract_sentence,13,The impact of comorbid conditions on treatment response was not taken into account. ,27897326
2516,2,2_abstract_sentence,14,Adherence to the manualized approach was not measured. ,27897326
2516,3,1_title,0,Dialectical behavior therapy approaches with disruptive behavior disorders.  ,27642799
2516,3,2_abstract_sentence,0,Disruptive behaviour disorders comprise the diagnosis conduct disorder (CD) and in adults the diagnosis antisocial personality disorder (APD). ,27642799
2516,3,2_abstract_sentence,1,CD is seen as a difficult-to-treat disorder with a high risk for persistent behavioral problems. ,27642799
2516,3,2_abstract_sentence,2," In addition, CD is seen as the precursor to antisocial personality disorder (Kretschmer et al., 2014). ",27642799
2516,3,2_abstract_sentence,3,"Dialectical behavior therapy (DBT) was originally developed by Marsha Linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, DBT is also increasingly being recommended for the treatment  of CD and APD. ",27642799
2516,3,2_abstract_sentence,4,This review presents DBT adaptions for the forensic setting and for the treatment of CD/APD. ,27642799
2516,3,2_abstract_sentence,5,Clinical implications are discussed. ,27642799
2516,4,1_title,0,Dialectical behavior therapy for comorbid personality disorders.  ,18186120
2516,4,2_abstract_sentence,0,"Dialectical behavior therapy (DBT) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women). ",18186120
2516,4,2_abstract_sentence,1,"However, a number of complex disorders represent the dialectical opposite of BPD and related disorders; these disorders are characterized by being overcontrolled, emotionally constricted, perfectionistic, and highly risk-averse. ",18186120
2516,4,2_abstract_sentence,2,"In this article, the authors introduce a recent adaptation of DBT that targets cognitive-behavioral rigidity and emotional constriction and illustrates its application through the case of a man suffering from both paranoid personality disorder and obsessive-compulsive personality disorder. ",18186120
2516,5,1_title,0,Use of dialectical behavior therapy in inpatient treatment of borderline personality disorder: a systematic review.  ,22751905
2516,5,2_abstract_sentence,0,OBJECTIVE: Dialectical behavior therapy (DBT) is an empirically supported treatment for outpatients with borderline personality disorder. ,22751905
2516,5,2_abstract_sentence,1,"However, the utility of DBT strategies for inpatients with the disorder is unclear. ",22751905
2516,5,2_abstract_sentence,2,This review summarizes and synthesizes findings from trials of DBT in inpatient settings. ,22751905
2516,5,2_abstract_sentence,3,"METHODS: Multiple research databases were searched for articles published through June 2011 that reported on any implementation of DBT in an inpatient setting to address symptoms related to borderline personality disorder, including suicidal and self-injurious behavior. ",22751905
2516,5,2_abstract_sentence,4,RESULTS: Eleven studies that reported pre- and posttreatment symptoms related to  borderline personality disorder were evaluated. ,22751905
2516,5,2_abstract_sentence,5,"Studies indicated that many variations of standard DBT have been used in inpatient settings, including approaches that do not include phone consultation, that include group therapy only, and that vary in treatment duration (from two weeks to three months). ",22751905
2516,5,2_abstract_sentence,6,"Most  studies reported reductions in suicidal ideation, self-injurious behaviors, and symptoms of depression and anxiety, whereas results for reducing anger and violent behaviors were mixed. ",22751905
2516,5,2_abstract_sentence,7,Follow-up data indicated that symptom reduction was often maintained between one and 21 months posttreatment. ,22751905
2516,5,2_abstract_sentence,8,"On the basis of the evidence, the authors identify essential components of an inpatient DBT package and discuss its potential function as an ""intensive orientation"" to outpatient DBT services. ",22751905
2516,5,2_abstract_sentence,9,CONCLUSIONS: There is considerable variation in the configuration and duration of DBT implementation for inpatients with borderline personality disorder. ,22751905
2516,5,2_abstract_sentence,10,"However,  findings suggest that DBT may be effective in reducing symptoms related to borderline personality disorder in inpatient settings. ",22751905
2516,5,2_abstract_sentence,11,Future research should standardize and systematically test inpatient DBT. ,22751905
2516,5,2_abstract_sentence,12,"(Psychiatric Services 63:881-888, 2012; doi: 10.1176/appi.ps.201100311). ",22751905
2516,6,1_title,0,M. Linehan dialectic behavioral psychotherapy. A new concept in the treatment of borderline personality disorders.  ,9064551
2516,6,2_abstract_sentence,0,M. ,9064551
2516,6,2_abstract_sentence,1,"Linehan developed ""dialectical behavioral therapy"" specifically to treat chronically suicidal borderline patients. ",9064551
2516,6,2_abstract_sentence,2,It rests on a biosocial model that assumes a disorder in the regulation of emotions and in tolerance of stress. ,9064551
2516,6,2_abstract_sentence,3,"The  numerous dysfunctional patterns of behavior such as self-destructive behavior, inability to govern impulses or severe dissociative phenomena are regarded as attempts at problem-solving. ",9064551
2516,6,2_abstract_sentence,4,This concept of therapy focuses on the continuing balance between the necessity of accepting maladaptive behavior patterns in both  an intrapsychic and an interactional context while still working to change them. ,9064551
2516,6,2_abstract_sentence,5, A comprehensive manual outlines the clearly structured therapy and integrates a wide choice of therapeutic strategies. ,9064551
2516,6,2_abstract_sentence,6,"Parallel to development of the therapy itself, a method also was developed for testing therapist adherence to the manual's guidelines, thus providing a basis for empirical evaluation. ",9064551
2516,6,2_abstract_sentence,7,"An initial  controlled, randomized study demonstrated the significant superiority of this method to methods of unspecific psychotherapy at various levels. ",9064551
2516,6,2_abstract_sentence,8,"In the current endeavor to develop disorder-specific approaches to the treatment of personality  disorders, ""dialectical behavioral therapy"" is a noteworthy model. ",9064551
2516,7,1_title,0,Interpersonal outcome of cognitive behavioral treatment for chronically suicidal  borderline patients.  ,7977884
2516,7,2_abstract_sentence,0,OBJECTIVE: This study reports the efficacy of a cognitive behavioral outpatient treatment on interpersonal outcome variables for patients diagnosed with borderline personality disorder. ,7977884
2516,7,2_abstract_sentence,1,"METHOD: In a 1-year clinical trial, 26 female patients with borderline personality disorder were randomly assigned to either dialectical behavior therapy or a treatment-as-usual comparison condition. ",7977884
2516,7,2_abstract_sentence,2,All subjects met criteria of DSM-III-R and Diagnostic Interview for Borderline Patients for borderline personality disorder and were chronically suicidal. ,7977884
2516,7,2_abstract_sentence,3,"RESULTS: In both the intent-to-treat and treatment completion groups, dialectical behavior therapy subjects had significantly better scores on measures of anger, interviewer-rated global social adjustment, and the Global Assessment Scale and tended to rate themselves better on overall social adjustment than treatment-as-usual subjects. ",7977884
2516,7,2_abstract_sentence,4,CONCLUSIONS: These results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder. ,7977884
2516,8,1_title,0,Use of dialectical behavior therapy in a partial hospital program for women with  borderline personality disorder.  ,9603574
2516,8,2_abstract_sentence,0,"Dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women. ",9603574
2516,8,2_abstract_sentence,1,"Patients attend the program for  a minimum of five days of individual and group therapy, and full census is 12 women. ",9603574
2516,8,2_abstract_sentence,2,"About 65 percent of participants meet at least three criteria for borderline personality disorder, and most have suicidal and self-injurious behavior. ",9603574
2516,8,2_abstract_sentence,3,"Their comorbid diagnoses include trauma-related diagnoses and anxiety disorders, severe eating disorders, substance abuse, and depression. ",9603574
2516,8,2_abstract_sentence,4,The partial  hospital program is linked to an aftercare program offering six months of outpatient skills training based on dialectical behavior therapy. ,9603574
2516,8,2_abstract_sentence,5,"Both programs focus on teaching patients four skills: mindfulness (attention to one's experience), interpersonal effectiveness, emotional regulation, and distress tolerance. ",9603574
2516,8,2_abstract_sentence,6,"Two years of operation of the women's partial hospital program provides promising anecdotal evidence that dialectical behavioral therapy, an outpatient approach, can be effectively modified for partial hospital settings and a more diverse population. ",9603574
2516,9,1_title,0,Use of dialectical behavior therapy in borderline personality disorder: a view from residency.  ,17496179
2516,9,2_abstract_sentence,0,"OBJECTIVE: The authors describe the use of dialectical behavior therapy (DBT) in  treating borderline personality disorder during psychiatry residency, and assess  the status of DBT education within psychiatry residencies in the United States. ",17496179
2516,9,2_abstract_sentence,1,"METHOD: The authors present a patient with borderline personality disorder treated by a resident using DBT, along with perspectives from the resident's supervisors. ",17496179
2516,9,2_abstract_sentence,2,"Additionally, self-report surveys inquiring about the attitudes and  experiences of residency directors and PGY-4 residents regarding DBT were sent to program directors with available e-mail addresses on FREIDA online. ",17496179
2516,9,2_abstract_sentence,3,RESULTS: The DBT method employed by the resident had to be modified to fit the constraints of a residency program. ,17496179
2516,9,2_abstract_sentence,4,"The patient in therapy had a tumultuous course, ultimately resulting in the discontinuation of treatment. ",17496179
2516,9,2_abstract_sentence,5,"Survey results  suggested an underemphasis on the education and use of DBT during residency, though the strength of this conclusion is limited by the small proportion of surveys returned. ",17496179
2516,9,2_abstract_sentence,6,CONCLUSIONS: Achieving the efficacy of DBT-based treatment of borderline personality disorder reported in the literature in the setting of a residency program is challenging. ,17496179
2516,9,2_abstract_sentence,7,Greater exposure to DBT during residency may increase residents' skills in using the technique and the likelihood that they will use it after residency. ,17496179
2516,10,1_title,0,Teaching Dialectical Behavior Therapy to Psychiatry Residents: The Columbia Psychiatry Residency DBT Curriculum.  ,27481266
2516,10,2_abstract_sentence,0,OBJECTIVE: Dialectical behavior therapy (DBT) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (BPD). ,27481266
2516,10,2_abstract_sentence,1,"This study describes and evaluates a clinical curriculum to teach DBT to psychiatry residents, developed at a large urban university hospital. ",27481266
2516,10,2_abstract_sentence,2,"The  curriculum objectives are to (1) have psychiatry residents achieve basic understanding of DBT theory and clinical skill, (2) increase residents' ability and confidence in treating self-harm behaviors (both suicidal behavior and non-suicidal self-injury), and (3) enhance residents' willingness to treat individuals with BPD. ",27481266
2516,10,2_abstract_sentence,3,"METHODS: In addition to a 6-week didactic course on DBT offered to all residents  (nâ=â62), 25 elected to enroll in a year-long DBT clinical training curriculum over the course of a 5-year period. ",27481266
2516,10,2_abstract_sentence,4,"The DBT clinical training consisted of 15Â h of additional didactics, ongoing conduct of individual therapy and group DBT skills training, videotaping of individual therapy sessions, and weekly supervision meetings utilizing videotape to provide feedback. ",27481266
2516,10,2_abstract_sentence,5,"Residents participating in the clinical training program videotaped baseline and later sessions, which were rated for DBT adherence. ",27481266
2516,10,2_abstract_sentence,6,All 62 graduates of the program were surveyed regarding the impact of the training on their practice of psychiatry. ,27481266
2516,10,2_abstract_sentence,7,"RESULTS: Upon graduation, a high percentage (87Â % in the curriculum and 70Â % in the didactic course only) reported incorporating DBT into their psychiatry practice, as well as willingness and confidence in treating BPD and self-harm behaviors. ",27481266
2516,10,2_abstract_sentence,8,"Residents participating in the clinical training demonstrated significant improvement in their ability to utilize DBT interventions, particularly in structuring sessions, problem assessment, problem solving, and using validation and dialectical strategies. ",27481266
2516,10,2_abstract_sentence,9,CONCLUSION: This DBT curriculum was effective in preparing psychiatrists-in-training to incorporate evidence-based practices for effective treatment of BPD and self-harm behaviors and can serve as a model for teaching DBT during psychiatry residency training. ,27481266
2516,10,2_abstract_sentence,10,Limitations include a small sample size and lack of baseline survey measurement of attitudes for pre- and post-curriculum comparison. ,27481266
2516,11,1_title,0,Psychological Treatments for Borderline Personality Disorder: A Review of Cognitive-Behavioral Oriented Therapies.  ,28555557
2516,11,2_abstract_sentence,0,"INTRODUCTION: Borderline personality disorder is the most common personality disorder, with a global prevalence rate between 1.6% and 6%. ",28555557
2516,11,2_abstract_sentence,1,"It is characterized  by affective disturbance and impulsivity, which lead to a high number of self-harm behaviors and great amount of health services use. ",28555557
2516,11,2_abstract_sentence,2,International guidelines recommend psychotherapy as the primary treatment for borderline personality disorder. ,28555557
2516,11,2_abstract_sentence,3,This paper reviews evidence about the effects and efficacy  of cognitive-behavioral oriented psychological treatments for borderline personality disorder. ,28555557
2516,11,2_abstract_sentence,4,"MATERIAL AND METHODS: A literature review was conducted in Medline and PubMed databases, using the following keywords: borderline personality disorder, cognitive-behavioral psychotherapy and efficacy. ",28555557
2516,11,2_abstract_sentence,5,"RESULTS: Sixteen randomized clinical trials were evaluate in this review, which analyzed the effects of several cognitive-behavioral oriented psychotherapeutic interventions, namely dialectical behavioral therapy, cognitive behavioral therapy, schema-focused therapy and manual-assisted cognitive therapy. ",28555557
2516,11,2_abstract_sentence,6,"All above  stated treatments showed clinical beneficial effects, by reducing borderline personality disorder core pathology and associated general psychopathology, as well as by reducing the severity and frequency of self-harm behaviors, and by improving the overall social, interpersonal and global adjustment. ",28555557
2516,11,2_abstract_sentence,7,"Dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively. ",28555557
2516,11,2_abstract_sentence,8,"DISCUSSION: Although there were differences between the psychotherapeutic interventions analysed in this review, all showed clinical benefits in the treatment of borderline personality disorder. ",28555557
2516,11,2_abstract_sentence,9,"Dialectical behavioral therapy and  schema-focused therapy presented the strongest scientific data documenting their  efficacy, but both interventions are integrative cognitive-behavioral therapies which deviate from the traditional cognitive-behavioral model. ",28555557
2516,11,2_abstract_sentence,10,"CONCLUSION: In summary, the available studies support cognitive-behavioral psychological treatments as an efficacious intervention in borderline personality disorder. ",28555557
2516,11,2_abstract_sentence,11,"However, the existing scientific literature on this topic is still scarce and there is need for more studies, with higher methodological rigor, that should validate these results. ",28555557
2516,12,1_title,0,Treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the  therapists' perceptions.  ,14608551
2516,12,2_abstract_sentence,0,The aim was to investigate patients and therapists perception of receiving and giving dialectical behavioral therapy (DBT). ,14608551
2516,12,2_abstract_sentence,1,Ten deliberate self-harm patients with borderline personality disorder and four DBT-therapists were interviewed. ,14608551
2516,12,2_abstract_sentence,2,The interviews were analyzed with qualitative content analysis. ,14608551
2516,12,2_abstract_sentence,3,The patients unanimously regard the DBT-therapy as life saving and something that has given them a bearable life situation. ,14608551
2516,12,2_abstract_sentence,4,"The patients and the therapists are concordant on the effective components of the therapy: the understanding, respect, and confirmation in combination with the cognitive and behavioral skills. ",14608551
2516,12,2_abstract_sentence,5,The experienced effectiveness of DBT is contrasted by the patient's pronouncedly negative experiences from psychiatric care before entering DBT. ,14608551
2516,13,1_title,0,Dialectical behavior therapy for borderline personality disorder: a meta-analysis using mixed-effects modeling.  ,21114345
2516,13,2_abstract_sentence,0,"OBJECTIVE: At present, the most frequently investigated psychosocial intervention for borderline personality disorder (BPD) is dialectical behavior therapy (DBT). ",21114345
2516,13,2_abstract_sentence,1, We conducted a meta-analysis to examine the efficacy and long-term effectiveness  of DBT. ,21114345
2516,13,2_abstract_sentence,2,"METHOD: Systematic bibliographic research was undertaken to find relevant literature from online databases (PubMed, PsycINFO, PsychSpider, Medline). ",21114345
2516,13,2_abstract_sentence,3,"We excluded studies in which patients with diagnoses other than BPD were treated, the treatment did not comprise all components specified in the DBT manual or in the suggestions for inpatient DBT programs, patients failed to be diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, and the intervention group comprised fewer than 10 patients. ",21114345
2516,13,2_abstract_sentence,4,"Using a mixed-effect hierarchical modeling approach, we calculated global effect sizes and effect sizes for suicidal and self-injurious behaviors. ",21114345
2516,13,2_abstract_sentence,5,RESULTS: Calculations of postintervention global effect sizes were based on 16 studies. ,21114345
2516,13,2_abstract_sentence,6,"Of these, 8 were randomized controlled trials (RCTs), and 8 were neither randomized nor controlled (nRCT). ",21114345
2516,13,2_abstract_sentence,7,The dropout rate was 27.3% pre- to posttreatment. ,21114345
2516,13,2_abstract_sentence,8,"A moderate global effect and a moderate effect size for suicidal and self-injurious behaviors were found, when including a moderator for RCTs with borderline-specific treatments. ",21114345
2516,13,2_abstract_sentence,9,"There was no evidence for the influence of other  moderators (e.g., quality of studies, setting, duration of intervention). ",21114345
2516,13,2_abstract_sentence,10,"A small impairment was shown from posttreatment to follow-up, including 5 RCTs only. ",21114345
2516,13,2_abstract_sentence,11,CONCLUSIONS: Future research should compare DBT with other active borderline-specific treatments that have also demonstrated their efficacy using several long-term follow-up assessment points. ,21114345
2516,14,1_title,0,A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder.  ,19755574
2516,14,2_abstract_sentence,0,Erratum in     Am J Psychiatry. ,19755574
2516,14,2_abstract_sentence,1,2010 Oct;167(10):1283. ,19755574
2516,15,1_title,0,Compliance and patience is needed when meeting patients with personality disorder.  ,27959459
2516,15,2_abstract_sentence,0,Compliance and patience is needed when meeting patients with personality disorder To encounter patients with personality disorders in health care settings is often challenging. ,27959459
2516,15,2_abstract_sentence,1,Most treatment studies published have included only patients with borderline personality disorder. ,27959459
2516,15,2_abstract_sentence,2,"Of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (DBT) has the strongest research support, followed by mentalization based therapy (MBT). ",27959459
2516,15,2_abstract_sentence,3,Pharmacological treatment in personality disorders should focus on time-limited crisis intervention and treatment of comorbidity. ,27959459
2516,15,2_abstract_sentence,4,There are few studies on inpatient care of persons with personality disorder. ,27959459
2516,15,2_abstract_sentence,5,"However, there are some interesting projects on brief self-directed inpatient stays as crisis intervention. ",27959459
2516,15,2_abstract_sentence,6,There is a consensus to avoid long inpatient stays and coercive measures as far as possible. ,27959459
2516,16,1_title,0,Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder.  ,20579633
2516,16,2_abstract_sentence,0,A central component of Dialectical Behavior Therapy (DBT) is the teaching of specific behavioral skills with the aim of helping individuals with Borderline Personality Disorder (BPD) replace maladaptive behaviors with skillful behavior. ,20579633
2516,16,2_abstract_sentence,1," Although existing evidence indirectly supports this proposed mechanism of action, no study to date has directly tested it. ",20579633
2516,16,2_abstract_sentence,2,"Therefore, we examined the skills use of 108 women with BPD participating in one of three randomized control trials throughout one year of treatment and four months of follow-up. ",20579633
2516,16,2_abstract_sentence,3,"Using a hierarchical linear modeling approach we found that although all participants reported using some DBT skills before treatment started, participants treated with DBT reported using three times more skills at the end of treatment than participants treated with a control treatment. ",20579633
2516,16,2_abstract_sentence,4,Significant mediation effects also indicated that DBT skills use fully mediated the decrease in suicide attempts and depression and the increase in control of anger over time. ,20579633
2516,16,2_abstract_sentence,5,DBT skills use also partially mediated the decrease of nonsuicidal self-injury over time. ,20579633
2516,16,2_abstract_sentence,6,Anger suppression and expression were not mediated. ,20579633
2516,16,2_abstract_sentence,7,"This study is the first to clearly  support the skills deficit model for BPD by indicating that increasing skills use is a mechanism of change for suicidal behavior, depression, and anger control. ",20579633
2516,17,1_title,0,Neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.  ,27091455
2516,17,2_abstract_sentence,0,Neural underpinnings of emotion dysregulation in borderline personality disorder  (BPD) are characterized by limbic hyperactivity and disturbed prefrontal activity. ,27091455
2516,17,2_abstract_sentence,1,"It is unknown whether neural correlates of emotion regulation change after a psychotherapy which has the goal to improve emotion dysregulation in BPD, such as dialectical behavioral therapy (DBT). ",27091455
2516,17,2_abstract_sentence,2,We investigated distraction as a main emotion regulation strategy before and after DBT in female patients with BPD. ,27091455
2516,17,2_abstract_sentence,3,Thirty-one BPD patients were instructed to either passively view or memorize letters before being confronted with negative or neutral pictures in a distraction task during functional magnetic resonance imaging. ,27091455
2516,17,2_abstract_sentence,4,This paradigm was  applied before and after a 12-week residential DBT-based treatment program. ,27091455
2516,17,2_abstract_sentence,5,"We compared the DBT group to 15 BPD control patients, who continued their usual, non-DBT-based treatment or did not have any treatment, and 22 healthy participants. ",27091455
2516,17,2_abstract_sentence,6,"Behaviorally, BPD groups and healthy participants did not differ significantly with respect to alterations over time. ",27091455
2516,17,2_abstract_sentence,7,"On the neural level, BPD patients who received DBT-based treatment showed an activity decrease in the right inferior parietal lobe/supramarginal gyrus during distraction from negative rather than neutral stimuli when compared to both control groups. ",27091455
2516,17,2_abstract_sentence,8,This decrease was correlated with improvement in self-reported borderline symptom severity. ,27091455
2516,17,2_abstract_sentence,9,DBT responders exhibited decreased right perigenual anterior cingulate activity when  viewing negative (rather than neutral) pictures. ,27091455
2516,17,2_abstract_sentence,10,"In conclusion, our findings reveal changes in neural activity associated with distraction during emotion processing after DBT in patients with BPD. ",27091455
2516,17,2_abstract_sentence,11,These changes point to lower emotional susceptibility during distraction after BPD symptom improvement. ,27091455
2955,0,1_title,0,The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update.  ,25626182
2955,0,2_abstract_sentence,0,"The purpose of the RAZOR (randomized open vs robotic cystectomy) study is to compare open radical cystectomy (ORC) vs robot-assisted RC (RARC), pelvic lymph node dissection (PLND) and urinary diversion for oncological outcomes, complications and health-related quality of life (HRQL) measures with a primary endpoint of 2-year progression-free survival (PFS). ",25626182
2955,0,2_abstract_sentence,1,"RAZOR is a multi-institutional, randomized, non-inferior, phase III trial that will enrol at least 320 patients with T1-T4, N0-N1, M0 bladder cancer with â160 patients in both the RARC and ORC arms at 15 participating institutions. ",25626182
2955,0,2_abstract_sentence,2,"Data will be collected prospectively at each institution for cancer outcomes, complications of surgery and HRQL measures, and then submitted to trial data management services Cancer Research and Biostatistics (CRAB) for final analyses. ",25626182
2955,0,2_abstract_sentence,3,"To date, 306 patients have been randomized and accrual to the RAZOR trial is expected to conclude in 2014. ",25626182
2955,0,2_abstract_sentence,4,"In this study, we report the RAZOR trial experimental design, objectives, data safety, and monitoring, and accrual update. ",25626182
2955,0,2_abstract_sentence,5,"The RAZOR trial is a landmark study in urological oncology, randomizing T1-T4, N0-N1, M0 patients with bladder cancer to ORC vs RARC, PLND and urinary diversion. ",25626182
2955,0,2_abstract_sentence,6,"RAZOR is a multi-institutional, non-inferiority trial evaluating cancer outcomes, surgical complications and HRQL measures of ORC vs RARC with a primary endpoint of 2-year  PFS. ",25626182
2955,0,2_abstract_sentence,7,Full data from the RAZOR trial are not expected until 2016-2017. ,25626182
2955,1,1_title,0,Robot-assisted radical cystectomy with intracorporeal urinary diversion - The new 'gold standard'? Evidence from a systematic review.  ,30140466
2955,1,2_abstract_sentence,0,"Objective: To investigate whether a totally intracorporeally radical cystectomy (RC) can be considered the new 'gold standard' in bladder cancer, as open RC (ORC) is the current 'gold standard' for surgical treatment of muscle-invasive and high-grade non-muscle-invasive bladder cancer. ",30140466
2955,1,2_abstract_sentence,1,"However, robot-assisted radical cystectomy (RARC) is becoming the preferred surgical approach in many centres as it seems to maintain the oncological control of open surgery whilst offering improved perioperative benefits. ",30140466
2955,1,2_abstract_sentence,2,"Materials and methods: A review of the literature was conducted using the Pubmed/MEDLINE, ISI Web of Knowledge and Cochrane Databases to identify studies that included both ORC and RARC with intracorporeal and extracorporeal urinary diversion (UD) published up to July 2017. ",30140466
2955,1,2_abstract_sentence,3,Results: Evidence from four single-centre randomised controlled trials and now the multicentre Randomized Trial of Open versus Robotic Cystectomy (RAZOR) trial  demonstrate the oncological equivalence of RARC to ORC. ,30140466
2955,1,2_abstract_sentence,4,The only convincing evidence for the superiority of RARC is in the area of blood loss and transfusion rates. ,30140466
2955,1,2_abstract_sentence,5,"However, the UD procedure in these trials was performed extracorporeally and, to realise the full benefits of RARC, a totally intracorporeal approach is needed. ",30140466
2955,1,2_abstract_sentence,6,Intracorporeal UDs (ICUDs) have been shown to be technically feasible by  a few expert centres and have demonstrated some improved short-term perioperative outcomes compared to extracorporeal UDs. ,30140466
2955,1,2_abstract_sentence,7,"Conclusions: Although initial outcomes appear promising, RARC with ICUD is far from gaining 'gold standard' status. ",30140466
2955,1,2_abstract_sentence,8,Further studies are needed to confirm that outcomes are reproducible widely. ,30140466
2955,1,2_abstract_sentence,9,"Furthermore, the benefits of a totally intracorporeal approach must be confirmed in randomised controlled trials. ",30140466
2955,2,1_title,0,"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.  ",29976469
2955,2,2_abstract_sentence,0,Comment in     Lancet. ,29976469
2955,2,2_abstract_sentence,1,2018 Jun 23;391(10139):2479-2480. ,29976469
2955,2,2_abstract_sentence,2,    Eur Urol. ,29976469
2955,2,2_abstract_sentence,3,2018 Dec;74(6):840-841. ,29976469
2955,2,2_abstract_sentence,4,    Eur Urol. ,29976469
2955,2,2_abstract_sentence,5,2019 Jan;75(1):199. ,29976469
2955,2,2_abstract_sentence,6,    Eur Urol. ,29976469
2955,2,2_abstract_sentence,7,2019 Feb;75(2):e36. ,29976469
2955,2,2_abstract_sentence,8,    Lancet. ,29976469
2955,2,2_abstract_sentence,9,2019 Feb 16;393(10172):642-644. ,29976469
2955,2,2_abstract_sentence,10,    Lancet. ,29976469
2955,2,2_abstract_sentence,11,2019 Feb 16;393(10172):644-645. ,29976469
2955,2,2_abstract_sentence,12,    Lancet. ,29976469
2955,2,2_abstract_sentence,13,2019 Feb 16;393(10172):645. ,29976469
252,0,1_title,0,Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.  ,20457704
252,0,2_abstract_sentence,0,"Tuberous sclerosis, caused by germline mutations in the TSC1 or TSC2 genes, is associated with aberrant upregulation of the mammalian target of rapamycin (mTOR) signalling pathway, resulting in growth of tumours, including renal angiomyolipomas (AMLs). ",20457704
252,0,2_abstract_sentence,1,"AMLs may cause hypertension, renal failure and spontaneous life-threatening haemorrhage. ",20457704
252,0,2_abstract_sentence,2,"Previously, invasive interventions were required to treat AMLs. ",20457704
252,0,2_abstract_sentence,3,"More recently, mTOR inhibitors have been used as molecularly targeted treatment to treat AMLs. ",20457704
252,0,2_abstract_sentence,4,We present here the case of a paediatric patient with TSC in whom sirolimus has been used successfully to halt  growth of renal AMLs. ,20457704
252,1,1_title,0,Genetics and molecular biology of tuberous sclerosis complex.  ,19506736
252,1,2_abstract_sentence,0,"Tuberous Sclerosis Complex is a multisystem disorder exhibiting a wide range of manifestations characterized by tumour-like lesions called hamartomas in the brain, skin, eyes, heart, lungs and kidneys. ",19506736
252,1,2_abstract_sentence,1,Tuberous Sclerosis Complex is genetically determined with an autosomal dominant inheritance and is caused by inactivating mutations in either the TSC1 or TSC2 genes. ,19506736
252,1,2_abstract_sentence,2,"TSC1/2 genes play a fundamental role in the regulation of phosphoinositide 3-kinase (PI3K) signalling pathway, inhibiting the mammalian target of rapamycin (mTOR) through activation of the GTPase activity of Rheb. ",19506736
252,1,2_abstract_sentence,3,"Mutations in TSC1/2 genes impair the inhibitory function of the hamartin/tuberin complex, leading to phosphorylation of the downstream effectors of mTOR, p70 S6 kinase (S6K), ribosomal protein S6 and the elongation factor binding protein 4E-BP1, resulting in uncontrolled cell growth and tumourigenesis.Despite recent promising genetic, diagnostic, and therapeutic  advances in Tuberous Sclerosis Complex, continuing research in all aspects of this complex disease will be pivotal to decrease its associated morbidity and mortality. ",19506736
252,1,2_abstract_sentence,4,"In this review we will discuss and analyse all the important findings  in the molecular pathogenesis of Tuberous Sclerosis Complex, focusing on genetics and the molecular mechanisms that define this multisystemic disorder. ",19506736
252,2,1_title,0,"Expression, purification, crystallization and preliminary structural characterization of the GTPase domain of human Rheb.  ",15388940
252,2,2_abstract_sentence,0,Ras homologue enriched in brain (Rheb) represents a unique group of small GTPases and shares moderate sequence identity with the Ras/Rap subfamily. ,15388940
252,2,2_abstract_sentence,1,It acts downstream of nutrient signalling as the direct target of the tuberous sclerosis  complex (TSC) and upstream of mTOR/S6K1/4EBP in the insulin-signalling pathway. ,15388940
252,2,2_abstract_sentence,2,"The GTPase domain of human Rheb (hRheb) has been recombinantly expressed in Escherichia coli, purified and cocrystallized in complexes with GDP, GTP and GppNHp using the hanging-drop vapour-diffusion method. ",15388940
252,2,2_abstract_sentence,3,"Crystals of the hRheb-GDP  complex belong to space group P2(1)2(1)2(1), with unit-cell parameters a = 44.5,  b = 52.3, c = 70.6 A. ",15388940
252,2,2_abstract_sentence,4,"The hRheb-GppNHp complex crystallized in two crystal forms: one has the same space group and unit-cell parameters as the hRheb-GDP complex and the other belongs to space group C222(1), with unit-cell parameters a = 102.9, b = 99.2, c = 48.0 A. ",15388940
252,2,2_abstract_sentence,5,"The hRheb-GTP complex also crystallized in two crystal forms: one belongs to space group C222(1), with unit-cell parameters a =  102.4, b = 98.3, c = 47.9 A, and the other belongs to space group P2(1), with unit-cell parameters a = 77.3, b = 47.9, c = 71.9 A, beta = 89.0 degrees. ",15388940
252,2,2_abstract_sentence,6,All these crystals diffract X-rays to better than 2.8 A resolution and at least one diffraction data set has been collected for each crystal form using an in-house R-AXIS IV++ diffractometer. ,15388940
252,2,2_abstract_sentence,7,Structural studies of hRheb in complexes with various substrates may provide insights into the recognition and specificity of substrate and the catalytic mechanism of mammalian Rhebs and shed light on the biological functions of Rhebs in the mTOR signalling pathway. ,15388940
252,3,1_title,0,Rheb promotes cell growth as a component of the insulin/TOR signalling network.  ,12766776
252,3,2_abstract_sentence,0,Erratum in     Nat Cell Biol. ,12766776
252,3,2_abstract_sentence,1,2003 Jul;5(7):680. ,12766776
252,4,1_title,0,Rheb is an essential regulator of S6K in controlling cell growth in Drosophila.  ,12766775
252,4,2_abstract_sentence,0,"Understanding the mechanisms through which multicellular organisms regulate cell, organ and body growth is of relevance to developmental biology and to research on growth-related diseases such as cancer. ",12766775
252,4,2_abstract_sentence,1,"Here we describe a new effector in growth control, the small GTPase Rheb (Ras homologue enriched in brain). ",12766775
252,4,2_abstract_sentence,2,"Mutations in the Drosophila melanogaster Rheb gene were isolated as growth-inhibitors, whereas overexpression of Rheb promoted cell growth. ",12766775
252,4,2_abstract_sentence,3,"Our genetic and biochemical analyses suggest that Rheb functions downstream of the tumour suppressors Tsc1 (tuberous sclerosis 1)-Tsc2 in the TOR (target of rapamycin) signalling pathway to control  growth, and that a major effector of Rheb function is ribosomal S6 kinase (S6K). ",12766775
252,5,1_title,0,Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex.  ,23159330
252,5,2_abstract_sentence,0,"Tuberous Sclerosis Complex (TSC) is a multisystem genetic disorder caused by mutation in either Tsc1 or Tsc2 genes that leads to the hyper activation of the mTOR pathway, a key signalling pathway for synaptic plasticity. ",23159330
252,5,2_abstract_sentence,1,"TSC is characterized by benign tumors arising in different organs and severe neuropsychiatric symptoms, such as epilepsy, intellectual disability, autism, anxiety and depressive behaviour. ",23159330
252,5,2_abstract_sentence,2,Rapamycin is a potent inhibitor of mTOR and its efficacy in treating epilepsy and neurological symptoms remains elusive. ,23159330
252,5,2_abstract_sentence,3,"In a mouse model in which Tsc1 has been deleted in embryonic telencephalic neural stem cells, we analyzed anxiety- and depression-like behaviour by elevated-plus maze (EPM), open-field test (OFT), forced-swim test (FST) and tail-suspension test (TST), after chronic administration of rapamycin. ",23159330
252,5,2_abstract_sentence,4,"In addition, spectral analysis  of background EEG was performed. ",23159330
252,5,2_abstract_sentence,5,"Rapamycin-treated mutant mice displayed a reduction in anxiety- and depression-like phenotype, as shown by the EPM/OFT and  FST, respectively. ",23159330
252,5,2_abstract_sentence,6,These results were inline with EEG power spectra outcomes. ,23159330
252,5,2_abstract_sentence,7,The same effects of rapamycin were observed in wild-type mice. ,23159330
252,5,2_abstract_sentence,8,"Notably, in heterozygous animals we did not observe any EEG and/or behavioural variation after rapamycin treatment. ",23159330
252,5,2_abstract_sentence,9,"Together these results suggest that both TSC1 deletion and chronic rapamycin treatment might have a role in modulating behaviour and brain activity, and point out to the potential usefulness of background EEG analysis in tracking brain dysfunction in parallel with behavioural testing. ",23159330
252,6,1_title,0,Tuberous sclerosis: from tubers to mTOR.  ,12556239
252,6,2_abstract_sentence,0,Tuberous sclerosis (TSC) is an autosomal dominant hamartoma syndrome whose causative genes (TSC1 and TSC2) were identified 5 and 9 years ago respectively. ,12556239
252,6,2_abstract_sentence,1,"Their encoded proteins are large, and apart from a strong binding interaction with each other, relatively little was known about their biochemical function. ",12556239
252,6,2_abstract_sentence,2,Recent studies in Drosophila have pinpointed a critical function for the DrosophilaTSC1/TSC2 homologues in the regulation of cell size. ,12556239
252,6,2_abstract_sentence,3,Epistasis experiments and a variety of biochemical studies that followed have indicated a critical function for these proteins in the highly conserved PI-3-kinase-Akt-mTOR signalling pathway. ,12556239
252,7,1_title,0,The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.  ,15562827
252,7,2_abstract_sentence,0,"Gene deletion studies in mice and in Drosophila have shown that the 40S ribosomal protein S6 Kinases, dS6K in Drosophila and S6K1 and S6K2 in mice are important regulators of cell growth in response to insulin stimulation and nutrition availability. ",15562827
252,7,2_abstract_sentence,1,"Here we chiefly focus on dS6k and S6K1, whose activities are regulated by an upstream kinase termed the mammalian target of rapamycin (mTOR, or dTOR in Drosophila). ",15562827
252,7,2_abstract_sentence,2,Our understanding of the mechanisms regulating the mTOR/S6K1-signalling pathway will be fundamental in determining the mechanisms which control cell growth in response to insulin signalling. ,15562827
252,7,2_abstract_sentence,3,"Recent findings from this laboratory and others suggests that the tumour suppressor complex made of two proteins TSC1/hamartin and TSC2/tuberin, acts as a negative regulator of mTOR/S6K1 signalling. ",15562827
252,7,2_abstract_sentence,4,"Mutations in either TSC1 or TSC2 are genetically linked to  tuberous sclerosis complex (TSC) syndrome, which can lead to severe pathological  consequences, including mental retardation, epilepsy and autism, as well as cardiac, pulmonary and renal failure. ",15562827
252,7,2_abstract_sentence,5,"Despite a large number of initial reports on the TSC1/TSC2 complex, and the finding that its activity is regulated by protein kinase B (PKB), the direct target of the TSC1/TSC2 inhibitory complex was unknown until recently. ",15562827
252,7,2_abstract_sentence,6,"Since TSC2 has a GTPase-activating domain, or GAP-like sequence, others and we searched for a small GTP binding protein, which may serve as the target of TSC1/TSC2 inhibitory complex. ",15562827
252,7,2_abstract_sentence,7,In our case we took advantage of a genome wide screen in Drosophila for effectors of cell growth and in parallel searched for a small GTPase whose activity is up-regulated in TSC2-deficient cells. ,15562827
252,7,2_abstract_sentence,8,The identified gene was a member of the Ras family of GTPases termed Ras homologue enriched in brain or Rheb. ,15562827
252,7,2_abstract_sentence,9,Here we review recent findings demonstrating that the TSC1/TSC2 inhibitory complex normally acts on Rheb to mediate mTOR/S6K1-signalling. ,15562827
252,8,1_title,0,Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.  ,12711473
252,8,2_abstract_sentence,0,Mutations that inactivate either TSC1 or TSC2 cause tuberous sclerosis. ,12711473
252,8,2_abstract_sentence,1,"We have used immunoblotting and immunohistochemical analysis to see whether there is phosphorylation of p70 S6 kinase, and the ribosomal S6 protein in angiomyolipomas occurring in tuberous scierosis. ",12711473
252,8,2_abstract_sentence,2,Hamartin (encoded by TSC1) and S6K was expressed in all samples. ,12711473
252,8,2_abstract_sentence,3,"Tuberin (TSC2) was weak or absent in angiomyolipomas, but present in healthy kidney, whereas, phosphorylated p70 S6 kinase and p56 were present only in angiomyolipomas. ",12711473
252,8,2_abstract_sentence,4,"Our results indicate activation of a mammalian target of rapamycin metabolic pathway in tuberous sclerosis lesions, which contributes to their growth. ",12711473
252,8,2_abstract_sentence,5,We suggest that treatment with rapamycin and its analogues could benefit such patients. ,12711473
252,9,1_title,0,Expression of tuberin and hamartin in tuberous sclerosis complex-associated and sporadic cortical dysplasia of Taylor's balloon cell type.  ,18368626
252,9,2_abstract_sentence,0,Focal cortical dysplasia (FCD) type IIB is a malformation of cortical development characterized by presence of balloon cells. ,18368626
252,9,2_abstract_sentence,1,"These cells share phenotypic features of giant cells found in tuberous sclerosis complex (TSC), but the relationship between FCD type IIB and TSC is not well established. ",18368626
252,9,2_abstract_sentence,2,"TSC is an autosomal dominant disorder caused by mutation in either of two genes: TSC1, encoding hamartin, and TSC2, encoding tuberin. ",18368626
252,9,2_abstract_sentence,3,Both proteins form a complex inhibiting mTOR signalling pathway and thus regulate cell size and proliferation. ,18368626
252,9,2_abstract_sentence,4,"In this study, tuberin and hamartin expression was evaluated under a confocal microscope  in six cases of Taylor's balloon cell type FCD. ",18368626
252,9,2_abstract_sentence,5,Three patients met the clinical criteria for TSC. ,18368626
252,9,2_abstract_sentence,6,"In three other patients, TSC was excluded based on a panel of clinical and radiological examinations. ",18368626
252,9,2_abstract_sentence,7,"Additionally, two cases of FCD type I and 3 samples of normal brain tissue were used as a reference group. ",18368626
252,9,2_abstract_sentence,8,We found loss of tuberin and hamartin expression in FCD type IIB lesions from patients with TSC. ,18368626
252,9,2_abstract_sentence,9,"In sporadic FCD type IIB cases, only a few tuberin and hamartin positive cells were detected in the white-grey matter junction and in deeper parts of the white  matter. ",18368626
252,9,2_abstract_sentence,10,Cortical balloon cells showed loss of both tuberin and hamartin. ,18368626
252,9,2_abstract_sentence,11,"In contrast, the expression of tuberin and hamartin in FCD type I samples was strong, similarly to normal brain tissue. ",18368626
252,9,2_abstract_sentence,12,"In conclusion, loss of TSC1 and TSC2 products expression in balloon cells of both cortical dysplasia type IIB in TSC-related and sporadic patients suggests that FCD type IIB may represent the focal form of TSC. ",18368626
252,10,1_title,0,Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.  ,12172555
252,10,2_abstract_sentence,0,Comment in     Nat Cell Biol. ,12172555
252,10,2_abstract_sentence,1,2002 Sep;4(9):E214-6. ,12172555
668,0,1_title,0,Treatment and management of cluster headache.  ,11252143
668,0,2_abstract_sentence,0,Cluster headache is an uncommon yet well-defined neurovascular syndrome occurring in both episodic and chronic varieties. ,11252143
668,0,2_abstract_sentence,1,The most striking feature of cluster headache is the unmistakable circadian and circannual periodicity. ,11252143
668,0,2_abstract_sentence,2,Inheritance may play a role in some families. ,11252143
668,0,2_abstract_sentence,3,"The attacks are of extreme intensity, of short  duration, occur unilaterally, and are accompanied by signs and symptoms of autonomic dysfunction. ",11252143
668,0,2_abstract_sentence,4,"In contrast to migraine, during an attack the cluster patient prefers to pace about. ",11252143
668,0,2_abstract_sentence,5,Attacks frequently occur at night. ,11252143
668,0,2_abstract_sentence,6,"Although the pathophysiology of cluster headache remains to be fully elucidated, several seminal observations have recently been made. ",11252143
668,0,2_abstract_sentence,7,The medical treatment of cluster headache includes both acute therapy aimed at aborting individual attacks and prophylactic therapy aimed at preventing recurrent attacks during the cluster period. ,11252143
668,0,2_abstract_sentence,8,"Agents used for acute therapy include inhalation of oxygen, sumatriptan,  and dihydroergotamine. ",11252143
668,0,2_abstract_sentence,9,Transitional prophylaxis involves the short-term use of either corticosteroids or ergotamine derivatives. ,11252143
668,0,2_abstract_sentence,10,"The cornerstone of maintenance  prophylaxis is verapamil, yet methysergide, lithium, and divalproex sodium may also be employed. ",11252143
668,0,2_abstract_sentence,11,"In some patients, melatonin or topiramate may be useful adjunctive therapies. ",11252143
668,1,1_title,0,Diagnosis and treatment of cluster headache.  ,16628535
668,1,2_abstract_sentence,0,Cluster headache is an uncommon yet distinctive neurovascular syndrome occurring  in either episodic or chronic patterns. ,16628535
668,1,2_abstract_sentence,1,The most unique feature of cluster headache is the unmistakable circadian and circannual periodicity. ,16628535
668,1,2_abstract_sentence,2,"The attacks are stereotypical, that is, of extreme intensity, of short duration, occurring unilaterally, and associated with robust signs and symptoms of autonomic dysfunction. ",16628535
668,1,2_abstract_sentence,3,"Unlike migraine, during an attack the patient with cluster headache  often paces about. ",16628535
668,1,2_abstract_sentence,4,"Attacks frequently occur at night, awakening the patient from  sleep. ",16628535
668,1,2_abstract_sentence,5,"Although the pathophysiology of cluster headache remains to be fully elucidated, several seminal observations have recently been made. ",16628535
668,1,2_abstract_sentence,6,"The medical treatment of cluster headache includes acute, transitional, and maintenance prophylaxis. ",16628535
668,1,2_abstract_sentence,7,"Agents used for acute therapy include inhalation of oxygen and triptans, such as sumatriptan, and dihydroergotamine. ",16628535
668,1,2_abstract_sentence,8,Transitional prophylaxis refers to the short-term use of fast-acting agents. ,16628535
668,1,2_abstract_sentence,9,This typically involves either corticosteroids or ergotamine derivatives. ,16628535
668,1,2_abstract_sentence,10,The mainstay of prophylactic therapy is verapamil. ,16628535
668,1,2_abstract_sentence,11,"Lithium, divalproex sodium, or topiramate may also be useful. ",16628535
668,1,2_abstract_sentence,12,"As the sophistication of functional neuroimaging increases, so too will our ability to better understand the anatomic and metabolic perturbations that underlie cluster headache. ",16628535
668,2,1_title,0,Cluster headache and other trigeminal autonomic cephalalgias: diagnosis and treatment.  ,15651299
668,2,2_abstract_sentence,0,Cluster headaches are characterized by strictly unilateral paroxysmal attacks of  severe pain with associated autonomic sign and symptom. ,15651299
668,2,2_abstract_sentence,1,Prevalence is 5 times higher in men than in women in our cases. ,15651299
668,2,2_abstract_sentence,2,"About 10-15% of patients have chronic symptoms without remissions, but we estimated less frequent in Japanese (6.6% in  our series). ",15651299
668,2,2_abstract_sentence,3,"Pain almost invariably recurs on the same side, but in some patients (16.4%) the affected site switches. ",15651299
668,2,2_abstract_sentence,4,Cluster headache may be inherited in about 5% of our cases. ,15651299
668,2,2_abstract_sentence,5,Attacks frequently occur at night (60.7%). ,15651299
668,2,2_abstract_sentence,6,The patients (64.8%) are restless or agitated during an attack. ,15651299
668,2,2_abstract_sentence,7,Recent PET studies elucidated that acute attacks causes activation of the posterior hypothalamic grey matter. ,15651299
668,2,2_abstract_sentence,8,The excitement of the area might be responsible for peculiar clinical characteristics of agitation. ,15651299
668,2,2_abstract_sentence,9,Some patients (66.0%) have also have symptoms (especially a visual  aura) usually attributed to migraine. ,15651299
668,2,2_abstract_sentence,10,Treatment of cluster headache includes both acute therapy aimed at aborting individual attacks and prophylactic therapy aimed at preventing recurrent attacks during the cluster period. ,15651299
668,2,2_abstract_sentence,11,There are many choices using for both therapies. ,15651299
668,2,2_abstract_sentence,12,"Based on our clinical experience, we recommended the combination of nasal sumatriptan for acute attacks and verapamil 240 mg/day for prophylaxis. ",15651299
668,3,1_title,0,Cluster headache--acute and prophylactic therapy.  ,21284609
668,3,2_abstract_sentence,0,Cluster headache (CH) pain is the most severe of the primary headache syndromes. ,21284609
668,3,2_abstract_sentence,1, It is characterized by periodic attacks of strictly unilateral pain associated with ipsilateral cranial autonomic symptoms. ,21284609
668,3,2_abstract_sentence,2,"The majority of patients have episodic CH, with cluster periods that typically occur in a circannual rhythm, while 10% suffer from the chronic form, with no significant remissions between cluster periods. ",21284609
668,3,2_abstract_sentence,3,"Sumatriptan injection or oxygen inhalation is the first-line therapy for acute CH attacks, with the majority of patients responding to either  treatment. ",21284609
668,3,2_abstract_sentence,4,The calcium channel blocker verapamil is the drug of choice for CH prevention. ,21284609
668,3,2_abstract_sentence,5,"Other drugs that may be used for this purpose include lithium carbonate, topiramate, valproic acid, gabapentin, and baclofen. ",21284609
668,3,2_abstract_sentence,6,"Transitional prophylaxis, most commonly using corticosteroids, helps to control the attacks at the beginning of a cluster period. ",21284609
668,3,2_abstract_sentence,7,Peripheral neural blockade is effective for short-term pain control. ,21284609
668,3,2_abstract_sentence,8,"Recently, the therapeutic options for refractory CH patients have expanded with the emergence of both peripheral (mostly occipital nerve) and central (hypothalamic) neurostimulation. ",21284609
668,3,2_abstract_sentence,9,"With the emergence of these novel treatments, the role of ablative surgery in CH has declined. ",21284609
668,4,1_title,0,Botulinum toxin type-A therapy in cluster headache: an open study.  ,17901920
668,4,2_abstract_sentence,0,Comment in     J Headache Pain. ,17901920
668,4,2_abstract_sentence,1,2008 Apr;9(2):133. ,17901920
668,5,1_title,0,Cluster headache.  ,11026146
668,5,2_abstract_sentence,0,We present a review of 60 cases of cluster headache. ,11026146
668,5,2_abstract_sentence,1,"Most patients were males, ranging from 19 to 65 years of age at the time of the first visit. ",11026146
668,5,2_abstract_sentence,2,"Headaches consisted of short-lasting (from 15 to 210 minutes), intense, unilateral pain attacks, most frequently in the periorbital area, with ipsilateral autonomic signs (rhinorrhea, ptosis, tearing and conjunctival injection). ",11026146
668,5,2_abstract_sentence,3,"Between attacks,  patients were completely free of pain. ",11026146
668,5,2_abstract_sentence,4,"The attacks occurred in bouts lasting 1 to 6 months, in which patients had daily headaches (one to three times a day). ",11026146
668,5,2_abstract_sentence,5,Headaches responded well to oxygen or ergotamine. ,11026146
668,5,2_abstract_sentence,6,"Prophylactic therapy in most cases consisted of verapamil, also with a good response. ",11026146
668,5,2_abstract_sentence,7,We present this review in order to draw attention to this relatively rare form of headache with a specific therapy. ,11026146
668,6,1_title,0,Treatment of headache.  ,2520442
668,6,2_abstract_sentence,0,Headache is the most common complaint encountered in clinical practice. ,2520442
668,6,2_abstract_sentence,1,Approximately 45 million people in the United States experience chronic headaches. ,2520442
668,6,2_abstract_sentence,2,The management of migraine headache involves both pharmacologic and nondrug therapy. ,2520442
668,6,2_abstract_sentence,3,Drug therapy for migraine involves the use of abortive and prophylactic agents. ,2520442
668,6,2_abstract_sentence,4,"Abortive agents, such as ergotamine tartrate and ketoprofen, may be used to relieve the acute attack. ",2520442
668,6,2_abstract_sentence,5,Prophylactic therapy is focused on reducing the frequency and severity of the attacks. ,2520442
668,6,2_abstract_sentence,6,"beta-Adrenergic blocking agents, such as propranolol, remain the primary agents for many migraine patients, although other drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), including ketoprofen, or calcium-channel blocking agents, such as verapamil, may be beneficial for many patients. ",2520442
668,6,2_abstract_sentence,7,"For cluster headache and its variants, methysergide and corticosteroids are usually the drugs of choice. ",2520442
668,6,2_abstract_sentence,8,"Patients with chronic cluster headache may achieve good results from long-term treatment with other therapies, including lithium carbonate, verapamil, and ketoprofen. ",2520442
668,7,1_title,0,"Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate.  ",12390644
668,7,2_abstract_sentence,0,OBJECTIVE: To assess the efficacy and tolerability of topiramate for prophylaxis  of migraine and cluster headache via a retrospective chart analysis. ,12390644
668,7,2_abstract_sentence,1,BACKGROUND: Topiramate has multiple mechanisms of action that could potentially contribute to migraine prophylaxis. ,12390644
668,7,2_abstract_sentence,2,"We conducted a retrospective chart review to  assess the efficacy of topiramate as add-on therapy in patients with transformed  migraine or cluster headache, and as first-line therapy in patients with episodic migraine. ",12390644
668,7,2_abstract_sentence,3,"METHODS: Patients diagnosed with transformed migraine, episodic migraine, or cluster headache, who received topiramate either as add-on therapy or monotherapy were selected via retrospective chart review. ",12390644
668,7,2_abstract_sentence,4,Patients had begun topiramate therapy at 25 mg/day for the first week and increased their dosage by 25 mg/week  to a maximum of 200 mg/day. ,12390644
668,7,2_abstract_sentence,5,"Topiramate was used as add-on therapy for patients with transformed migraine and cluster headache, and as a first-line monotherapy in patients with episodic migraine who had no previous prophylactic therapy. ",12390644
668,7,2_abstract_sentence,6,"The  outcome parameters examined included a mean 28-day migraine frequency, migraine severity, number of headache days/month, number of abortive medication tablets/month, patient global evaluation, and the MIDAS scale. ",12390644
668,7,2_abstract_sentence,7,RESULTS: One hundred seventy-eight patients (transformed migraine: n = 96; episodic migraine: n = 70; and cluster headache: n = 12) were included in the retrospective analysis. ,12390644
668,7,2_abstract_sentence,8,The mean dose of topiramate for all patients was 87.5 mg/day. ,12390644
668,7,2_abstract_sentence,9,"For patients with transformed migraine, mean migraine frequency decreased from 6.3/28 days to 3.7 (P = 0.005). ",12390644
668,7,2_abstract_sentence,10,"Mean severity decreased from 7.1 to 3.8 on a 10-point scale, with 10 representing the most severe pain (P = 0.003). ",12390644
668,7,2_abstract_sentence,11,"The mean number of headache days/month decreased from 22.1 to 9.6 (P = 0.001), and the mean number of abortive medication tablets decreased from 28.7/month to 10.6 (P = 0.001). ",12390644
668,7,2_abstract_sentence,12,Patient global evaluation indicated substantial or moderate improvement in 53% of patients with transformed migraine who used topiramate as add-on therapy. ,12390644
668,7,2_abstract_sentence,13,Mean MIDAS scale values decreased from 90.2 to 24.9 (P< 0.0001). ,12390644
668,7,2_abstract_sentence,14,"The 70  episodic migraine patients who were administered topiramate as first-line therapy exhibited a decrease in mean migraine frequency (5.8/28 days to 1.9, P = 0.001),  while mean migraine severity decreased from 8.1 to 2.0 (P = 0.003). ",12390644
668,7,2_abstract_sentence,15,Sixty-one percent of patients reported marked improvement. ,12390644
668,7,2_abstract_sentence,16,"Nine of the 12 cluster headache  patients exhibited substantial or moderate improvement in symptoms, whereas three had no improvement. ",12390644
668,7,2_abstract_sentence,17,"The most common adverse effects were paresthesias (12%), cognitive effects (11%), and dizziness (6%). ",12390644
668,7,2_abstract_sentence,18,Eight patients discontinued topiramate due to adverse effects; cognitive effects were the most common reason. ,12390644
668,7,2_abstract_sentence,19,No patient discontinued topiramate treatment due to lack of efficacy. ,12390644
668,7,2_abstract_sentence,20,Twelve percent of patients lost more than 5 lbs during treatment (a range of 5-120 lbs). ,12390644
668,7,2_abstract_sentence,21,"CONCLUSION: For both patients with transformed migraine (add-on therapy) and patients with episodic migraine (first-line monotherapy), topiramate yielded significant reductions in migraine frequency, migraine severity, number of headache days/month, and use of abortive medications. ",12390644
668,7,2_abstract_sentence,22,Topiramate also appears to  be well tolerated and useful in the adjunctive treatment of cluster headache. ,12390644
668,7,2_abstract_sentence,23,"Prospective double-blind, placebo-controlled trials will be required to confirm our results. ",12390644
668,8,1_title,0,Cluster headache: diagnosis and treatment.  ,20352587
668,8,2_abstract_sentence,0,Cluster headache is a rare yet exquisitely painful primary headache disorder occurring in either episodic or chronic patterns. ,20352587
668,8,2_abstract_sentence,1,The unique feature of cluster headache is the distinctive circadian and circannual periodicity in the episodic  forms. ,20352587
668,8,2_abstract_sentence,2,"The attacks are stereotypic--they are of extreme intensity and short duration, occur unilaterally, and are associated with robust signs and symptoms of autonomic dysfunction. ",20352587
668,8,2_abstract_sentence,3,"Although the pathophysiology of cluster headache remains to be fully understood, there have been a number of recent seminal observations. ",20352587
668,8,2_abstract_sentence,4,"To exclude structural mimics, patients presenting with symptoms suggestive of cluster headache warrant at least a brain magnetic resonance imaging (MRI) scan in their work-up. ",20352587
668,8,2_abstract_sentence,5,"The medical treatment of cluster headache includes acute, transitional, and maintenance prophylaxis. ",20352587
668,8,2_abstract_sentence,6,"Agents used for acute  therapy include inhalation of oxygen, triptans, such as sumatriptan, and dihydroergotamine. ",20352587
668,8,2_abstract_sentence,7,Transitional prophylaxis refers to the short-term use of fast-acting agents. ,20352587
668,8,2_abstract_sentence,8,This typically involves either corticosteroids or an occipital nerve block. ,20352587
668,8,2_abstract_sentence,9,The mainstay of prophylactic therapy is verapamil. ,20352587
668,8,2_abstract_sentence,10,"Yet, other medications, including lithium, divalproex sodium, topiramate, methysergide, gabapentin, and even indomethacin, may be useful when the headache  fails to respond to verapamil. ",20352587
668,8,2_abstract_sentence,11,"For medically refractory patients, surgical interventions, occipital nerve stimulation, and deep brain stimulation remain an  option. ",20352587
668,8,2_abstract_sentence,12,"As the sophistication of functional neuroimaging increases, better insight into the pathophysiological mechanisms that underlie cluster headache is  expected. ",20352587
668,9,1_title,0,Cluster headache pharmacotherapy.  ,16041199
668,9,2_abstract_sentence,0,"Cluster headache is a well-known primary headache syndrome with a prevalence of about 5/10,000 of the adult population, making it much less common than migraine. ",16041199
668,9,2_abstract_sentence,1,"Diagnostic terms such as histaminic cephalalgia, Horton's headache and ciliary neuralgia have been used for what is now known as cluster headache. ",16041199
668,9,2_abstract_sentence,2,This disorder can be differentiated from migraine by clinical and pathophysiologic features. ,16041199
668,9,2_abstract_sentence,3,Cluster headache also exhibits a differing therapeutic response to medications when compared with migraine. ,16041199
668,9,2_abstract_sentence,4,The pharmacologic treatment of cluster is reviewed in this article. ,16041199
668,9,2_abstract_sentence,5,"In contrast to migraine, men are 3-4 times more likely to be diagnosed with cluster headache than women, and the cluster headache population is older. ",16041199
668,9,2_abstract_sentence,6,"Cluster attacks are known for their brief intense unilateral excruciating pain during susceptible periods known as cluster periods, which typically last weeks. ",16041199
668,9,2_abstract_sentence,7,Attack-free months generally follow. ,16041199
668,9,2_abstract_sentence,8,"Pain is experienced in the distribution of the trigeminal nerve, with unilateral autonomic features. ",16041199
668,9,2_abstract_sentence,9,Most patients are successfully managed with medical therapy. ,16041199
668,9,2_abstract_sentence,10,Medication management can be divided into abortive treatments for an ongoing attack and prophylactic treatment. ,16041199
668,9,2_abstract_sentence,11,Prophylaxis aims to induce and maintain a remission. ,16041199
668,9,2_abstract_sentence,12,"There are a variety of different medications for abortive and prophylactic therapy, accompanied by a variable amount of evidence-based medicine. ",16041199
668,9,2_abstract_sentence,13,"For patients refractory to medical management, interventional procedures are available as a last resort. ",16041199
668,9,2_abstract_sentence,14,"Most procedures are directed against the sensory trigeminal nerve and associated ganglia, eg, anesthetizing the sphenopalatine ganglion. ",16041199
2446,0,1_title,0,MARS: improving multiple circular sequence alignment using refined sequences.  ,28088189
2446,0,2_abstract_sentence,0,BACKGROUND: A fundamental assumption of all widely-used multiple sequence alignment techniques is that the left- and right-most positions of the input sequences are relevant to the alignment. ,28088189
2446,0,2_abstract_sentence,1,"However, the position where a sequence starts or ends can be totally arbitrary due to a number of reasons: arbitrariness in the linearisation (sequencing) of a circular molecular structure; or inconsistencies introduced into sequence databases due to different linearisation standards. ",28088189
2446,0,2_abstract_sentence,2,"These scenarios are relevant, for instance, in the process of multiple sequence alignment of mitochondrial DNA, viroid, viral or other genomes, which have a circular molecular structure. ",28088189
2446,0,2_abstract_sentence,3,A solution for these inconsistencies would be to identify a suitable rotation (cyclic shift) for each sequence; these refined sequences may in turn lead to improved multiple sequence alignments using the preferred multiple sequence alignment program. ,28088189
2446,0,2_abstract_sentence,4,"RESULTS: We present MARS, a new heuristic method for improving Multiple circular  sequence Alignment using Refined Sequences. ",28088189
2446,0,2_abstract_sentence,5,MARS was implemented in the C++ programming language as a program to compute the rotations (cyclic shifts) required to best align a set of input sequences. ,28088189
2446,0,2_abstract_sentence,6,"Experimental results, using real and synthetic data, show that MARS improves the alignments, with respect to standard genetic measures and the inferred maximum-likelihood-based phylogenies,  and outperforms state-of-the-art methods both in terms of accuracy and efficiency. ",28088189
2446,0,2_abstract_sentence,7,"Our results show, among others, that the average pairwise distance in the multiple sequence alignment of a dataset of widely-studied mitochondrial DNA  sequences is reduced by around 5% when MARS is applied before a multiple sequence alignment is performed. ",28088189
2446,0,2_abstract_sentence,8,CONCLUSIONS: Analysing multiple sequences simultaneously is fundamental in biological research and multiple sequence alignment has been found to be a popular method for this task. ,28088189
2446,0,2_abstract_sentence,9,Conventional alignment techniques cannot be used effectively when the position where sequences start is arbitrary. ,28088189
2446,0,2_abstract_sentence,10,"We present here a method, which can be used in conjunction with any multiple sequence alignment program, to address this problem effectively and efficiently. ",28088189
562,0,1_title,0,Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC).  ,3939491
562,1,1_title,0,Should folic acid be given to women treated with valproic acid and/or carbamazepine? Folic acid and pregnancy in epilepsy.  ,10339792
562,1,2_abstract_sentence,0,Fetal exposure to valproic acid or carbamazepine increases the risk of neural tube defect (NTD). ,10339792
562,1,2_abstract_sentence,1,The risk of a mother having a baby with spina bifida has been  estimated at 1-2 p. ,10339792
562,1,2_abstract_sentence,2,"100, close to the rate of risk of recurrent cases. ",10339792
562,1,2_abstract_sentence,3,No study has evaluated the effect of folic acid in neonates of women treated with valproic acid or carbamazepine although the protective effect against NTD has been proven  in other populations. ,10339792
562,1,2_abstract_sentence,4,"Periconceptional folic acid supplementation, 0.4 to 1 mg/day, for at least one month prior to conception and until the date of the second missed menstrual period or later decreases the incidence of a first occurrence of neural tube defect. ",10339792
562,1,2_abstract_sentence,5,"Periconceptional folic acid supplementation, 4  mg/day, decreases the recurrence of NTD in women who had previously had a child with NTD. ",10339792
562,1,2_abstract_sentence,6,It seems pertinent to recommend periconceptional folic acid supplementation in women treated with carbamazepine or valporic acid. ,10339792
562,1,2_abstract_sentence,7,There are very few data in women on which to base a decision to advise taking 4 mg/day (as  used in recurrence prevention) or low doses of 0.4 mg/day (used in primary prevention). ,10339792
562,2,1_title,0,Maternal carbamazepine and infant spina bifida.  ,8075508
562,2,2_abstract_sentence,0,Women with epilepsy giving birth during 1973 to 1991 were identified by record linkage of Swedish health registries. ,8075508
562,2,2_abstract_sentence,1,"Among 3,625 identified infants, 9 had spina bifida. ",8075508
562,2,2_abstract_sentence,2,"A nested case-control study was performed, comparing drugs used in early  pregnancy in the 9 cases and in 18 controls, matched for year of delivery, maternal age, and parity. ",8075508
562,2,2_abstract_sentence,3,Six of the spina bifida mothers had used carbamazepine  and two had used valproic acid. ,8075508
562,2,2_abstract_sentence,4,"Among the controls, 5 women used carbamazepine and one valproic acid. ",8075508
562,2,2_abstract_sentence,5,"There is an apparent excess risk for spina bifida after use of either of these two drugs, but it is not statistically significant when the analysis is restricted to drug-using women. ",8075508
562,2,2_abstract_sentence,6,The findings support earlier reports in the literature of an association between carbamazepine and spina bifida. ,8075508
562,3,1_title,0,Fetal hydantoin syndrome and its anaesthetic implications: a case report.  ,23082254
562,3,2_abstract_sentence,0,Fetal hydantoin syndrome is a rare disorder that is believed to be caused by exposure of a fetus to the anticonvulsant drug phenytoin. ,23082254
562,3,2_abstract_sentence,1,"The classic features of fetal hydantoin syndrome include craniofacial anomalies, prenatal and postnatal growth deficiencies, underdeveloped nails of the fingers and toes, and mental retardation. ",23082254
562,3,2_abstract_sentence,2,"Less frequently observed anomalies include cleft lip and palate, microcephaly, ocular defects, cardiovascular anomalies, hypospadias, umbilical and inguinal hernias, and significant developmental delays. ",23082254
562,3,2_abstract_sentence,3,Anaesthesia for incidental surgery in such a patient poses unique challenges for the anesthesiologist. ,23082254
562,3,2_abstract_sentence,4,"We report the successful management of a 4-year-old male child  with fetal hydantoin syndrome, cleft palate, spina bifida, atrial septal defect,  and dextrocardia for tibialis anterior lengthening under subarachnoid block. ",23082254
562,4,1_title,0,"Multiple point action mechanism of valproic acid-teratogenicity alleviated by folic acid, vitamin C, and N-acetylcysteine in chicken embryo model.  ",22051200
562,4,2_abstract_sentence,0,Comment in     Toxicology. ,22051200
562,4,2_abstract_sentence,1,2012 Mar 11;293(1-3):132-3. ,22051200
562,5,1_title,0,Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma.  ,17075842
562,5,2_abstract_sentence,0,"Valproic acid, a drug commonly used to treat seizures and other psychiatric disorders, causes neural tube defects (NTDs) in exposed fetuses at a rate 20 times higher than in the general population. ",17075842
562,5,2_abstract_sentence,1,"Failure of the neural tube to close  during development results in exencephaly or anencephaly, as well as spina bifida. ",17075842
562,5,2_abstract_sentence,2,"In mice, nonspecific activation of the maternal immune system can reduce  fetal abnormalities caused by diverse etiologies, including diabetes-induced NTDs. ",17075842
562,5,2_abstract_sentence,3,We hypothesized that nonspecific activation of the maternal immune system with interferon-gamma (IFN-gamma) and granulocyte-macrophage colony-stimulating factor (GM-CSF) could reduce valproic acid (VA)-induced defects as well. ,17075842
562,5,2_abstract_sentence,4,Female CD-1 mice were given immune stimulant prebreeding: either IFN-gamma or GM-CSF. ,17075842
562,5,2_abstract_sentence,5,Approximately half of the control and immune-stimulated pregnant females were then exposed to 500 mg/kg VA on the morning of gestational day 8. ,17075842
562,5,2_abstract_sentence,6,"The incidence of developmental defects was determined on gestational day 17 from at least eight litters in each of the following treatment groups: control, VA only, IFN-gamma only, IFN-gamma+VA, GM-CSF only, and GM-CSF+VA. ",17075842
562,5,2_abstract_sentence,7,"The incidence of NTDs was 18% in  fetuses exposed to VA alone, compared to 3.7% and 2.9% in fetuses exposed to IFN-gamma+VA, or GM-CSF+VA respectively. ",17075842
562,5,2_abstract_sentence,8,Ocular defects were also significantly reduced from 28.0% in VA exposed groups to 9.8% in IFN-gamma+VA and 12.5% in GM-CSF+VA groups. ,17075842
562,5,2_abstract_sentence,9,"The mechanisms by which maternal immune stimulation prevents birth defects remain unclear, but may involve maternal or fetal production of cytokines or growth factors which protect the fetus from the dysregulatory effects of teratogens. ",17075842
562,6,1_title,0,"Pregnancy, delivery, and outcome for the child in maternal epilepsy.  ",19490036
562,6,2_abstract_sentence,0,"PURPOSE: To investigate pregnancy, delivery, and child outcome in an unselected population of women with both treated and untreated epilepsy. ",19490036
562,6,2_abstract_sentence,1,"METHODS: In the compulsory Medical Birth Registry of Norway, all 2,861 deliveries by women with epilepsy recorded from 1999-2005 were compared to all 369,267 nonepilepsy deliveries in the same period. ",19490036
562,6,2_abstract_sentence,2,"RESULTS: The majority (66%, n = 1900) in the epilepsy group did not use antiepileptic drugs (AEDs) during pregnancy. ",19490036
562,6,2_abstract_sentence,3,A total of 961 epilepsy-pregnancies  were exposed to AEDs. ,19490036
562,6,2_abstract_sentence,4,"Compared to nonepilepsy controls, AED-exposed infants were  more often preterm (p = 0.01), and more often had birth weight <2,500 g (p < 0.001), head circumference <2.5 percentile (p < 0.001), and low Apgar score (p =  0.03). ",19490036
562,6,2_abstract_sentence,5,Small-for-gestational-age (SGA) infants (<10 percentile) occurred more frequently in both AED-exposed (p = 0.05) and unexposed (p = 0.02) epilepsy-pregnancies. ,19490036
562,6,2_abstract_sentence,6,Frequency of major congenital malformations (MCMs) was 2.8% (n = 81) in the epilepsy group versus 2.5% in controls (p = 0.3). ,19490036
562,6,2_abstract_sentence,7,"Increased risk  for MCMs could be demonstrated only for exposure to valproate (5.6%, p = 0.005) and AED polytherapy (6.1%, p = 0.02). ",19490036
562,6,2_abstract_sentence,8,"Neonatal spina bifida was not significantly increased, but was a major indication for elective pregnancy termination among women with epilepsy. ",19490036
562,6,2_abstract_sentence,9,"Cesarean section was performed more often in maternal epilepsy, regardless of AED-exposure (p < 0.001). ",19490036
562,6,2_abstract_sentence,10,"DISCUSSION: Adverse pregnancy and birth outcome in women with epilepsy is mainly  confined to AED-exposed pregnancies, although some risks are associated also with untreated epilepsy. ",19490036
562,6,2_abstract_sentence,11,The risk for congenital malformations was lower than previously reported. ,19490036
562,6,2_abstract_sentence,12,"This could be due to a shift in AED selection, folic acid supplement, or possibly reflect the true risks in an unselected epilepsy population. ",19490036
562,7,1_title,0,Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE).  ,11077457
562,7,2_abstract_sentence,0,PURPOSE: The study goal was to assess teratogenic effects of antiepileptic drugs  (AEDs) through the use of a surveillance system (MADRE) of infants with malformations. ,11077457
562,7,2_abstract_sentence,1,METHODS: Information on all malformed infants (1990-1996) with maternal first-trimester drug exposure was collected by the International Clearinghouse for Birth Defects and Monitoring Systems (ICBDMS). ,11077457
562,7,2_abstract_sentence,2,"Cases were defined as infants  presenting with a specific malformation, and controls were defined as infants presenting with any other birth defect. ",11077457
562,7,2_abstract_sentence,3,Exposure was defined by the use of AEDs during the first trimester of pregnancy. ,11077457
562,7,2_abstract_sentence,4,The association of AEDs with malformations was then estimated by calculating the odds ratios with 95% confidence intervals and testing their homogeneity among registries. ,11077457
562,7,2_abstract_sentence,5,"RESULTS: Among 8005 cases of malformations, 299 infants were exposed in utero to  AEDs. ",11077457
562,7,2_abstract_sentence,6,"Of those exposed to monotherapy, 65 were exposed to phenobarbital, 10 to methylphenobarbital, 80 to valproic acid, 46 to carbamazepine, 24 to phenytoin, and 16 to other AEDs. ",11077457
562,7,2_abstract_sentence,7,Associations were found for spina bifida with valproic acid. ,11077457
562,7,2_abstract_sentence,8,Infants exposed to phenobarbital and to methylphenobarbital showed an increased risk of oral clefts. ,11077457
562,7,2_abstract_sentence,9,"Cardiac malformations were found to be associated  with phenobarbital, methylphenobarbital, valproic acid, and carbamazepine. ",11077457
562,7,2_abstract_sentence,10,Hypospadias was associated with valproic acid. ,11077457
562,7,2_abstract_sentence,11,"Porencephaly and other specified anomalies of brain, anomalies of face, coarctation of aorta, and limb reduction defects were found to be associated with valproic acid. ",11077457
562,7,2_abstract_sentence,12,"CONCLUSIONS: Using the MADRE system, we confirmed known teratogenic effects of AEDs. ",11077457
562,7,2_abstract_sentence,13,We also found increased risks for malformations that had never been reported associated with AEDs or for which the association was suggested by case  reports. ,11077457
562,8,1_title,0,Anticonvulsant drugs and malformations is there a drug specificity?  ,2707392
562,8,2_abstract_sentence,0,The distribution of anticonvulsant drug therapy was studied in 318 malformed infants with known histories of maternal epilepsy. ,2707392
562,8,2_abstract_sentence,1,Data on the infants was collected from six birth defect monitoring programs in Europe and South America. ,2707392
562,8,2_abstract_sentence,2, Use of specific types of anticonvulsants varies widely among reporting countries. ,2707392
562,8,2_abstract_sentence,3,"Heterogeneity of drug-malformation distribution, was analyzed to determine whether use of specific drugs were linked to specific malformations. ",2707392
562,8,2_abstract_sentence,4,"A significant association was seen between maternal use of valproic acid and spina  bifida, and a weaker, non-significant one between carbamazepine and spina bifida. ",2707392
562,8,2_abstract_sentence,5,Facial clefts were associated with both diphenylhydantoin and phenobarbitone use  and also with polytherapy. ,2707392
562,8,2_abstract_sentence,6,These differences indicate that the actual drug used is significant for the teratogenic process. ,2707392
562,8,2_abstract_sentence,7,The technique may be useful in analysis of other drug-related teratogenic questions. ,2707392
562,9,1_title,0,Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States.  ,21766433
562,9,2_abstract_sentence,0,Selected antiepileptic drugs (AEDs) increase the risk of birth defects. ,21766433
562,9,2_abstract_sentence,1,To assess the impact of influencing AED prescribing practices on spina bifida and cleft palate we searched the literature for estimates of the association between valproic acid or carbamazepine use during pregnancy and these defects and summarized the associations using meta-analyses. ,21766433
562,9,2_abstract_sentence,2,We estimated distributions of the prevalence of valproic acid and carbamazepine use among women of childbearing age based on analyses of four data sets. ,21766433
562,9,2_abstract_sentence,3,We estimated the attributable fractions  and the number of children born with each defect that could be prevented annually in the United States if valproic acid and carbamazepine were not used during pregnancy. ,21766433
562,9,2_abstract_sentence,4,The summary odds ratio estimate for the association between valproic acid and spina bifida was 11.9 (95% uncertainty interval (UI): 4.0-21.2); for valproic acid and cleft palate 5.8 (95% UI: 3.3-9.5); for carbamazepine and spina bifida 3.6 (95% UI: 1.3-7.8); and for carbamazepine and cleft palate 2.4 (95% UI: 1.1-4.5) in the United States. ,21766433
562,9,2_abstract_sentence,5,Approximately 40 infants (95% UI: 10-100) with spina bifida and 35 infants (95% UI: 10-70) with cleft palate could be born without these defects each year if valproic acid were not used during pregnancy;  5 infants (95% UI: 0-15) with spina bifida and 5 infants (95% UI: 0-15) with cleft palate could be born without these defects each year if carbamazepine were  not used during pregnancy. ,21766433
562,9,2_abstract_sentence,6,This modeling approach could be extended to other medications to estimate the impact of translating pharmacoepidemiologic data to evidence-based prenatal care practice. ,21766433
2628,0,1_title,0,Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys.  ,27865001
2628,0,2_abstract_sentence,0,"Romosozumab (Romo), a humanized sclerostin antibody, is a bone-forming agent under development for treatment of osteoporosis. ",27865001
2628,0,2_abstract_sentence,1,"To examine the effects of Romo on bone quality, mature cynomolgus monkeys (cynos) were treated 4 months post- ovariectomy (OVX) with vehicle, 3âmg/kg, or 30âmg/kg Romo for 12 months, or with  30âmg/kg Romo for 6 months followed by vehicle for 6 months (30/0). ",27865001
2628,0,2_abstract_sentence,2,"Serum bone formation markers were increased by Romo during the first 6 months, corresponding to increased cancellous, endocortical, and periosteal bone formation in rib and iliac biopsies at months 3 and 6. ",27865001
2628,0,2_abstract_sentence,3,"Dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) was increased by 14% to 26% at the lumbar spine and proximal femur at month 12, corresponding to significant increases in bone strength at 3 and 30âmg/kg in lumbar vertebral bodies and cancellous cores, and at 30âmg/kg in the femur diaphysis and neck. ",27865001
2628,0,2_abstract_sentence,4,"Bone mass remained positively correlated with strength at these sites, with no changes in calculated material properties at cortical sites. ",27865001
2628,0,2_abstract_sentence,5,"These bone-quality measures were also maintained in the 30/0 group, despite a gradual loss of accrued bone mass. ",27865001
2628,0,2_abstract_sentence,6,Normal bone mineralization was confirmed by histomorphometry and ash analyses. ,27865001
2628,0,2_abstract_sentence,7,"At the radial  diaphysis, a transient, reversible 2% reduction in cortical BMD was observed with Romo at month 6, despite relative improvements in bone mineral content (BMC). ",27865001
2628,0,2_abstract_sentence,8,High-resolution pQCT confirmed this decline in cortical BMD at the radial diaphysis and metaphysis in a second set of OVX cynos administered 3âmg/kg Romo for 6 months. ,27865001
2628,0,2_abstract_sentence,9,Radial diaphyseal strength was maintained and metaphyseal strength  improved with Romo as estimated by finite element modeling. ,27865001
2628,0,2_abstract_sentence,10,"Decreased radial cortical BMD was a consequence of increased intracortical remodeling, with no increase in cortical porosity. ",27865001
2628,0,2_abstract_sentence,11,"Romo resulted in marked improvements in bone mass, architecture, and bone strength, while maintaining bone quality in OVX cynos, supporting its bone efficacy and safety profile. ",27865001
2628,0,2_abstract_sentence,12,Â© 2016 American Society for Bone and Mineral Research. ,27865001
2628,1,1_title,0,Update on romosozumab : a humanized monoclonal antibody to sclerostin.  ,24665957
2628,1,2_abstract_sentence,0,INTRODUCTION: Disorders with inactivating mutations of the SOST gene result in reduced or absent expression of sclerostin and are associated with high bone mass. ,24665957
2628,1,2_abstract_sentence,1,Sclerostin is an important regulator of bone formation due to its inhibitory actions in the osteoanabolic Wnt signaling pathway. ,24665957
2628,1,2_abstract_sentence,2,Advances in understanding the mechanisms of action of this signaling molecule have led to the development of a pharmacological inhibitor of sclerostin with potential clinical  applications as an osteoanabolic drug for the treatment of osteoporosis. ,24665957
2628,1,2_abstract_sentence,3,AREAS COVERED: Romosozumab is the first humanized monoclonal sclerostin antibody  to be tested in clinical trials. ,24665957
2628,1,2_abstract_sentence,4,"Similar to preclinical animal studies with sclerostin antibodies, initial clinical studies show that romosozumab increases bone formation and bone mineral density. ",24665957
2628,1,2_abstract_sentence,5,EXPERT OPINION: Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited. ,24665957
2628,2,1_title,0,Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys.  ,28428078
2628,2,2_abstract_sentence,0,"Romosozumab, a humanized monoclonal sclerostin antibody under development for the treatment of osteoporosis, has a unique mechanism of action on bone-increasing bone formation and decreasing bone resorption. ",28428078
2628,2,2_abstract_sentence,1,"The effects on bone formation are  transient, eliciting a rapid increase in bone formation that attenuates with continued treatment. ",28428078
2628,2,2_abstract_sentence,2,"Although bone formation attenuates, bone mineral density (BMD) continues to increase. ",28428078
2628,2,2_abstract_sentence,3,"To explore potential tissue-level mechanisms that could contribute to a progressive increase in spine BMD, we used kinetic reconstruction techniques to examine the effects of romosozumab on modeling and remodeling units in vertebral cancellous bone from adult cynomolgus monkeys administered romosozumab for 10 and 28weeks. ",28428078
2628,2,2_abstract_sentence,4,"The 10-week study duration captured  a period of high modeling-based bone formation, and the 28-week study duration followed the self-regulation or attenuation of bone formation in cancellous bone  that occurs with long-term treatment. ",28428078
2628,2,2_abstract_sentence,5,"Sequential fluorochrome labels applied for  the kinetic reconstruction were also used to evaluate treatment effects on osteoblast function as early as 3weeks, and on bone formation and bone accrual in the vertebral cortex over 28weeks. ",28428078
2628,2,2_abstract_sentence,6,Kinetic reconstruction of remodeling and modeling formation sites in vertebral cancellous bone revealed that romosozumab effected significant transient increases in mineral apposition rate in remodeling sites at week 3 that was not sustained with continued treatment. ,28428078
2628,2,2_abstract_sentence,7,"However, romosozumab treatment caused sustained improvement in fractional labeling of osteoid, an index of osteoblast efficiency, at remodeling formative sites at both weeks 10 and 28 that was the major contributor to significant increases in final  wall thickness (W.Th) of remodeling packets. ",28428078
2628,2,2_abstract_sentence,8,Remodeling W.Th matched the final W.Th of modeling packets at week 10. ,28428078
2628,2,2_abstract_sentence,9,"At both weeks 10 and 28, romosozumab significantly decreased eroded surface (ES/BS). ",28428078
2628,2,2_abstract_sentence,10,"At week 28, romosozumab also significantly reduced resorption period (Rs.P) and final resorption depth (Rs.De). ",28428078
2628,2,2_abstract_sentence,11,The reduced final Rs.De combined with the increased W.Th resulted in a significant increase in bone balance (BB) at the level of the remodeling unit. ,28428078
2628,2,2_abstract_sentence,12,"Assessment of bone formation on the vertebral periosteal and endocortical surfaces following 28weeks of treatment revealed that romosozumab significantly increased bone formation on these surfaces, which had attenuated by week 28, resulting in significant increases in new periosteal and endocortical bone by week 28. ",28428078
2628,2,2_abstract_sentence,13,These data suggest that multiple factors potentially contribute to the increase in spine BMD with romosozumab treatment. ,28428078
2628,2,2_abstract_sentence,14,"In the early period of treatment, increased modeling-based bone formation, increased W.Th at remodeling  sites, a decrease in remodeling space secondary to decreased ES/BS in vertebral cancellous bone, and increased periosteal and endocortical bone formation in the  vertebral cortex contribute to the early increase in spine BMD. ",28428078
2628,2,2_abstract_sentence,15,"Following the self-regulation of bone formation when modeling-based bone formation has attenuated, a decrease in remodeling space secondary to reduced ES/BS and a positive BB secondary to decreased final Rs.De and increased W.Th contribute to the progressive increase in spine BMD with long-term treatment. ",28428078
2628,3,1_title,0,Romosozumab for the treatment of osteoporosis.  ,28064540
2628,3,2_abstract_sentence,0,"INTRODUCTION: Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation pathway. ",28064540
2628,3,2_abstract_sentence,1,"Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD). ",28064540
2628,3,2_abstract_sentence,2,Clinical studies with romosozumab  have shown dramatic improvements in BMD at the spine and hip. ,28064540
2628,3,2_abstract_sentence,3,"Romosozumab is associated with improvement in bone strength through mechanisms that include increases in bone formation and, different from classical osteoanabolic agents, suppression of bone resorption. ",28064540
2628,3,2_abstract_sentence,4,"Areas covered: Herein, the authors highlight the  available data on romosozumab for the treatment of osteoporosis. ",28064540
2628,3,2_abstract_sentence,5,"This includes the latest data on the efficacy, pharmacokinetics and pharmacodynamics as well as safety and tolerability data. ",28064540
2628,3,2_abstract_sentence,6,"Expert opinion: Monthly subcutaneous dosing of romosozumab reduces the risk of vertebral and clinical fractures in women with postmenopausal osteoporosis, with a favorable balance of benefits and risks. ",28064540
2628,3,2_abstract_sentence,7,Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture. ,28064540
2628,4,1_title,0,Romosozumab Treatment Converts Trabecular Rods into Trabecular Plates in Male Cynomolgus Monkeys.  ,28246926
2628,4,2_abstract_sentence,0,"Treatment with sclerostin antibody (romosozumab) increases bone formation while reducing bone resorption, leading to increases in bone volume and bone mineral density. ",28246926
2628,4,2_abstract_sentence,1,Sclerostin antibody treatment may also provide beneficial changes in trabecular microarchitecture and strength that are not reflected in bone volume and density. ,28246926
2628,4,2_abstract_sentence,2,Here we use three-dimensional dynamic histomorphometry to determine  longitudinal changes in vertebral trabecular microarchitecture in adolescent male cynomolgus monkeys (4-5Â years old) treated with sclerostin antibody. ,28246926
2628,4,2_abstract_sentence,3,"Animals were treated bi-weekly with either sclerostin antibody (30Â mg/kg, sc, nâ=â6) or vehicle (nâ=â6) for 10Â weeks. ",28246926
2628,4,2_abstract_sentence,4,"Animals were administered fluorochrome bone formation labels on days 14 and 24 (tetracycline) and on days 56 and 66 (calcein), followed by necropsy on day 70. ",28246926
2628,4,2_abstract_sentence,5,"Cylindrical specimens of cancellous bone from the 5th lumbar vertebrae were used to generate high-resolution, three-dimensional images of bone and fluorescent labels of bone formation (0.7âÃâ0.7âÃâ5.0Â Âµm/voxel). ",28246926
2628,4,2_abstract_sentence,6,The three-dimensional images of the bone formation labels were used to determine the bone volume formed between days 14 and 66 and the resulting alterations in trabecular microarchitecture within each bone. ,28246926
2628,4,2_abstract_sentence,7,Treatment with sclerostin antibody resulted in a conversion of rod-like trabeculae into plate-like trabeculae at a higher rate than in vehicle-treated animals (pâ=â0.01). ,28246926
2628,4,2_abstract_sentence,8,Plate bone volume fraction was greater in the sclerostin antibody group relative to vehicle (mean 43 vs. ,28246926
2628,4,2_abstract_sentence,9,"30%, pâ<â0.05). ",28246926
2628,4,2_abstract_sentence,10,"Bone formation increased the thickness of trabeculae in all three trabecular orientations (axial, oblique, and transverse, pâ<â0.05). ",28246926
2628,4,2_abstract_sentence,11,The volume of bone formed between days 14Â to 66 was greater in sclerostin antibody-treated groups (9.0 vs. ,28246926
2628,4,2_abstract_sentence,12,"5.4%, pâ=â0.02), and new bone formation due to sclerostin antibody treatment was associated with increased apparent stiffness as determined from finite element models. ",28246926
2628,4,2_abstract_sentence,13,Our results demonstrate that increased bone formation associated with sclerostin antibody treatment increases plate-like trabecular morphology and improves mechanical performance. ,28246926
2628,5,1_title,0,Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study.  ,27569204
2628,5,2_abstract_sentence,0,"Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling. ",27569204
2628,5,2_abstract_sentence,1,"Blockade of sclerostin binding to low-density lipoprotein receptor-related proteins 5 and 6 (LRP5 and LRP6) allows Wnt ligands to activate canonical Wnt signaling in bone, increasing  bone formation and decreasing bone resorption, making sclerostin an attractive target for osteoporosis therapy. ",27569204
2628,5,2_abstract_sentence,2,"Because romosozumab is a bone-forming agent and  an activator of canonical Wnt signaling, questions have arisen regarding a potential carcinogenic risk. ",27569204
2628,5,2_abstract_sentence,3,"Weight-of-evidence factors used in the assessment of human carcinogenic risk of romosozumab included features of canonical Wnt signaling, expression pattern of sclerostin, phenotype of loss-of-function mutations in humans and mice, mode and mechanism of action of romosozumab, and findings from romosozumab chronic toxicity studies in rats and monkeys. ",27569204
2628,5,2_abstract_sentence,4,"Although  the weight-of-evidence factors supported that romosozumab would pose a low carcinogenic risk to humans, the carcinogenic potential of romosozumab was assessed in a rat lifetime study. ",27569204
2628,5,2_abstract_sentence,5,There were no romosozumab-related effects on tumor incidence in rats. ,27569204
2628,5,2_abstract_sentence,6,The findings of the lifetime study and the weight-of-evidence factors collectively indicate that romosozumab administration  would not pose a carcinogenic risk to humans. ,27569204
2628,6,1_title,0,Novel therapies for osteoporosis.  ,26277199
2628,6,2_abstract_sentence,0,"Since the identification of osteoporosis as a major health issue in aging populations and the subsequent development of the first treatment modalities for  its management, considerable progress has been made in our understanding of the mechanisms controlling bone turnover and disease pathophysiology, thus enabling the pinpointing of new targets for intervention. ",26277199
2628,6,2_abstract_sentence,1,"This progress, along with advances in biotechnology, has rendered possible the development of ever more sophisticated treatments employing novel mechanisms of action. ",26277199
2628,6,2_abstract_sentence,2,"Denosumab, a monoclonal antibody against RANKL, approved for the treatment of postmenopausal and male osteoporosis, significantly and continuously increases bone mineral density (BMD) and maintains a low risk of vertebral, non-vertebral, and hip fractures for up to 8 years. ",26277199
2628,6,2_abstract_sentence,3,Currently available combinations of estrogens with selective estrogen receptor modulators moderately increase BMD without causing the extra-skeletal adverse effects of each compound alone. ,26277199
2628,6,2_abstract_sentence,4,"The cathepsin K inhibitor odanacatib has recently been shown to decrease vertebral, non-vertebral, and hip fracture rates and is nearing approval. ",26277199
2628,6,2_abstract_sentence,5,"Romosozumab, an anti-sclerosin antibody, and abaloparatide, a PTH-related peptide analog, are at  present in advanced stages of clinical evaluation, so far demonstrating efficaciousness together with a favorable safety profile. ",26277199
2628,6,2_abstract_sentence,6,"Several other agents are currently in earlier clinical and preclinical phases of development, including dickkopf-1 antagonists, activin A antagonists, Î²-arrestin analogs, calcilytics, and Src tyrosine kinase inhibitors. ",26277199
2628,7,1_title,0,Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.  ,27487526
2628,7,2_abstract_sentence,0,"Romosozumab, a monoclonal antibody that binds sclerostin, has a dual effect on bone by increasing bone formation and reducing bone resorption, and thus has favorable effects in both aspects of bone volume regulation. ",27487526
2628,7,2_abstract_sentence,1,"In a phase 2 study,  romosozumab increased areal BMD at the lumbar spine and total hip as measured by  DXA compared with placebo, alendronate, and teriparatide in postmenopausal women  with low bone mass. ",27487526
2628,7,2_abstract_sentence,2,"In additional analyses from this international, randomized study, we now describe the effect of romosozumab on lumbar spine and hip volumetric BMD (vBMD) and BMC at month 12 as assessed by QCT in the subset of participants receiving placebo, s.c. ",27487526
2628,7,2_abstract_sentence,3,"teriparatide (20 Âµg once daily), and s.c. ",27487526
2628,7,2_abstract_sentence,4,romosozumab (210âmg once monthly). ,27487526
2628,7,2_abstract_sentence,5,"QCT measurements were performed at the lumbar  spine (mean of L1 and L2 entire vertebral bodies, excluding posterior processes)  and hip. ",27487526
2628,7,2_abstract_sentence,6,"One year of treatment with romosozumab significantly increased integral  vBMD and BMC at the lumbar spine and total hip from baseline, and compared with placebo and teriparatide (all pâ<â0.05). ",27487526
2628,7,2_abstract_sentence,7,"Trabecular vertebral vBMD improved significantly and similarly from baseline (pâ<â0.05) with both romosozumab (18.3%) and teriparatide (20.1%), whereas cortical vertebral vBMD gains were larger with romosozumab compared with teriparatide (13.7% versus 5.7%, pâ<â0.0001). ",27487526
2628,7,2_abstract_sentence,8,"Trabecular hip vBMD gains were significantly larger with romosozumab than with teriparatide (10.8% versus 4.2%, pâ=â0.01), but were similar for cortical vBMD (1.1% versus -0.9%, pâ=â0.12). ",27487526
2628,7,2_abstract_sentence,9,"Cortical BMC gains were larger with  romosozumab compared with teriparatide at both the spine (23.3% versus 10.9%, pâ<â0.0001) and hip (3.4% versus 0.0%, pâ=â0.03). ",27487526
2628,7,2_abstract_sentence,10,These improvements are expected to result in strength gains and support the continued clinical investigation of romosozumab as a potential therapy to rapidly reduce fracture risk in ongoing phase 3 studies. ,27487526
2628,7,2_abstract_sentence,11,Â© 2016 American Society for Bone and Mineral Research. ,27487526
2628,8,1_title,0,Recent advances in the management of osteoporosis.  ,28529724
2628,8,2_abstract_sentence,0,There has been substantial progress in the management of patients with osteoporosis and the prevention of osteoporotic fractures. ,28529724
2628,8,2_abstract_sentence,1,"Currently available strong anti-resorptive agents are bisphosphonates and an anti-receptor activator  of nuclear factor-kappa B ligand (RANKL) antibody, denosumab. ",28529724
2628,8,2_abstract_sentence,2,"Although bisphosphonates and denosumab both inhibit bone resorption and prevent vertebral  and non-vertebral fractures, their mechanisms of action are different. ",28529724
2628,8,2_abstract_sentence,3,"Whereas bisphosphonates' effects on bone mineral density and fracture peak around 3 to 5  years and become plateaued, those of denosumab are maintained for up to 10 years. ",28529724
2628,8,2_abstract_sentence,4,There are differences in the modes of action of these two drugs. ,28529724
2628,8,2_abstract_sentence,5,"Bisphosphonates  accumulate on the mineralized bone surface and are released by the acid environment under osteoclastic bone resorption, whereas denosumab is not accumulated on bone but directly binds RANKL and inhibits its binding to the receptor RANK. ",28529724
2628,8,2_abstract_sentence,6,"Thus, the reduction in denosumab concentration 4 to 6 months after injection may enable RANK to bind to RANKL, where it is highly expressed, such as in damaged bone regions. ",28529724
2628,8,2_abstract_sentence,7,"As anabolic agents, only teriparatide has been available for a long time, but abaloparatide, a synthetic analog of PTHrP(1-34), is currently under development. ",28529724
2628,8,2_abstract_sentence,8,"Because of the difference in the preferential binding conformations of PTH1 receptor between teriparatide and abaloparatide, the latter shows anabolic effects with fewer bone resorptive effects. ",28529724
2628,8,2_abstract_sentence,9,"Romosozumab, an anti-sclerostin antibody, inhibits the action of sclerostin, a canonical Wnt signal inhibitor secreted from osteocytes, and enhances canonical Wnt signaling. ",28529724
2628,8,2_abstract_sentence,10,Romosozumab robustly increases vertebral and proximal femoral bone mineral density within 12 months and inhibits vertebral and clinical fractures in patients with osteoporosis by enhancing bone formation and inhibiting bone resorption. ,28529724
2628,8,2_abstract_sentence,11,"In this review, we summarize the recent advances in therapeutic agents for the treatment of osteoporosis and discuss future prospects with their  use. ",28529724
2628,9,1_title,0,Romosozumab: from basic to clinical aspects.  ,24835636
2628,9,2_abstract_sentence,0,The Wnt pathway has an important role in bone formation. ,24835636
2628,9,2_abstract_sentence,1,"Inactivation of sclerostin, an inhibitor of this pathway, has been associated with increased bone mass both in animal experiments and in human clinical trials. ",24835636
2628,9,2_abstract_sentence,2,Romosozumab is a humanized monoclonal antibody targeting sclerostin. ,24835636
2628,9,2_abstract_sentence,3,Preclinical studies showed that this antibody primarily increases bone formation resulting in increased bone mineral density. ,24835636
2628,9,2_abstract_sentence,4,Initial studies carried out in humans are in line with data obtained in animals. ,24835636
2628,9,2_abstract_sentence,5,"If these results are confirmed in larger studies with fracture end-points, this monoclonal antibody with its anabolic action, will become a key drug in the treatment of osteoporosis. ",24835636
2628,10,1_title,0,Profile of romosozumab and its potential in the management of osteoporosis.  ,28458516
2628,10,2_abstract_sentence,0,Increased understanding of bone biology has led to the discovery of several unique signaling pathways that regulate bone formation and resorption. ,28458516
2628,10,2_abstract_sentence,1,"The Wnt signaling pathway plays a significant role in skeletal development, adult skeletal homeostasis, and bone remodeling. ",28458516
2628,10,2_abstract_sentence,2,Sclerostin is an inhibitor of the Wnt  signaling pathway. ,28458516
2628,10,2_abstract_sentence,3,"Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect. ",28458516
2628,10,2_abstract_sentence,4,"Therefore,  in the presence of romosozumab, the Wnt signaling pathway is activated leading to bone formation and bone mineral density gain. ",28458516
2628,10,2_abstract_sentence,5,Clinical studies of romosozumab have shown that this agent is one of the most potent bone anabolic agents in development to date. ,28458516
2628,10,2_abstract_sentence,6,"Romosozumab does not act solely as an anabolic agent, but rather, it has effects on increasing bone formation as well as reducing bone resorption. ",28458516
2628,10,2_abstract_sentence,7,"In the clinical studies, patients tolerated romosozumab well with no  major safety signals reported. ",28458516
2628,10,2_abstract_sentence,8,"In a Phase III study, romosozumab as compared to placebo has been shown to reduce vertebral fractures by 73% after 1 year of treatment. ",28458516
2628,10,2_abstract_sentence,9,Sequential therapy with romosozumab for 1 year followed by denosumab in the second year reduced vertebral fractures by 75% as compared to the group that received placebo for 1 year and denosumab in the second year. ,28458516
2628,10,2_abstract_sentence,10,"Romosozumab holds significant potential, by a novel mechanism of action, to expand our ability to treat osteoporosis. ",28458516
2628,10,2_abstract_sentence,11,More studies are needed to determine the ideal setting in which romosozumab may be used to optimize osteoporosis treatment. ,28458516
2628,11,1_title,0,Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model.  ,26451332
2628,11,2_abstract_sentence,0,"The goal of this work was to extend a mathematical, multiscale systems model of bone function, remodeling, and health in order to explore hypotheses related to therapeutic modulation of sclerostin and quantitatively describe purported osteocyte activity within bone remodeling events. ",26451332
2628,11,2_abstract_sentence,1,"A pharmacokinetic model with first-order absorption and dual elimination pathways was used to describe the kinetics of romosozumab, a monoclonal antibody (mAb) against sclerostin. ",26451332
2628,11,2_abstract_sentence,2,"To describe total circulating sclerostin, an extended indirect response model of inhibition of offset was developed. ",26451332
2628,11,2_abstract_sentence,3,"These models were subsequently linked to the  systems model, with sclerostin signaling changes in resorption and formation through established osteocyte-mediated mechanisms. ",26451332
2628,11,2_abstract_sentence,4,"The model proposes relative contributions of the osteocyte to the RANKL pool, a major player in feedback signaling, and is used to explore hypotheses surrounding attenuation of anabolic  activity after multiple doses of sclerostin mAbs, a phenomenon whose mechanism is poorly understood. ",26451332
3049,0,1_title,0,Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.  ,30016770
3049,0,2_abstract_sentence,0,BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited. ,30016770
3049,0,2_abstract_sentence,1,SUMMARY: L-ornithine L-aspartate (LOLA) has hepatoprotective properties in patients with fatty liver of diverse etiology and results of a multicenter randomized clinical trial reveal that 12 weeks treatment with oral LOLA (6-9 g/d) results in a dose-related reduction in activities of liver enzymes and triglycerides together with significant improvements of liver/spleen CT ratios. ,30016770
3049,0,2_abstract_sentence,2,A preliminary report described improvements of hepatic microcirculation in patients with non-alcoholic steatohepatitis (NASH) following treatment with LOLA. ,30016770
3049,0,2_abstract_sentence,3,"Mechanisms responsible for the beneficial effects of LOLA in NAFLD/NASH involve,  in addition to its established ammonia-lowering effect, metabolic transformations of the LOLA-constituent amino acids L-ornithine and L-aspartate into L-glutamine, L-arginine, and glutathione. ",30016770
3049,0,2_abstract_sentence,4,"These metabolites have well-established actions implicated in the prevention of lipid peroxidation, improvement of hepatic microcirculation in addition to anti-inflammatory, and anti-oxidant properties. ",30016770
3049,0,2_abstract_sentence,5,Key Messages: (1) LOLA is effective for the treatment of key indices in NAFLD/NASH. ,30016770
3049,0,2_abstract_sentence,6,(2) Mechanisms other than LOLA's ammonia-lowering action have been postulated. ,30016770
3049,0,2_abstract_sentence,7,(3) Further assessments in the clinical setting are now required. ,30016770
3049,1,1_title,0,Pharmacotherapy for NASH: Current and emerging.  ,29122694
3049,1,2_abstract_sentence,0,Erratum in     J Hepatol. ,29122694
3049,1,2_abstract_sentence,1,2018 Mar 19;:. ,29122694
3049,2,1_title,0,Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.  ,29448843
3049,2,2_abstract_sentence,0,INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) has an increasing prevalence worldwide. ,29448843
3049,2,2_abstract_sentence,1,"At present, no specific pharmacotherapy is approved for NAFLD. ",29448843
3049,2,2_abstract_sentence,2,Simple steatosis and nonalcoholic steatohepatitis (NASH) can progress to liver fibrosis that is associated with mortality in NAFLD. ,29448843
3049,2,2_abstract_sentence,3,The recruitment of inflammatory monocytes and macrophages via chemokine receptor CCR2 as well as of  lymphocytes and hepatic stellate cells via CCR5 promote the progression of NASH to fibrosis. ,29448843
3049,2,2_abstract_sentence,4,"Areas covered: I summarize preclinical and clinical data on the efficacy and safety of the dual CCR2/CCR5 inhibitor cenicriviroc (CVC, also TBR-652 or TAK-652) for the treatment of NASH and fibrosis. ",29448843
3049,2,2_abstract_sentence,5,"In animal models of liver diseases, CVC potently inhibits macrophage accumulation in the liver and ameliorates fibrosis. ",29448843
3049,2,2_abstract_sentence,6,"In a phase 2b clinical trial (CENTAUR) on 289 patients with NASH and fibrosis, CVC consistently demonstrated liver fibrosis improvement after 1Â year of therapy and had an excellent safety profile, leading to the implementation of a phase 3 trial (AURORA). ",29448843
3049,2,2_abstract_sentence,7,Expert opinion: Preclinical and clinical data support the development of CVC as a safe and potent antifibrotic agent. ,29448843
3049,2,2_abstract_sentence,8,"However, open questions around CVC are the durability of antifibrotic responses, divergent effects on NASH versus fibrosis, potential long-term concerns and the expected path to approval. ",29448843
3049,3,1_title,0,Current and future pharmacological therapies for NAFLD/NASH.  ,29247356
3049,3,2_abstract_sentence,0,"Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. ",29247356
3049,3,2_abstract_sentence,1,"The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. ",29247356
3049,3,2_abstract_sentence,2,"GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects. ",29247356
3049,3,2_abstract_sentence,3,Innovative NASH therapies include four main pathways. ,29247356
3049,3,2_abstract_sentence,4,The first approach is targeting hepatic fat accumulation. ,29247356
3049,3,2_abstract_sentence,5,"Medications in this approach include modulation of peroxisome proliferator-activator receptors (e.g., pemafibrate, elafibranor), medications targeting farnesoid X receptor axis [obeticholic acid; OCA)], inhibitors of de novo lipogenesis (aramchol, ACC inhibitor), and fibroblast growth factor-21 analogues. ",29247356
3049,3,2_abstract_sentence,6,"A second target is oxidative stress, inflammation, and apoptosis. ",29247356
3049,3,2_abstract_sentence,7,This class of drug includes apoptosis signaling kinase 1 (ASK1) inhibitor and emricasan (an irreversible caspase inhibitor). ,29247356
3049,3,2_abstract_sentence,8,A third target is intestinal microbiomes and metabolic endotoxemia. ,29247356
3049,3,2_abstract_sentence,9,"Several agents are in ongoing trials, including IMMe124, TLR4 antagonist, and solithromycin (macrolide antibiotics). ",29247356
3049,3,2_abstract_sentence,10,"The final target is hepatic fibrosis, which is strongly associated with all-cause or liver-related mortality in NASH. ",29247356
3049,3,2_abstract_sentence,11,Antifibrotic agents are a cysteine-cysteine motif chemokine receptor-2/5 antagonist (cenicriviroc; CVC) and galectin 3 antagonist. ,29247356
3049,3,2_abstract_sentence,12,"Among a variety of medications in development, four agents such as OCA, elafibranor, ASK1 inhibitor, and CVC are currently being evaluated in an international phase 3 trial for the treatment of NASH. ",29247356
3049,3,2_abstract_sentence,13,"Within the next few years, the availability of therapeutic options for NASH will hopefully curb the rising trend of NASH-related diseases. ",29247356
753,0,1_title,0,Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications.  ,21982627
753,0,2_abstract_sentence,0,"BACKGROUND: Type 2 Gaucher disease is a rare and progressive subtype of this lysosomal storage disorder, marked by rapid, early-onset neurodegeneration. ",21982627
753,0,2_abstract_sentence,1,"Distinguishing type 2 from types 1 and 3 Gaucher disease has remained challenging, due to the lack of a clear correlation between phenotype and enzymatic activity or genotype. ",21982627
753,0,2_abstract_sentence,2,"Î²-glucocerebrosidase, the enzyme deficient in Gaucher disease, also has an essential role in maintaining epidermal permeability function, by regulating the ratio of ceramides to glucosylceramides in the stratum corneum of the skin. ",21982627
753,0,2_abstract_sentence,3,OBJECTIVES: To further assess the diagnostic utility of epidermal evaluations in  distinguishing patients with type 2 Gaucher disease in an expanded cohort. ,21982627
753,0,2_abstract_sentence,4,"STUDY DESIGN: Epidermal samples were evaluated from twenty children with type 2,  three patients with type 3 Gaucher disease and two adults with type 1 Gaucher disease with different clinical manifestations and genotypes. ",21982627
753,0,2_abstract_sentence,5,Electron microscopy on ruthenium tetroxide post-fixed tissue was performed. ,21982627
753,0,2_abstract_sentence,6,"RESULTS: Compared to controls and subjects with type 1 and type 3 Gaucher disease, only patients with type 2 Gaucher disease displayed characteristic electron dense, non-lamellar clefts and immature-lamellar membranes. ",21982627
753,0,2_abstract_sentence,7,CONCLUSION: The appearance of characteristic alterations in epidermal ultrastructure provides an early and specific diagnostic tool to help in distinguishing type 2 from the other types of Gaucher disease. ,21982627
753,1,1_title,0,Gaucher disease with prenatal onset and perinatal death due to compound heterozygosity for the missense R131C and null Rec Nci I GBA mutations.  ,20946052
753,1,2_abstract_sentence,0,"Gaucher disease is an autosomal recessive disorder resulting from deficient activity of the lysosomal enzyme glucocerebrosidase (GBA, E.C.3.2.1.45). ",20946052
753,1,2_abstract_sentence,1,"Three clinical forms of Gaucher disease have been described: type 1, nonneuronopathic;  type 2, acute neuronopathic; and type 3, subacute neuronopathic (OMIM 230800, 230900, 231000). ",20946052
753,1,2_abstract_sentence,2,"Over the past decade, recognition of a distinct, perinatal lethal form of Gaucher disease (PLGD) has led researchers and clinicians to evaluate Gaucher disease in the differential diagnosis of congenital ichthyosis and nonimmune hydrops fetalis. ",20946052
753,1,2_abstract_sentence,3,"To date, more than 30 cases of PLGD have been genotyped and reported. ",20946052
753,1,2_abstract_sentence,4,"It has been observed that homozygosity for recombinant GBA alleles, which are fundamentally null alleles, leads to early lethality, usually in utero or during the 1st few days of life, whereas genotypes involving  a recombinant allele and a missense mutation may be less detrimental. ",20946052
753,1,2_abstract_sentence,5,"Here, we report a case of Gaucher disease with prenatal onset and death within hours of birth, likely due to compound heterozygosity for the GBA Rec Nci I null allele and a R131C missense mutation. ",20946052
753,1,2_abstract_sentence,6,"In view of the patient's severe clinical course, and based on reviews of other PLGD cases, we postulate that a missense mutation that abruptly disrupts the structure/function of GBA, in combination with a null  allele, may result in early lethality in patients with PLGD. ",20946052
753,1,2_abstract_sentence,7,"We also speculate that R131C is an extremely severe mutation that has occurred more than once in different populations and, in either the homozygous form or heterozygous with another severe mutation, will result in a poor prognosis. ",20946052
753,2,1_title,0,Gaucher disease.  ,17644022
753,2,2_abstract_sentence,0,"Although Gaucher disease is a rare disorder, recent developments in novel means for therapeutic intervention have invigorated both academic research and pharmaceutical industry discovery programmes. ",17644022
753,2,2_abstract_sentence,1,"The common mutations found in the lysosomal enzyme deficient in Gaucher disease, beta-glucocerebrosidase, earmark these proteins for destruction by the endoplasmic reticulum-localised protein folding machinery, resulting in enzyme insufficiency, lysosomal glycolipid storage and subsequent pathology. ",17644022
753,2,2_abstract_sentence,2,"However, many of these mutants can be rescued from global misfolding to preserve glycolipid substrate binding and eventual catalysis in the lysosome, by the addition of subinhibitory concentrations of pharmacologically active small molecules. ",17644022
753,2,2_abstract_sentence,3,"This novel, chaperon-mediated approach  has benefited from insights into the molecular understanding of beta-glucocerebrosidase structure, drug design and development in cellular models for disease. ",17644022
753,3,1_title,0,Imiglucerase and its use for the treatment of Gaucher's disease.  ,18627336
753,3,2_abstract_sentence,0,BACKGROUND: Gaucher's disease is caused by deficient lysosomal glucocerebrosidase activity. ,18627336
753,3,2_abstract_sentence,1,"Intravenous enzyme replacement therapy with imiglucerase (Cerezyme, Genzyme Corporation, Cambridge, MA), a recombinant human glucocerebrosidase, ameliorates systemic manifestations such as hepatosplenomegaly, anemia, thrombocytopenia and skeletal abnormalities in patients with type 1 (non-neuronopathic) and type 3 (chronic neuronopathic) Gaucher's disease. ",18627336
753,3,2_abstract_sentence,2,OBJECTIVE/METHODS: The aim of this study was to identify and comment on the current issues related to imiglucerase for Gaucher's disease based on a review of published English language literature and personal clinical experience. ,18627336
753,3,2_abstract_sentence,3,"RESULTS: The following topics were covered with respect to imiglucerase: development, pharmacokinetics, preparation and administration, efficacy, pediatrics, pregnancy, type 3 Gaucher's disease, dosing, treatment interruptions, safety and alternative pharmacological therapies. ",18627336
753,3,2_abstract_sentence,4,CONCLUSION: Imiglucerase is safe and well tolerated. ,18627336
753,3,2_abstract_sentence,5,"In addition, it corrects the hepatic, splenic, hematologic and bone abnormalities observed with types 1 and 3  Gaucher's disease effectively and enhances health-related quality of life. ",18627336
753,4,1_title,0,Autosomal recessive mutations in the development of Parkinson's disease.  ,20945983
753,4,2_abstract_sentence,0,"Although Parkinson's disease was long considered a nongenetic disorder, it is now clear that there are multiple predisposing genes, and that the disorder can exhibit either Mendelian or non-Mendelian modes of inheritance. ",20945983
753,4,2_abstract_sentence,1,The identification of several of these genes has provided important insights into the pathogenesis of this common complex disorder. ,20945983
753,4,2_abstract_sentence,2,"This article presents an overview of the genes associated with autosomal recessive Parkinson's disease, including Parkin (PARK2), PINK1 (PARK6), DJ1 (PARK7) and ATP13A2 (PARK9). ",20945983
753,4,2_abstract_sentence,3,"Recently, it was  recognized that mutations in the gene encoding glucocerebrosidase, the enzyme deficient in Gaucher disease, are associated with an increased incidence of parkinsonism. ",20945983
753,4,2_abstract_sentence,4,"While Gaucher disease is an autosomal recessive inherited disorder, patients with Parkinson's disease can be Gaucher heterozygotes or homozygotes. ",20945983
753,4,2_abstract_sentence,5,Elucidating the basis for this association may shed light on new disease mechanisms that contribute to the development of parkinsonism. ,20945983
753,5,1_title,0,The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow.  ,22843412
753,5,2_abstract_sentence,0,"Mutations in GBA, the gene encoding glucocerebrosidase, the enzyme deficient in Gaucher disease, are common risk factors for Parkinson disease, as patients with  Parkinson disease are over five times more likely to carry GBA mutations than healthy controls. ",22843412
753,5,2_abstract_sentence,1,Patients with GBA mutations generally have an earlier onset of  Parkinson disease and more cognitive impairment than those without GBA mutations. ,22843412
753,5,2_abstract_sentence,2,"We investigated whether GBA mutations alter the neurobiology of Parkinson disease, studying brain dopamine synthesis and resting regional cerebral blood flow in 107 subjects (38 women, 69 men). ",22843412
753,5,2_abstract_sentence,3,"We measured dopamine synthesis with (18)F-fluorodopa positron emission tomography, and resting regional cerebral blood flow with H(2)(15)O positron emission tomography in the wakeful, resting state in four study groups: (i) patients with Parkinson disease and Gaucher disease (n = 7, average age = 56.6 Â± 9.2 years); (ii) patients with Parkinson disease without GBA mutations (n = 11, 62.1 Â± 7.1 years); (iii) patients with Gaucher disease without parkinsonism, but with a family history of Parkinson disease (n = 14, 52.6 Â± 12.4 years); and (iv) healthy GBA-mutation carriers with  a family history of Parkinson disease (n = 7, 50.1 Â± 18 years). ",22843412
753,5,2_abstract_sentence,4,We compared each  study group with a matched control group. ,22843412
753,5,2_abstract_sentence,5,Data were analysed with region of interest and voxel-based methods. ,22843412
753,5,2_abstract_sentence,6,"Disease duration and Parkinson disease functional and staging scores were similar in the two groups with parkinsonism, as was striatal dopamine synthesis: both had greatest loss in the caudal striatum (putamen Ki loss: 44 and 42%, respectively), with less reduction in the caudate (20 and 18% loss). ",22843412
753,5,2_abstract_sentence,7,"However, the group with both Parkinson and Gaucher diseases showed decreased resting regional cerebral blood flow in the lateral parieto-occipital association cortex and precuneus bilaterally. ",22843412
753,5,2_abstract_sentence,8,"Furthermore, two  subjects with Gaucher disease without parkinsonian manifestations showed diminished striatal dopamine. ",22843412
753,5,2_abstract_sentence,9,"In conclusion, the pattern of dopamine loss in patients with both Parkinson and Gaucher disease was similar to sporadic Parkinson disease, indicating comparable damage in midbrain neurons. ",22843412
753,5,2_abstract_sentence,10,"However, H(2)(15)O positron emission tomography studies indicated that these subjects have decreased resting activity in a pattern characteristic of diffuse Lewy body disease. ",22843412
753,5,2_abstract_sentence,11,These findings provide insight into the pathophysiology of GBA-associated parkinsonism. ,22843412
753,6,1_title,0,Structural features of membrane-bound glucocerebrosidase and Î±-synuclein probed by neutron reflectometry and fluorescence spectroscopy.  ,25429104
753,6,2_abstract_sentence,0,"Mutations in glucocerebrosidase (GCase), the enzyme deficient in Gaucher disease, are a common genetic risk factor for the development of Parkinson disease and related disorders, implicating the role of this lysosomal hydrolase in the disease etiology. ",25429104
753,6,2_abstract_sentence,1,"A specific physical interaction exists between the Parkinson disease-related protein Î±-synuclein (Î±-syn) and GCase both in solution and on the lipid membrane, resulting in efficient enzyme inhibition. ",25429104
753,6,2_abstract_sentence,2,"Here, neutron reflectometry was employed as a first direct structural characterization of GCase and Î±-synÂ·GCase complex on a sparsely-tethered lipid bilayer, revealing the orientation of the membrane-bound GCase. ",25429104
753,6,2_abstract_sentence,3,GCase binds to and partially inserts into the bilayer with its active site most likely lying just above the membrane-water interface. ,25429104
753,6,2_abstract_sentence,4,"The interaction was further characterized by intrinsic  Trp fluorescence, circular dichroism, and surface plasmon resonance spectroscopy. ",25429104
753,6,2_abstract_sentence,5,"Both Trp fluorescence and neutron reflectometry results suggest a rearrangement of loops surrounding the catalytic site, where they extend into the hydrocarbon chain region of the outer leaflet. ",25429104
753,6,2_abstract_sentence,6,"Taking advantage of contrasting neutron scattering length densities, the use of deuterated Î±-syn versus protiated GCase showed a large change in the membrane-bound structure of Î±-syn in the complex. ",25429104
753,6,2_abstract_sentence,7,"We propose a model of Î±-synÂ·GCase on the membrane, providing structural insights into inhibition of GCase by Î±-syn. ",25429104
753,6,2_abstract_sentence,8,"The interaction displaces GCase away from the  membrane, possibly impeding substrate access and perturbing the active site. ",25429104
753,6,2_abstract_sentence,9,"GCase greatly alters membrane-bound Î±-syn, moving helical residues away from the  bilayer, which could impact the degradation of Î±-syn in the lysosome where these  two proteins interact. ",25429104
753,7,1_title,0,Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression.  ,8294487
753,7,2_abstract_sentence,0,"Structure/function relationships of acid beta-glucosidase, the enzyme deficient in Gaucher disease, were evaluated by characterizing the proteins expressed from  cDNAs encoding normal and mutant enzymes. ",8294487
753,7,2_abstract_sentence,1,"Twenty-two Gaucher disease mutations or created mutations were expressed in Spodoptera frugiperda (Sf9) cells and analyzed for catalytic properties, stability, inhibitor binding, and modifier interactions. ",8294487
753,7,2_abstract_sentence,2,Many Gaucher disease mutations encoded highly disruptive amino acid substitutions (e.g. ,8294487
753,7,2_abstract_sentence,3,P289L and D409V) and produced severely compromised proteins with very reduced activity (kcat < 1% of normal) and/or stability. ,8294487
753,7,2_abstract_sentence,4,Six mutant enzymes had sufficient catalytic activity (kcat approximately 5-30% of normal) for extensive studies. ,8294487
753,7,2_abstract_sentence,5,"The highly conservative substitutions, i.e. ",8294487
753,7,2_abstract_sentence,6,"F216Y or S364T and V394L, led to severe, but selective, abnormalities of enzyme stability or large decreases in catalytic activity, respectively. ",8294487
753,7,2_abstract_sentence,7,"The T323I, N370S, and V394L  enzymes interacted abnormally with active site-directed inhibitors and localized  these residues to the glycon binding region. ",8294487
753,7,2_abstract_sentence,8,"Selected mutant enzymes were poorly  activated by phosphatidylserine (V394L, L444P, and R463C) or by saposin C (L444P  and T323I), indicating that the enzyme sites for interaction with these activators were within the carboxyl one-third of the enzyme. ",8294487
753,7,2_abstract_sentence,9,"Substitutions of Ser, Glu, and/or Gly at residues Asp-443 and/or Asp-445 demonstrated important steric roles for these residues in the active site, but neither is the catalytic  nucleophile. ",8294487
753,7,2_abstract_sentence,10,"Together with previous studies, the present analyses provide an insight into the pathogenesis of Gaucher disease and the functional organization  of acid beta-glucosidase. ",8294487
753,8,1_title,0,"A novel alteration in metaxin 1, F202L, is associated with N370S in Gaucher disease.  ",15024629
753,8,2_abstract_sentence,0,"The gene for glucocerebrosidase ( GBA), the enzyme deficient in Gaucher disease,  is located in a gene-rich region on 1q21. ",15024629
753,8,2_abstract_sentence,1,Metaxin 1( MTX1) is a convergently transcribed gene contiguous to the 3' end of the GBA pseudogene. ,15024629
753,8,2_abstract_sentence,2,"A single nucleotide alteration in MTX1, 628T-->C, resulting in the amino acid change F202L, was identified in patients with Gaucher disease in association with the common N370S mutation in GBA. ",15024629
753,8,2_abstract_sentence,3,"The polymorphism was also present on 4.6% of 152 control alleles, but could have functional consequences that have a modifying role in Gaucher disease. ",15024629
753,9,1_title,0,Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.  ,20074983
753,9,2_abstract_sentence,0,"Gaucher disease (GD) is a lysosomal storage disorder, caused by deficient activity of the enzyme glucocerebrosidase. ",20074983
753,9,2_abstract_sentence,1,GD is classically divided into three major phenotypes. ,20074983
753,9,2_abstract_sentence,2,"The most prevailing form is type 1, which presents with variable hepatosplenomegaly, cytopenia, and/or bone disease. ",20074983
753,9,2_abstract_sentence,3,"In adult patients with mild manifestations, progress of disease might be slow or even absent. ",20074983
753,9,2_abstract_sentence,4,"As a  consequence, treatment with intravenous enzyme replacement or substrate reduction is not always necessary. ",20074983
753,9,2_abstract_sentence,5,"In the Netherlands, the follow-up of GD patients is centralized, which allows detailed investigation of untreated patients. ",20074983
753,9,2_abstract_sentence,6,"A retrospective study was conducted in 18 type 1 GD patients, (2 teenagers: 15 and  16 years of age at first visit) who were not treated for at least one year. ",20074983
753,9,2_abstract_sentence,7,"The chitotriosidase activity, platelet count, hemoglobin level, lumbar bone marrow fat content measured with quantitative chemical shift imaging (QCSI), liver ratio (ml/kg body weight), and spleen volume were recorded. ",20074983
753,9,2_abstract_sentence,8,"Criteria were developed to  score regression, stability or progression of disease. ",20074983
753,9,2_abstract_sentence,9,During a mean follow up of 4.5 years (range 1.1-12.2) seven patients (39%) showed spontaneous regression of  GD. ,20074983
753,9,2_abstract_sentence,10,Eight patients (44%) were stable. ,20074983
753,9,2_abstract_sentence,11,"Two patients had progressive disease, solely based upon a sustained increase in chitotriosidase activity. ",20074983
753,9,2_abstract_sentence,12,"A pediatric patient had an increase in splenomegaly but an improvement in bone marrow fat fraction, probably due to aging. ",20074983
753,9,2_abstract_sentence,13,"Nine patients fulfilled the local criteria to start treatment at first visit, of whom six started treatment within 1.1 to 6.8 years. ",20074983
753,9,2_abstract_sentence,14,"The other three refused therapy, but nevertheless showed stability or even regression of the disease during a follow up of 4.6, 9.5 and 11.4 years respectively. ",20074983
753,9,2_abstract_sentence,15,None of the parameters was predictive of progression or regression  of disease. ,20074983
753,9,2_abstract_sentence,16,"In conclusion, GD in adults can, in some cases, regress spontaneously. ",20074983
753,9,2_abstract_sentence,17,No parameters for accurately predicting future disease course exist. ,20074983
753,10,1_title,0,Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.  ,17433057
753,10,2_abstract_sentence,0,PURPOSE: Gaucher disease (GD) is an autosomal recessive lysosomal disorder caused by a deficiency of glucocerebrosidase. ,17433057
753,10,2_abstract_sentence,1,The neurologic manifestations of GD patients have to date been refractory to any treatment approach. ,17433057
753,10,2_abstract_sentence,2,We present a report of a neuronopathic GD patient whose myoclonic epilepsy improved after combination therapy with imiglucerase and miglustat. ,17433057
753,10,2_abstract_sentence,3,"METHODS: In an adult type 3 GD patient who, despite good visceral and analytic response to ERT, developed progressive neurologic deterioration with marked myoclonic epilepsy and dystonia, we added miglustat to the enzyme-replacement therapy. ",17433057
753,10,2_abstract_sentence,4,"RESULTS: After 2 years of combined miglustat (200 mg, 3 t.i.d.) and imiglucerase  (60 IU/kg every 2 weeks), generalized tonic-clonic seizures decreased, speech improved, and the general neurologic clinical picture improved markedly. ",17433057
753,10,2_abstract_sentence,5,The EEG  showed a reduction in focal and generalized paroxysmal discharges. ,17433057
753,10,2_abstract_sentence,6,No significant adverse effects were observed. ,17433057
753,10,2_abstract_sentence,7,CONCLUSIONS: Combined imiglucerase and miglustat therapy may be beneficial for some neuronopathic forms of GD. ,17433057
753,11,1_title,0,Gaucher's disease uncovered late.  ,15453048
753,11,2_abstract_sentence,0,"Gaucher's disease is an uncommon inborn recessive autosomal disease, due to a deficient activity of the lysosomal enzyme beta glucocerebrosidase. ",15453048
753,11,2_abstract_sentence,1,"This disease  is usually diagnosed in the first or second decade of life with the arising of bone pains, splenomegaly and hemorragic manifestations due to thrombocytopenia. ",15453048
753,11,2_abstract_sentence,2,"When the enlarged spleen is not evident, or after splenectomy, patients may be mis-identified as having Gaucher's disease. ",15453048
753,11,2_abstract_sentence,3,"We present here two cases of elderly  patients aged 70 and 46 years respectively, in whom the disease was a surprising  finding of bone marrow examination, during check up for pancytopenia. ",15453048
753,12,1_title,0,Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.  ,21653695
753,12,2_abstract_sentence,0,"The presynaptic protein Î±-synuclein (Î±-syn), particularly in its amyloid form, is widely recognized for its involvement in Parkinson disease (PD). ",21653695
753,12,2_abstract_sentence,1,Recent genetic studies reveal that mutations in the gene GBA are the most widespread genetic risk factor for parkinsonism identified to date. ,21653695
753,12,2_abstract_sentence,2,"GBA encodes for glucocerebrosidase (GCase), the enzyme deficient in the lysosomal storage disorder, Gaucher disease (GD). ",21653695
753,12,2_abstract_sentence,3,"In this work, we investigated the possibility of  a physical linkage between Î±-syn and GCase, examining both wild type and the GD-related N370S mutant enzyme. ",21653695
753,12,2_abstract_sentence,4,"Using fluorescence and nuclear magnetic resonance spectroscopy, we determined that Î±-syn and GCase interact selectively under lysosomal solution conditions (pH 5.5) and mapped the interaction site to the Î±-syn C-terminal residues, 118-137. ",21653695
753,12,2_abstract_sentence,5,"This Î±-syn-GCase complex does not form at pH  7.4 and is stabilized by electrostatics, with dissociation constants ranging from 1.2 to 22 Î¼m in the presence of 25 to 100 mm NaCl. ",21653695
753,12,2_abstract_sentence,6,"Intriguingly, the N370S mutant form of GCase has a reduced affinity for Î±-syn, as does the inhibitor conduritol-Î²-epoxide-bound enzyme. ",21653695
753,12,2_abstract_sentence,7,"Immunoprecipitation and immunofluorescence studies verified this interaction in human tissue and neuronal cell culture, respectively. ",21653695
753,12,2_abstract_sentence,8,"Although our data do not preclude protein-protein interactions in other cellular milieux, we suggest that the Î±-syn-GCase association is favored in the lysosome, and that this noncovalent interaction provides the groundwork to explore molecular mechanisms linking PD with mutant GBA alleles. ",21653695
753,13,1_title,0,Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease.  ,8437594
753,13,2_abstract_sentence,0,Comment in     N Engl J Med. ,8437594
753,13,2_abstract_sentence,1,1993 Mar 18;328(11):801-2. ,8437594
753,14,1_title,0,Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease.  ,20947659
753,14,2_abstract_sentence,0,Pathogenic variants in the glucocerebrosidase gene (GBA) encoding the enzyme deficient in Gaucher's disease (GD) are associated with Parkinson's disease (PD). ,20947659
753,14,2_abstract_sentence,1,"To investigate the sequence variants, their association with PD and the related phenotypes in a large cohort of European, mostly French, patients and controls, we sequenced all exons of GBA in 786 PD patients from 525 unrelated multiplex families, 605 patients with apparently sporadic PD and 391 ethnically matched controls. ",20947659
753,14,2_abstract_sentence,2,"GBA mutations were significantly more frequent (odds ratio=6.98, 95% confidence interval 2.54-19.21; P=0.00002) in the PD patients (76/1130=6.7%) than in controls (4/391=1.0%) and in patients with family histories of PD (8.4%) than  in isolated cases (5.3%). ",20947659
753,14,2_abstract_sentence,3,"Twenty-eight different mutations were identified in patient and control groups, including seven novel variants. ",20947659
753,14,2_abstract_sentence,4,N370S and L444P accounted for 70% of all mutant alleles in the patient group. ,20947659
753,14,2_abstract_sentence,5,PD patients with GBA mutations more frequently had bradykinesia as the presenting symptom and levodopa-induced dyskinesias. ,20947659
753,14,2_abstract_sentence,6,"The phenotype was similar in patients with one, two or complex GBA mutations, although the two patients with c.1263del+RecTL and N370S/RecÎ55 mutations had signs of GD. ",20947659
753,14,2_abstract_sentence,7,"Segregation analyses in 21 multiplex families showed that 17% of the affected relatives did not carry GBA mutations found in the given family, indicating heterogeneity of the aetiology, but 46% of  the unaffected relatives were GBA mutation carriers. ",20947659
753,14,2_abstract_sentence,8,"These genotype and clinical  analyses on the largest homogeneous sample of European patients studied to date confirmed that GBA mutations are the most common genetic risk factor for PD, particularly in familial forms. ",20947659
753,15,1_title,0,Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism.  ,16781064
753,15,2_abstract_sentence,0,"Alteration G2019S in the leucine-rich repeat kinase 2 gene (LRRK2) has been identified in several populations of patients with parkinsonism, including Ashkenazi Jewish subjects with Parkinson disease. ",16781064
753,15,2_abstract_sentence,1,"Mutations in glucocerebrosidase (GBA), the enzyme deficient in Gaucher disease, are also identified at an increased frequency among Parkinson probands, including those of Ashkenazi Jewish ancestry. ",16781064
753,15,2_abstract_sentence,2,A Taqman Assay-by-Design SNP genotyping strategy was utilized to establish whether G2019S was found in association with GBA mutations. ,16781064
753,15,2_abstract_sentence,3,"Among 37 subjects with parkinsonism who were heterozygous for a GBA mutation, none carried G2019S. ",16781064
753,15,2_abstract_sentence,4,"Furthermore, G2019S was not found in 18 patients with Gaucher disease who developed parkinsonian manifestations and 11 other Gaucher probands with parkinsonism in a first degree relative. ",16781064
753,15,2_abstract_sentence,5,"Among 45 patients with Gaucher disease without a history of parkinsonism, one G2019S carrier was found. ",16781064
753,15,2_abstract_sentence,6,These findings suggest that GBA and LRRK2 mutations are discrete risk factors for parkinsonism in both Ashkenazi Jewish and non-Jewish subjects. ,16781064
753,16,1_title,0,French results of enzyme replacement therapy in Gaucher's disease.  ,12412377
753,16,2_abstract_sentence,0,Gaucher disease is an inborn recessive autosomal disease due to a partial deficiency of the lysosomal enzyme beta glucocerebrosidase. ,12412377
753,16,2_abstract_sentence,1,"The deficient activity leads to accumulation of the lipid glucocerebroside in the liver, the spleen and bone marrow with concomitant anemia and thrombocytopenia. ",12412377
753,16,2_abstract_sentence,2,"Patients with Gaucher disease have been classified in three types: type I is the more common, neurological manifestations occur in types II and III. ",12412377
753,16,2_abstract_sentence,3,Enzyme replacement therapy (ERT) with modified placental human glucocerebrosidase (ceredase) or recombinant glucocerebrosidase (cerezyme) is effective in most type I Gaucher disease and has become the current standard care administered to thousand of patients worldwide. ,12412377
753,16,2_abstract_sentence,4,ERT has obviated the need for bone marrow transplantation and virtually eliminated the need for splenectomy. ,12412377
753,16,2_abstract_sentence,5,We report here the French study including adults and children. ,12412377
753,16,2_abstract_sentence,6,ERT of 30 to 60 U/K every two weeks as starting dose was administrated to 108 patients with severe type I Gaucher disease. ,12412377
753,16,2_abstract_sentence,7,ERT fully reverse many of the manifestations of the disease. ,12412377
753,16,2_abstract_sentence,8,"ERT regimen alleviated fatigue, and hematological and visceral signs and symptoms in nearly all severely-ill patients. ",12412377
753,16,2_abstract_sentence,9,Skeletal responses to treatment develop much more slowly than hematological or visceral responses. ,12412377
753,16,2_abstract_sentence,10,Studies in pediatrics show that the disease is more severe in children. ,12412377
753,16,2_abstract_sentence,11,These children should be treated early in the course of their disease to avoid irreparable damage. ,12412377
753,16,2_abstract_sentence,12,Hematological manifestation  in type II cannot be reversed with enzyme replacement. ,12412377
753,16,2_abstract_sentence,13,In type III treatment can  rarely reverse neurological deficit. ,12412377
753,16,2_abstract_sentence,14,Gaucher disease is also an excellent candidate for gene therapy. ,12412377
753,17,1_title,0,Current development and usefulness of biomarkers for Gaucher disease follow up.  ,18228687
753,17,2_abstract_sentence,0,"Gaucher's disease is due to glucocerebrosidase deficiency which is responsible for the accumulation of non degraded glucosylceramide within the lysosomes of macrophages: these ""Gaucher cells"", overloaded and alternatively activated, release in patient's plasma numerous compounds (cytokines, chemokines, hydrolases...) some of which contribute to the various tissue damages. ",18228687
753,17,2_abstract_sentence,1,"Some of these compounds are surrogate biomarkers which contribute to the evaluation of disease severity, progression and stabilisation or regression during treatment. ",18228687
753,17,2_abstract_sentence,2,"To date, the most interesting biomarkers are chitotriosidase and the chemokine CCL18/PARC, especially in chitotriosidase deficient patients. ",18228687
753,17,2_abstract_sentence,3,"These biomarkers together with the clinical evaluation help to therapeutic choice (treatment by enzyme replacement therapy or substrate reduction therapy) and initiation decision, response follow-up and dose adjustments. ",18228687
753,17,2_abstract_sentence,4,Biomarkers should be assessed  every 12 months together with clinical evaluation in patients not receiving specific treatments. ,18228687
753,17,2_abstract_sentence,5,An assessment every 3 months is recommended during the first year of treatment. ,18228687
753,17,2_abstract_sentence,6,"Then when clinical goals have been achieved, the frequency can be reduced to every 12 months if the therapeutic scheme is not modified. ",18228687
753,18,1_title,0,Alglucerase. A review of its therapeutic use in Gaucher's disease.  ,1379912
753,18,2_abstract_sentence,0,"Alglucerase is a mannose-terminated form of human placental glucocerebrosidase, developed to treat patients with Gaucher's disease. ",1379912
753,18,2_abstract_sentence,1,"Functional glucocerebrosidase is deficient in Gaucher's disease, an autosomal recessive lipid storage disorder  that affects people of all ethnic backgrounds, but has a higher incidence among East European Jews (Ashkenazim). ",1379912
753,18,2_abstract_sentence,2,"Gaucher's disease manifests with hepatosplenomegaly, bleeding disorders and bone disease, with the more rare subtypes (types 2 and 3) featuring neurological dysfunction. ",1379912
753,18,2_abstract_sentence,3,"Prior to the development of enzyme replacement therapy, treatment for Gaucher's disease was mainly symptomatic relief. ",1379912
753,18,2_abstract_sentence,4,Primary treatment with glucocerebrosidase focuses on removal of the lipid metabolite that causes the pathology. ,1379912
753,18,2_abstract_sentence,5,"Because of the rarity  of Gaucher's disease clinical trials are small, and much of the data investigating alglucerase therapy have been obtained from studies of patients with type 1 disease, the prevalent subtype. ",1379912
753,18,2_abstract_sentence,6,"Nonetheless, after intravenous administration of alglucerase, improvements are evident within 6 months of therapy. ",1379912
753,18,2_abstract_sentence,7,"Patients have increased haemoglobin levels and platelet counts, and decreased incidences of epistaxis and bruising. ",1379912
753,18,2_abstract_sentence,8,"Spleen and liver size are reduced, and skeletal parameters improve. ",1379912
753,18,2_abstract_sentence,9,Children gain height and most patients  receiving alglucerase therapy are able to resume work and daily activities. ,1379912
753,18,2_abstract_sentence,10,"Alglucerase is well tolerated, with few mild adverse reactions reported. ",1379912
753,18,2_abstract_sentence,11,"Although the pharmacokinetic and pharmacodynamic information for alglucerase is limited, its unequivocal efficacy justifies enzyme replacement therapy with this compound  as first-line treatment for patients with Gaucher's disease, for whom treatment options are limited. ",1379912
753,19,1_title,0,Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.  ,10155294
753,19,2_abstract_sentence,0,Comment in     Pharmacoeconomics. ,10155294
753,19,2_abstract_sentence,1,1995 Jul;8(1):82-3. ,10155294
753,20,1_title,0,Lysosomal integral membrane protein-2: a new player in lysosome-related pathology.  ,24389070
753,20,2_abstract_sentence,0,Lysosomes require the presence of many specialized proteins to facilitate their roles in cellular maintenance. ,24389070
753,20,2_abstract_sentence,1,"One such protein that has proven to be an important player in the lysosomal field is lysosomal integral membrane protein-2  (LIMP-2), encoded by the gene SCARB2. ",24389070
753,20,2_abstract_sentence,2,"LIMP-2 is required for the normal biogenesis and maintenance of lysosomes and endosomes and has been identified as  the specific receptor for glucocerebrosidase, the enzyme deficient in Gaucher disease. ",24389070
753,20,2_abstract_sentence,3,Research into LIMP-2 and the SCARB2 gene indicate that it may be a factor contributing to the clinical heterogeneity seen among patients with Gaucher disease. ,24389070
753,20,2_abstract_sentence,4,"Mutations in SCARB2 have also been identified as the cause of action myoclonus renal failure (AMRF), and in some cases progressive myoclonic epilepsy. ",24389070
753,20,2_abstract_sentence,5,A total of 14 disease-causing SCARB2 mutations have been identified to  date. ,24389070
753,20,2_abstract_sentence,6,"The role of LIMP-2 in human pathology has expanded with its identification  as a component of the intercalated disk in cardiac muscle and as a receptor for specific enteroviruses, two unanticipated findings that reaffirm the myriad roles of lysosomal proteins. ",24389070
753,20,2_abstract_sentence,7,"Studies into the full impact of LIMP-2 deficiency and the  LIMP2/glucocerebrosidase molecular pathway will lead to a better understanding of disease pathogenesis in Gaucher disease and AMRF, and to new insights into lysosomal processing, trafficking and function. ",24389070
753,21,1_title,0,A novel SCARB2 mutation in progressive myoclonus epilepsy indicated by reduced Î²-glucocerebrosidase activity.  ,24485911
753,21,2_abstract_sentence,0,Action myoclonus renal failure (AMRF) syndrome is a rare form of progressive myoclonus epilepsy with renal dysfunction related to mutations in the SCARB2 gene. ,24485911
753,21,2_abstract_sentence,1,"This gene is involved in lysosomal mannose-6-phosphate-independent trafficking of Î²-glucocerebrosidase (GC), an enzyme deficient in Gaucher disease. ",24485911
753,21,2_abstract_sentence,2,"We report a family with myoclonic epilepsy, ataxia and skeletal muscle atrophy but without cognitive impairment or overt renal disease. ",24485911
753,21,2_abstract_sentence,3,A novel SCARB2 mutation  was indicated by a striking discrepancy between lymphocyte and fibroblast GC activity in the proband evaluated for possible Gaucher disease. ,24485911
753,21,2_abstract_sentence,4,Our findings expand the genetic and phenotypic diversity of AMRF and suggest that low GC activity may present an important biochemical clue to the diagnosis of AMRF. ,24485911
753,22,1_title,0,Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.  ,2023606
753,22,2_abstract_sentence,0,Comment in     N Engl J Med. ,2023606
753,22,2_abstract_sentence,1,1991 Dec 19;325(25):1809-11. ,2023606
753,22,2_abstract_sentence,2,    N Engl J Med. ,2023606
753,22,2_abstract_sentence,3,1993 May 27;328(21):1564; author reply 1567-8. ,2023606
753,23,1_title,0,The role of saposin C in Gaucher disease.  ,22652185
753,23,2_abstract_sentence,0,"Saposin C is one of four homologous proteins derived from sequential cleavage of  the saposin precursor protein, prosaposin. ",22652185
753,23,2_abstract_sentence,1,"It is an essential activator for glucocerebrosidase, the enzyme deficient in Gaucher disease. ",22652185
753,23,2_abstract_sentence,2,"Gaucher disease is a rare autosomal recessive lysosomal storage disorder caused by mutations in the GBA gene that exhibits vast phenotypic heterogeneity, despite its designation as  a ""simple"" Mendelian disorder. ",22652185
753,23,2_abstract_sentence,3,The observed phenotypic variability has led to a search for disease modifiers that can alter the Gaucher phenotype. ,22652185
753,23,2_abstract_sentence,4,The PSAP gene  encoding saposin C is a prime candidate modifier for Gaucher disease. ,22652185
753,23,2_abstract_sentence,5,"In humans,  saposin C deficiency due to mutations in PSAP results in a Gaucher-like phenotype, despite normal in vitro glucocerebrosidase activity. ",22652185
753,23,2_abstract_sentence,6,Saposin C deficiency has also been shown to modify phenotype in one mouse model of Gaucher  disease. ,22652185
753,23,2_abstract_sentence,7,"The role of saposin C as an activator required for normal glucocerebrosidase function, and the consequences of saposin C deficiency are described, and are being explored as potential modifying factors in patients with Gaucher disease. ",22652185
1527,0,1_title,0,Diurnal cortisol profile in Williams syndrome in novel and familiar settings.  ,23734615
1527,0,2_abstract_sentence,0,Williams syndrome (WS) is a neurodevelopmental genetic disorder associated with high rates of anxiety and social issues. ,23734615
1527,0,2_abstract_sentence,1,"We examined diurnal cortisol, a biomarker of the stress response, in adults with WS in novel and familiar settings, and compared these profiles to typically developing (TD) adults. ",23734615
1527,0,2_abstract_sentence,2,"WS and TD participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol late in the day in the novel setting when social demands were higher. ",23734615
1527,0,2_abstract_sentence,3,The cortisol awakening response in WS was associated with parent-reported levels of somatic complaints and social difficulties. ,23734615
1527,0,2_abstract_sentence,4,Results suggest that adults with WS have a typical diurnal cortisol profile that may be sensitive to social and activity transitions throughout the day. ,23734615
1527,1,1_title,0,Successful treatment of a morbidly obese and growth-retarded adolescent with Williams-Beuren Syndrome by combining the medication of growth hormone and sibutramine.  ,18204753
1527,1,2_abstract_sentence,0,"A 16-year-old male adolescent diagnosed to have the Williams-Beuren syndrome was  referred to our obesity outpatient clinic, due to his morbid obesity (body mass index 39.2 kilograms per square metre) and gluttony. ",18204753
1527,1,2_abstract_sentence,1,"After several unsuccessful dietary treatments, we started therapy with sibutramine. ",18204753
1527,1,2_abstract_sentence,2,"As growth hormone (GH) deficiency was diagnosed by an additional GH-stimulation test, we commenced with  a GH-treatment. ",18204753
1527,1,2_abstract_sentence,3,This well-tolerated combination therapy led to a remarkable weight loss of 10 kg and a growth-rate acceleration of 3.7 cm/year. ,18204753
1527,1,2_abstract_sentence,4,"Nine months after stopping the treatment with sibutramine, a partial weight gain was noticed. ",18204753
1527,1,2_abstract_sentence,5,This case report justifies further research work on a combination therapy with sibutramine and GH for similar cases. ,18204753
1527,2,1_title,0,Growth hormone treatment in a child with Williams-Beuren syndrome: a case report.  ,10378390
1527,2,2_abstract_sentence,0,Growth retardation is a consistent finding in Williams-Beuren syndrome. ,10378390
1527,2,2_abstract_sentence,1,The cause of short stature in this syndrome is unknown. ,10378390
1527,2,2_abstract_sentence,2,Endocrine studies have failed to reveal abnormalities in the growth hormone-insulin-like growth factor I axis. ,10378390
1527,2,2_abstract_sentence,3,"We  report a boy with confirmed Williams-Beuren syndrome, who was found to have classical growth hormone deficiency and responded well to growth hormone therapy.CONCLUSION: Although growth hormone deficiency is not likely to be a common cause of short stature in Williams-Beuren syndrome, we nevertheless recommend evaluation of the growth hormone-insulin-like growth factor I axis in all cases. ",10378390
1527,3,1_title,0,Growth hormone deficiency in a child with Williams-Beuren syndrome. The response  to growth hormone therapy.  ,15751610
1527,3,2_abstract_sentence,0,Pre- and postnatal growth retardation of unknown pathogenesis is a common clinical feature in patients with Williams-Beuren syndrome (WBS). ,15751610
1527,3,2_abstract_sentence,1,"However, growth hormone deficiency (GHD) has not been considered a major cause of growth retardation. ",15751610
1527,3,2_abstract_sentence,2,There is only one patient in the literature with confirmed GHD who responded well to human growth hormone (hGH) therapy. ,15751610
1527,3,2_abstract_sentence,3,"We report a female infant with confirmed WBS who, through provocative testing, was found to have GHD and who responded satisfactorily to hGH therapy. ",15751610
1527,3,2_abstract_sentence,4,Height SDS was -4.2 at the age of 12 months when hGH was initiated and increased to -0.8 at the age of 4.25 years. ,15751610
1527,3,2_abstract_sentence,5,The pathogenesis of GHD in our patient is unclear. ,15751610
1527,3,2_abstract_sentence,6,"Nevertheless, the elevated levels  of prolactin and the response of hGH to growth hormone releasing hormone (GHRH) administration are indicative of a hypothalamic rather than pituitary defect. ",15751610
1527,3,2_abstract_sentence,7,"In  conclusion, GH deficiency might contribute to the growth failure in a number of patients with WBS and in such cases hGH therapy will most likely improve final height. ",15751610
1527,4,1_title,0,Thyroid function and morphology in patients affected by Williams syndrome.  ,16181239
1527,4,2_abstract_sentence,0,OBJECTIVE: To evaluate the prevalence of abnormalities of thyroid function and morphology in a cohort of patients with Williams syndrome (WS). ,16181239
1527,4,2_abstract_sentence,1,"METHODS: Serum concentrations of free-T3, free-T4, TSH, thyroperoxidase antibodies (TPOA) and thyroglobulin antibodies (TgA), as well as ultrasonographic data, of 20 patients with WS (12 females and eight males), aged 1.7-34.9 years, were evaluated. ",16181239
1527,4,2_abstract_sentence,2,RESULTS: Three cases (15%) of subclinical hypothyroidism were identified. ,16181239
1527,4,2_abstract_sentence,3,Overt hypothyroidism was diagnosed in two cases (10%). ,16181239
1527,4,2_abstract_sentence,4,Thyroid antibodies were negative in all patients. ,16181239
1527,4,2_abstract_sentence,5,Fourteen patients (70%) showed thyroid hypoplasia involving the  entire gland. ,16181239
1527,4,2_abstract_sentence,6,"In these patients, the left thyroid lobe appeared usually, but not  significantly, reduced compared with the right thyroid lobe. ",16181239
1527,4,2_abstract_sentence,7,One patient (5%) showed thyroid hemiagenesis. ,16181239
1527,4,2_abstract_sentence,8,"Only five patients (25%) showed a thyroid with normal volume, and of these five, one patient showed marked thyroid hypoplasia of the left lobe. ",16181239
1527,4,2_abstract_sentence,9,"In all WS patients with diagnosis of subclinical or overt hypothyroidism, thyroid hypoplasia was detected. ",16181239
1527,4,2_abstract_sentence,10,No cases of subclinical or overt hypothyroidism were found in WS with normal thyroid volume. ,16181239
1527,4,2_abstract_sentence,11,CONCLUSIONS: This study confirms the presence of alterations of thyroid function  in WS and also suggests the frequent occurrence of abnormalities of thyroid morphology in these patients. ,16181239
1527,4,2_abstract_sentence,12,"Patients with WS should be monitored for thyroid function and a thyroid ultrasound screening should be considered, especially in those patients with changes in thyroid function. ",16181239
1527,5,1_title,0,"Oxytocin and vasopressin are dysregulated in Williams Syndrome, a genetic disorder affecting social behavior.  ",22719898
1527,5,2_abstract_sentence,0,The molecular and neural mechanisms regulating human social-emotional behaviors are fundamentally important but largely unknown; unraveling these requires a genetic systems neuroscience analysis of human models. ,22719898
1527,5,2_abstract_sentence,1,"Williams Syndrome (WS), a  condition caused by deletion of ~28 genes, is associated with a gregarious personality, strong drive to approach strangers, difficult peer interactions, and attraction to music. ",22719898
1527,5,2_abstract_sentence,2,WS provides a unique opportunity to identify endogenous human gene-behavior mechanisms. ,22719898
1527,5,2_abstract_sentence,3,"Social neuropeptides including oxytocin (OT) and  arginine vasopressin (AVP) regulate reproductive and social behaviors in mammals, and we reasoned that these might mediate the features of WS. ",22719898
1527,5,2_abstract_sentence,4,"Here we established  blood levels of OT and AVP in WS and controls at baseline, and at multiple timepoints following a positive emotional intervention (music), and a negative physical stressor (cold). ",22719898
1527,5,2_abstract_sentence,5,We also related these levels to standardized indices of social behavior. ,22719898
1527,5,2_abstract_sentence,6,"Results revealed significantly higher median levels of OT in WS  versus controls at baseline, with a less marked increase in AVP. ",22719898
1527,5,2_abstract_sentence,7,"Further, in WS,  OT and AVP increased in response to music and to cold, with greater variability and an amplified peak release compared to controls. ",22719898
1527,5,2_abstract_sentence,8,"In WS, baseline OT but not AVP, was correlated positively with approach, but negatively with adaptive social behaviors. ",22719898
1527,5,2_abstract_sentence,9,"These results indicate that WS deleted genes perturb hypothalamic-pituitary release not only of OT but also of AVP, implicating more complex neuropeptide circuitry for WS features and providing evidence for their roles in endogenous regulation of human social behavior. ",22719898
1527,5,2_abstract_sentence,10,"The data suggest a possible biological basis for amygdalar involvement, for increased anxiety, and for the paradox of increased approach but poor social relationships in WS. ",22719898
1527,5,2_abstract_sentence,11,They also offer insight for translating genetic and neuroendocrine knowledge into treatments for disorders of social behavior. ,22719898
1527,6,1_title,0,High prevalence of diabetes and pre-diabetes in adults with Williams syndrome.  ,20425788
1527,6,2_abstract_sentence,0,A standard oral glucose tolerance test (OGTT) was administered to 28 adults with  Williams syndrome (WS). ,20425788
1527,6,2_abstract_sentence,1,"Three quarters of the WS subjects showed abnormal glucose curves, meeting diagnostic criteria for either diabetes or the pre-diabetic state of impaired glucose tolerance. ",20425788
1527,6,2_abstract_sentence,2,"Fasting mean glucose and median insulin levels did not differ significantly in the total WS cohort versus age-gender-BMI matched controls, though the glucose area under the curve was greater in the WS subjects. ",20425788
1527,6,2_abstract_sentence,3,HbA1c levels were not as reliable as the OGTT in diagnosing the presence of diabetes. ,20425788
1527,6,2_abstract_sentence,4,"Given the high prevalence of impaired glucose regulation, adults with WS should be screened for diabetes, and when present should be treated in accordance with standard medical practice. ",20425788
1527,6,2_abstract_sentence,5,Hemizygosity for a gene mapping to the Williams syndrome chromosome region (WSCR) is likely the major factor responsible for the high frequency of diabetes in WS. ,20425788
1527,6,2_abstract_sentence,6,"Syntaxin-1A is a prime candidate gene based on its location in the WSCR, its role in insulin release, and the presence  of abnormal glucose metabolism in mouse models with aberrantly expressed Stx-1a. ",20425788
1527,7,1_title,0,Thyroid anomalies in Williams syndrome: investigation of 95 patients.  ,16596673
1527,7,2_abstract_sentence,0,"Thyroid involvement in Williams syndrome (WS) was recently reported in two small  groups of patients, both showing an increased prevalence of elevation of TSH serum concentration; in one of the two reports, 70% of the patients demonstrated  a hypoplasia of thyroid gland as well. ",16596673
1527,7,2_abstract_sentence,1,"In our institution, we currently follow a  large population of WS patients who periodically undergo a multispecialist clinical evaluation that includes ultrasound evaluation of the thyroid gland, and levels of FT3, FT4, TSH, and anti-thyroid antibodies. ",16596673
1527,7,2_abstract_sentence,2,"Here, we report on the prevalence of thyroid structural and functional anomalies, in a population of 95  WS patients, half of them followed for more than 5 years. ",16596673
1527,7,2_abstract_sentence,3,Our study confirms the  increased incidence of both elevated TSH serum values (37.9% in our sample) and thyroid gland hypoplasia (74.7%). ,16596673
1527,7,2_abstract_sentence,4,"Moreover, we demonstrated that TSH elevation declines with age. ",16596673
1527,7,2_abstract_sentence,5,"For this reason, we suggest that a complete thyroid evaluation be performed in every patient with WS, and that this medical complication should  be periodically searched for in follow-up visits. ",16596673
1527,8,1_title,0,New case of thyroid dysgenesis and clinical signs of hypothyroidism in Williams syndrome.  ,15108207
1527,8,2_abstract_sentence,0,"The authors report a female presenting with congenital heart defects, liver hemangiomas, and facial dysmorphisms admitted to hospital at 3 months of age because of feeding difficulties and poor growth. ",15108207
1527,8,2_abstract_sentence,1,"She had hypotonia and large tongue, ""coarse"" face, and umbilical hernia in presence of complex congenital cardiovascular malformations. ",15108207
1527,8,2_abstract_sentence,2,In spite of normal neonatal screening we performed  serum levels of thyroid hormones. ,15108207
1527,8,2_abstract_sentence,3,"Thyrotropin level was very high (>50 microU/ml; normal value 0.2-4 microU/ml), while serum free T(3) (FT3) and free T(4) (FT4) levels were normal (FT3 3.6 pg/ml, normal value 2.8-5.6 pg/ml; FT4 11.6 pg/ml, normal value 6.6-14 pg/ml); antithyroid autoantibodies were absent. ",15108207
1527,8,2_abstract_sentence,4,"Thyroid scintigraphy with sodium 99m Tc pertechnetate showed a small ectopic thyroid located in sublingual position, so treatment with L-thyroxine 37.5 microg/24 hr was started with rapid improvement of the clinical picture. ",15108207
1527,8,2_abstract_sentence,5,At 17 months of age the patient developed the complete characteristic phenotype of Williams syndrome  (WS); the clinical diagnosis was proven by fluorescent in situ hybridization (FISH) analysis which showed hemizygous deletion of the elastin gene on chromosome 7. ,15108207
1527,8,2_abstract_sentence,6,Recently a case of thyroid hemiagenesis in a child with WS has been reported; our patient underscores the association of hypothyroidism and WS. ,15108207
1527,8,2_abstract_sentence,7,"Moreover, our case shows that clinical manifestations of hypothyroidism may be present and the treatment may be necessary as it is in isolated congenital hypothyroidism. ",15108207
1527,9,1_title,0,Exclusion of calcitonin as a candidate gene for the basic defect in a family with autosomal dominant supravalvular aortic stenosis.  ,3164411
1527,9,2_abstract_sentence,0,Supravalvular aortic stenosis (SVAS) may occur as an isolated autosomal dominant  trait or as a feature of Williams syndrome. ,3164411
1527,9,2_abstract_sentence,1,It has been suggested that a defect in calcitonin function may play a role in Williams syndrome. ,3164411
1527,9,2_abstract_sentence,2,We have excluded calcitonin as a candidate gene for SVAS using a gene specific probe. ,3164411
1527,10,1_title,0,Thyroid morphology and subclinical hypothyroidism in children and adolescents with Williams syndrome.  ,17188616
1527,10,2_abstract_sentence,0,OBJECTIVE: To verify the prevalence of morpho-volumetric and functional thyroid abnormalities in young patients with Williams syndrome (WS). ,17188616
1527,10,2_abstract_sentence,1,"STUDY DESIGN: Ninety-two patients with WS (49 boys and 43 girls, 0.2-17.2 years of age) underwent evaluation of thyroid function by means of thyroid-stimulating  hormone (TSH), fT3, and fT4 measurement. ",17188616
1527,10,2_abstract_sentence,2,Thyroid ultrasonography was performed in 37 patients. ,17188616
1527,10,2_abstract_sentence,3,Thyroid antibodies (thyroid peroxidase and thyroglobulin) were measured in all patients with abnormal thyroid function tests. ,17188616
1527,10,2_abstract_sentence,4,RESULTS: None of our patients had overt hypothyroidism; 29 patients (31.5%) had subclinical hypothyroidism. ,17188616
1527,10,2_abstract_sentence,5,Thyroid antibodies were absent in all patients. ,17188616
1527,10,2_abstract_sentence,6,The prevalence of patients with subclinical hypothyroidism was significantly higher in the younger patients. ,17188616
1527,10,2_abstract_sentence,7,Ultrasonography revealed morphological or volumetric abnormalities of the thyroid gland in 67.5% of patients; these abnormalities were more frequently observed in the older children. ,17188616
1527,10,2_abstract_sentence,8,CONCLUSIONS: Subclinical hypothyroidism is a frequent but stable finding in young children with WS. ,17188616
1527,10,2_abstract_sentence,9,"The great majority of patients with WS >10 years, either with normal or hypoplastic thyroid, have normal thyroid function. ",17188616
1527,10,2_abstract_sentence,10,"Therefore, we suggest yearly monitoring of thyroid function and sonographic studies at least once in patients with WS. ",17188616
1527,10,2_abstract_sentence,11,Treatment should be reserved for the patients with overt hypothyroidism or for those whose thyroid function shows signs of progressive deterioration. ,17188616
1527,11,1_title,0,Characterization of the calcitonin/CGRP gene in Williams syndrome.  ,1867260
1527,11,2_abstract_sentence,0,We have investigated the possibility of mutations in the calcitonin/calcitonin gene related peptide (CGRP) gene in children with Williams syndrome. ,1867260
1527,11,2_abstract_sentence,1,"Involvement  of the calcitonin/CGRP gene in Williams syndrome is postulated on the basis that  Williams syndrome children often have infantile hypercalcemia and deficient expression of calcitonin, a hormone that lowers serum calcium levels. ",1867260
1527,11,2_abstract_sentence,2,"To test the hypothesis that mutations in the calcitonin/CGRP gene might be responsible for the reduced calcitonin levels, we examined the calcitonin/CGRP gene structure in  Williams syndrome children. ",1867260
1527,11,2_abstract_sentence,3,Analysis of white blood cell DNA by Southern blot hybridizations in 5 individuals did not show any detectable large deletions or rearrangements in the calcitonin/CGRP gene locus. ,1867260
1527,11,2_abstract_sentence,4,The possibility of small deletions or point mutations within the exon encoding the mature calcitonin hormone is unlikely based on ribonuclease protection assays with patient DNA amplified by the polymerase chain reaction (PCR) technique. ,1867260
1527,11,2_abstract_sentence,5,These findings suggest that the calcitonin deficiency might be due either to mutations elsewhere in the gene or to defects in the cellular machinery needed for calcitonin synthesis and/or secretion. ,1867260
1527,12,1_title,0,Imparied calcitonin secretion in patients with Williams syndrome.  ,4056970
1527,13,1_title,0,Thyroid hypoplasia as a cause of congenital hypothyroidism in Williams syndrome.  ,18824871
1527,13,2_abstract_sentence,0,"In the Williams-Beuren syndrome (WBS), disorders of the thyroid function and morphology have been reported and programs of thyroid screening and surveillance  are recommended. ",18824871
1527,13,2_abstract_sentence,1,"However, the frequency of biochemical thyroid assessment, particularly in the first year of life, is being debated. ",18824871
1527,13,2_abstract_sentence,2,"In this report we describe an infant with WBS and congenital hypothyroidism, due to an important thyroid hypoplasia. ",18824871
1527,13,2_abstract_sentence,3,"The patient, a 1-month-old female, negative at primary neonatal thyroid screening, was referred to our hospital for dyspnea. ",18824871
1527,13,2_abstract_sentence,4,Thyroid function tests showed a raised TSH (42 mIU/l; normal range 0.5-4 mIU/l) with a low FT(4) concentration (10.21 pmol/l; normal range: 10.29-24.45 pmol/l). ,18824871
1527,13,2_abstract_sentence,5,"Ultrasound examination of the neck showed a significant thyroid hypoplasia, whereas (99m)Tc-pertechnetate thyroid scintigraphy evidenced a thyroid gland in normal position, with reduced shape and overall weak fixation. ",18824871
1527,13,2_abstract_sentence,6,"Therefore, treatment with L-thyroxinewas started. ",18824871
1527,13,2_abstract_sentence,7,Thyroid hypoplasia is a frequent characteristic of WBS and abnormalities of thyroid function are common in patients with this feature. ,18824871
1527,13,2_abstract_sentence,8,"Therefore, the possibility of congenital hypothyroidism should always be taken into consideration too and, even if congenital hypothyroidism neonatal screening is negative, thyroid (morphology and function) evaluation should be regularly assessed when the diagnosis is made and, thereafter, every year in the first years of life. ",18824871
1527,14,1_title,0,Thyroid hemiagenesis and elevated thyrotropin levels in a child with Williams syndrome.  ,10405448
1527,14,2_abstract_sentence,0,"A girl with Williams syndrome (WS) presented with elevated thyrotropin (TSH) levels (7.0 microU/ml), normal free thyroid hormone concentrations, and absent antithyroid autoantibodies. ",10405448
1527,14,2_abstract_sentence,1,Thyroid ultrasonography and scintigraphy showed hemiagenesis of the left lobe and no evidence of ectopic tissue. ,10405448
1527,14,2_abstract_sentence,2,"TSH response to  thyrotropin-releasing hormone (TRH) injection (200 microg/mq, i.v.) was exaggerated and prolonged, suggesting subclinical hypothyroidism. ",10405448
1527,14,2_abstract_sentence,3,"The biological  activity of circulating TSH was slightly below the normal range [TSH bioactivity  (B) to immunoreactivity (I) ratio (TSH B/I) = 0.4, normal: 0.6-2.2]. ",10405448
1527,14,2_abstract_sentence,4,These abnormalities are similar to those seen in patients with hypothalamic hypothyroidism. ,10405448
1527,14,2_abstract_sentence,5,Thyroid function is not a recognized manifestation of WS and is not routinely investigated. ,10405448
1527,14,2_abstract_sentence,6,"However, abnormalities of the hypothalamic-pituitary-thyroid (HPT) axis and thyroid dysgenesis have been found  in other WS cases. ",10405448
1527,14,2_abstract_sentence,7,"Genes mapping at 7q11.23, contiguous to the chromosomal region deleted in most WS patients, may be involved in the development of the thyroid gland, contributing to the complex phenotype of WS. ",10405448
1527,15,1_title,0,Williams syndrome associated with chronic renal failure and various endocrinological abnormalities.  ,8835601
1527,15,2_abstract_sentence,0,A 31-year-old man who had been under regular hemodialysis for 6 months was diagnosed as Williams syndrome (WS) by fluorescence in situ hybridization (FISH)  chromosomal analysis. ,8835601
1527,15,2_abstract_sentence,1,The association of WS and chronic renal failure (CRF) is only rarely encountered. ,8835601
1527,15,2_abstract_sentence,2,Endocrinological examinations revealed hypergonadotropic hypogonadism. ,8835601
1527,15,2_abstract_sentence,3,Prolonged and exaggerated responses of adrenocorticotropin (ACTH) to insulin-induced hypoglycemia and corticotropin releasing hormone (CRH) were also noted. ,8835601
1527,15,2_abstract_sentence,4,"While most of the endocrinological abnormalities observed in this patient could be attributed to altered endocrine circumstances in CRF, some findings stand in contrast. ",8835601
1527,15,2_abstract_sentence,5,"Furthermore, the testicular biopsy specimen showed severe hypospermatogenesis. ",8835601
1527,15,2_abstract_sentence,6,"Endocrine disorders observed in this patient may be at least in part, responsible for various clinical features underlying WS. ",8835601
1888,0,1_title,0,Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea.  ,25537565
1888,0,2_abstract_sentence,0,"We assessed whether intermittent hypoxia, which emulates one of the hallmarks of  obstructive sleep apnoea (OSA), leads to altered faecal microbiome in a murine model. ",25537565
1888,0,2_abstract_sentence,1,In vivo partial pressure of oxygen was measured in colonic faeces during intermittent hypoxia in four anesthetised mice. ,25537565
1888,0,2_abstract_sentence,2,10 mice were subjected to a pattern of chronic intermittent hypoxia (20âs at 5% O2 and 40âs at room air for 6âhÂ·day(-1)) for 6âweeks and 10 mice served as normoxic controls. ,25537565
1888,0,2_abstract_sentence,3,Faecal samples  were obtained and microbiome composition was determined by 16S rRNA pyrosequencing and bioinformatic analysis by Quantitative Insights into Microbial Ecology. ,25537565
1888,0,2_abstract_sentence,4,Intermittent hypoxia exposures translated into hypoxia/re-oxygenation patterns in the faeces proximal to the bowel epithelium (<200âÎ¼m). ,25537565
1888,0,2_abstract_sentence,5,A significant  effect of intermittent hypoxia on global microbial community structure was found. ,25537565
1888,0,2_abstract_sentence,6,"Intermittent hypoxia increased the Î±-diversity (Shannon index, p<0.05) and induced a change in the gut microbiota (ANOSIM analysis of Î²-diversity, p<0.05). ",25537565
1888,0,2_abstract_sentence,7," Specifically, intermittent hypoxia-exposed mice showed a higher abundance of Firmicutes and a smaller abundance of Bacteroidetes and Proteobacteria phyla than controls. ",25537565
1888,0,2_abstract_sentence,8,"Faecal microbiota composition and diversity are altered as a result of  intermittent hypoxia realistically mimicking OSA, suggesting the possibility that physiological interplays between host and gut microbiota could be deregulated in  OSA. ",25537565
1888,1,1_title,0,"Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models.  ",20926643
1888,1,2_abstract_sentence,0,Comment in     Gut. ,20926643
1888,1,2_abstract_sentence,1,2010 Dec;59(12):1589-90. ,20926643
1888,2,1_title,0,Metagenomic analysis of the pygmy loris fecal microbiome reveals unique functional capacity related to metabolism of aromatic compounds.  ,23457582
1888,2,2_abstract_sentence,0,"The animal gastrointestinal tract contains a complex community of microbes, whose composition ultimately reflects the co-evolution of microorganisms with their animal host. ",23457582
1888,2,2_abstract_sentence,1,"An analysis of 78,619 pyrosequencing reads generated from pygmy loris fecal DNA extracts was performed to help better understand the microbial diversity and functional capacity of the pygmy loris gut microbiome. ",23457582
1888,2,2_abstract_sentence,2,The taxonomic analysis of the metagenomic reads indicated that pygmy loris fecal microbiomes were dominated by Bacteroidetes and Proteobacteria phyla. ,23457582
1888,2,2_abstract_sentence,3,The hierarchical clustering of several gastrointestinal metagenomes demonstrated the  similarities of the microbial community structures of pygmy loris and mouse gut systems despite their differences in functional capacity. ,23457582
1888,2,2_abstract_sentence,4,The comparative analysis of function classification revealed that the metagenome of the pygmy loris was characterized by an overrepresentation of those sequences involved in aromatic compound metabolism compared with humans and other animals. ,23457582
1888,2,2_abstract_sentence,5,The key enzymes related to the benzoate degradation pathway were identified based on the  Kyoto Encyclopedia of Genes and Genomes pathway assignment. ,23457582
1888,2,2_abstract_sentence,6,"These results would contribute to the limited body of primate metagenome studies and provide a framework for comparative metagenomic analysis between human and non-human primates, as well as a comparative understanding of the evolution of humans and their microbiome. ",23457582
1888,2,2_abstract_sentence,7,"However, future studies on the metagenome sequencing of pygmy loris and other prosimians regarding the effects of age, genetics, and environment on the composition and activity of the metagenomes are required. ",23457582
1888,3,1_title,0,An efficient RNA extraction method for estimating gut microbial diversity by polymerase chain reaction.  ,19159975
1888,3,2_abstract_sentence,0,An extraction method was developed to recover high-quality RNA from rumen digesta and mouse feces for phylogenetic analysis of metabolically active members of the  gut microbial community. ,19159975
1888,3,2_abstract_sentence,1,Four extraction methods were tested on different amounts of the same samples and compared for efficiency of recovery and purity of RNA. ,19159975
1888,3,2_abstract_sentence,2,Trizol extraction after bead beating produced a higher quantity and quality of RNA than a similar method using phenol/chloroform. ,19159975
1888,3,2_abstract_sentence,3,Dissociation solution produced a 1.5- to 2-fold increase in RNA recovery compared with phosphate-buffered saline during the dissociation of microorganisms from rumen digesta or fecal particles. ,19159975
1888,3,2_abstract_sentence,4," The identity of metabolically active bacteria in the samples was analyzed by sequencing 87 amplicons produced using bacteria-specific 16S rDNA primers, with cDNA synthesized from the extracted RNA as the template. ",19159975
1888,3,2_abstract_sentence,5,"Amplicons representing the major phyla encountered in the rumen (Firmicutes, 43.7%; Proteobacteria, 28.7%; Bacteroidetes, 25.3%; Spirochea, 1.1%, and Synergistes, 1.1%) were recovered, showing that development of the RNA extraction method enables RNA-based analysis of metabolically active bacterial groups from the rumen and other environments. ",19159975
1888,3,2_abstract_sentence,6,"Interestingly, in rumen samples, about 30% of the sequenced random 16S rRNA amplicons were related to the Proteobacteria, providing the first evidence that this group may have greater importance in rumen metabolism than previously attributed by DNA-based analysis. ",19159975
1110,0,1_title,0,Techniques for reduction and posterior fixation through the anterior approach.  ,8769442
1110,0,2_abstract_sentence,0,"Pelvic fractures, especially those of a Malgaigne type, frequently occur in patients who are polytraumatized. ",8769442
1110,0,2_abstract_sentence,1,"Sacroiliac disruption reflects a massive, disruptive energy force with concurrent soft tissue injury. ",8769442
1110,0,2_abstract_sentence,2,Fixation through an anterior approach facilitates the accurate and stable fixation and avoids many soft tissue wound problems associated with open anterior approaches. ,8769442
1110,0,2_abstract_sentence,3,The absolute indication for the approach is a posterior disruption of the sacroiliac joint with or without an iliac wing fracture that is unreducible by closed reduction techniques. ,8769442
1110,1,1_title,0,Conservative treatment of Malgaigne fracture in young female--case report.  ,24502106
1110,1,2_abstract_sentence,0,"INTRODUCTION: Pelvic ring injuries usually result from high-energy trauma, and cranial and abdominal multiple injuries are frequently present. ",24502106
1110,1,2_abstract_sentence,1,"Malgaigne fracture is referred to pelvic ring disruption at two sites, and is often treated surgically for its instability. ",24502106
1110,1,2_abstract_sentence,2,We present a case of nonoperative treatment of Malgaigne pelvic fracture. ,24502106
1110,1,2_abstract_sentence,3,CASE OUTLINE: A 17-year-old girl sustained a Malgaigne fracture falling off a horse. ,24502106
1110,1,2_abstract_sentence,4,"After ruling out urgent multiple trauma in local hospital, she was then transferred to Pediatric Orthopedic and Trauma Service at the Institute of Orthopedic Surgery ""Banjica"" Belgrade, with provisional cutaneous traction of 2 kg applied to her right leg. ",24502106
1110,1,2_abstract_sentence,5,"After the status evaluation, the supracondylar femoral traction was applied for three months, combined with pelvic cradle for first 73 days. ",24502106
1110,1,2_abstract_sentence,6,"Weight of traction was gradually adjusted according to x-ray check-up, ranging from 1-16 kg (1/4 of body weight). ",24502106
1110,1,2_abstract_sentence,7,"Antibiotic prophylaxis was administered for 10 days, and thromboprophylaxis for two months. ",24502106
1110,1,2_abstract_sentence,8,"After the removal of traction, physical therapy was applied and the patient achieved full weight bearing four months after the injury. ",24502106
1110,1,2_abstract_sentence,9,"Treatment outcome was a symmetric and stable pelvic ring, equal leg length, full range of motion in both hip joints and normal walking. ",24502106
1110,1,2_abstract_sentence,10,"CONCLUSION: Traction therapy, combined with gravitational suspension in pelvic cradle, resulted in excellent clinical result. ",24502106
1110,1,2_abstract_sentence,11,"Although significantly longer and  more loaded than usual, normal weight bearing and walking were promptly achieved  using intensive physical therapy. ",24502106
1110,2,1_title,0,External fixation of unstable Malgaigne fractures: the comparative mechanical performance of a new configuration.  ,1465304
1110,2,2_abstract_sentence,0,An external fixator has been designed that is rigid enough to eliminate the need  for skeletal traction in patients with unstable pelvic-ring fractures. ,1465304
1110,2,2_abstract_sentence,1,This Wichita frame is similar to the Pittsburgh frame but is stiffened by the use of locked crossbars connecting the side triangles. ,1465304
1110,2,2_abstract_sentence,2,The frame was tested in cadaveric specimens by techniques previously reported. ,1465304
1110,2,2_abstract_sentence,3,"In addition, finite-element modeling of the various frame designs was performed to ensure that the frame configuration was optimal and to supplement in vitro test results. ",1465304
1110,2,2_abstract_sentence,4,Multiple variables that can  influence frame failure loads were examined. ,1465304
1110,3,1_title,0,Pathologic Malgaigne fracture following pelvic irradiation. A case report.  ,3111770
1110,4,1_title,0,Chiropractic care of a patient with low back pain associated with subluxations and a Malgaigne-type pelvic fracture.  ,15195043
1110,4,2_abstract_sentence,0,OBJECTIVE: To describe the chiropractic care of a patient with a pelvic ring fracture and concomitant subluxations of multiple segments of the spinal column. ,15195043
1110,4,2_abstract_sentence,1,"CLINICAL FEATURES: A 23-year-old male, after falling down a flight of stairs, was initially hospitalized for fractures of the pelvis. ",15195043
1110,4,2_abstract_sentence,2,"Five weeks posthospitalization, the patient initiated chiropractic care with complaints of severe low back pain with lower extremity involvement. ",15195043
1110,4,2_abstract_sentence,3,He also complained of neck pain and occipital headache. ,15195043
1110,4,2_abstract_sentence,4,The patient had several positive low back orthopedic tests with bilaterally absent Achilles deep tendon reflexes. ,15195043
1110,4,2_abstract_sentence,5,"The anteroposterior  radiographic view revealed ununited fractures at the left superior and inferior pubic ramus, noted as a type I Malgaigne fracture. ",15195043
1110,4,2_abstract_sentence,6,"Subluxations were detected at  the left innominate (ie, fracture-subluxation) and at the patient's lumbar, thoracic, and cervical spine. ",15195043
1110,4,2_abstract_sentence,7,"INTERVENTION AND OUTCOME: The patient was cared for with contact-specific, high-velocity, low-amplitude adjustments to sites of vertebral and sacroiliac subluxations. ",15195043
1110,4,2_abstract_sentence,8,"The patient's response to care was positive, receiving great pain relief. ",15195043
1110,4,2_abstract_sentence,9,"Less than 3 months after initiating care, the patient returned to work on regular duty. ",15195043
1110,4,2_abstract_sentence,10,CONCLUSION: There are indications that patients suffering from the injuries described above may derive benefits from chiropractic care. ,15195043
1110,4,2_abstract_sentence,11,The practitioner must pay careful attention to issues of biomechanical and vascular stability and adjustment modifications in these types of patients. ,15195043
1110,5,1_title,0,Pelvic fracture and associated urologic injuries.  ,11775195
1110,5,2_abstract_sentence,0,"Successful management of patients with major pelvic injuries requires a team approach including orthopedic, urologic, and trauma surgeons. ",11775195
1110,5,2_abstract_sentence,1,Each unstable pelvic disruption must be treated aggressively to minimize complications and maximize long-term functional outcome. ,11775195
1110,5,2_abstract_sentence,2,"Commonly associated urologic injuries include injuries of the urethra, corpora cavernosa (penis), bladder, and bladder  neck. ",11775195
1110,5,2_abstract_sentence,3,Bladder injuries are usually extraperitoneal and result from shearing forces or direct laceration by a bone spicule. ,11775195
1110,5,2_abstract_sentence,4,"Posterior urethral injuries occur  more commonly with vertically applied forces, which typically create Malgaigne-type fractures. ",11775195
1110,5,2_abstract_sentence,5,"Common complications of urethral disruption are urethral stricture, incontinence, and impotence. ",11775195
1110,5,2_abstract_sentence,6,"Acute urethral injury management is controversial, although it appears that early primary realignment has promise  for minimizing the complications. ",11775195
1110,5,2_abstract_sentence,7,"Impotence after pelvic fracture is predominantly vascular in origin, not neurologic as once thought. ",11775195
1110,6,1_title,0,Open reduction and internal fixation of an acetabular fracture during pregnancy.  ,1403261
1110,6,2_abstract_sentence,0,Fractures of the pelvis and acetabulum are common injuries in a mechanized society and frequently occur in the younger age groups. ,1403261
1110,6,2_abstract_sentence,1,"Commonly associated injuries such as hemorrhage, urethral tears, gastrointestinal injuries, and major vessel damage are well reported and well known to orthopaedic surgeons. ",1403261
1110,6,2_abstract_sentence,2,Another less frequently reported complication of pelvic fractures is the potential association with pregnancy and subsequent childbirth. ,1403261
1110,6,2_abstract_sentence,3,"This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic  fracture who subsequently died during childbirth. ",1403261
1110,6,2_abstract_sentence,4,A review of the literature reveals numerous articles addressing potential problems with parturition subsequent to a pelvic fracture and several articles dealing with pelvic fractures occurring during pregnancy. ,1403261
1110,6,2_abstract_sentence,5,"The current literature on pelvic fractures  during pregnancy, however, recommends only nonoperative treatment and, to our knowledge, there have been no reports of operative fixation during pregnancy. ",1403261
1110,6,2_abstract_sentence,6,"The purpose of this article is to report a case of an acetabular fracture in a pregnant woman treated with open reduction and internal fixation, who went on to  carry a full-term baby and have a normal delivery. ",1403261
1110,7,1_title,0,Fractures of the sacrum and disk herniation: rare lesions in the pediatric surgical patient?  ,1498111
1110,7,2_abstract_sentence,0,Fractures of the sacrum and lesions of the intervertebral disks are seldom reported in childhood and adolescence. ,1498111
1110,7,2_abstract_sentence,1,"In our report, illustrated by three representative cases that we treated during the past six months, we show that sacrum fractures, not an easy diagnosis, may be more frequent than currently assumed, and that in quite a number of children and adolescents an anterior pelvic fracture may in fact be an unrecognized Malgaigne type pelvic fracture with a posterior fracture plane cutting through the sacrum. ",1498111
1110,7,2_abstract_sentence,2,They may be accompanied by herniations and/or lacerations of intervertebral disks. ,1498111
1110,8,1_title,0,CT detection of serious internal and skeletal injuries in patients with pelvic fractures.  ,10894080
1110,8,2_abstract_sentence,0,"RATIONALE AND OBJECTIVES: The purpose of this study was to determine the percentage of patients with known pelvic fractures who have additional findings of intraabdominal injury, as diagnosed at abdominal computed tomography (CT), and to determine if patients with specific types or patterns of fractures are more likely to have additional injuries. ",10894080
1110,8,2_abstract_sentence,1,"MATERIALS AND METHODS: The authors reviewed the medical records of 200 consecutive patients (125 women, 75 men; age range, 4-86 years) who had been admitted to a level 1 trauma center with osseous pelvic injury secondary to blunt trauma and who had undergone abdominal CT examinations. ",10894080
1110,8,2_abstract_sentence,2,"Abdominal CT findings in  these patients were classified as negative, positive, or minimal and correlated with mechanism of pelvic fracture. ",10894080
1110,8,2_abstract_sentence,3,"RESULTS: Sixty-five (32%) of the 200 patients had negative CT findings, 43 (22%)  had findings attributable to the trauma but required no follow-up, and 92 (46%) had positive findings that required nonsurgical management or exploratory laparotomy. ",10894080
1110,8,2_abstract_sentence,4,Additional pelvic fractures were identified in 63 (32%) patients. ,10894080
1110,8,2_abstract_sentence,5,"The highest prevalence of additional injuries was in patients with Malgaigne fractures (four of 15, 27%) or bilateral pubic rami fractures (six of 18, 33%). ",10894080
1110,8,2_abstract_sentence,6,CONCLUSION: CT examinations revealed that 135 (68%) of 200 patients with pelvic fractures secondary to blunt trauma had concomitant internal or skeletal injuries and that 92 (46%) patients had injuries severe enough to require nonsurgical management or exploratory laparotomy. ,10894080
1110,8,2_abstract_sentence,7,"Patients with bilateral pubic rami fractures or Malgaigne fractures were particularly prone to additional injuries;  therefore, abdominal CT examinations are recommended in these patients. ",10894080
1110,9,1_title,0,Symptomatic enterothorax in right-sided dorsal rupture of the diaphragm.  ,7876010
1110,9,2_abstract_sentence,0,Traumatic avulsion of the right diaphragm from the lumbocostal arch is a very rare lesion. ,7876010
1110,9,2_abstract_sentence,1,"The authours report the case of a 27-year-old man who had suffered a severe polytrauma with blunt thoracic injury, fracture of the lumbar spine, Malgaigne-type fracture of the pelvis and fracture of the femoral shaft on the right side, 10 years before. ",7876010
1110,9,2_abstract_sentence,2,At the time of injury the lesion of the diaphragm went unnoticed. ,7876010
1110,9,2_abstract_sentence,3,The diagnosis was made 10 years later when the patient was referred for chronic right thoracic pain combined with postprandial abdominal distension and crampy pain in the abdomen. ,7876010
1110,9,2_abstract_sentence,4,The chest radiogram and CT-scan showed displacement of the right kidney and most of the right colon into the thorax due  to avulsion of the diaphragm from its dorsal insertion on the lumbocostal arch. ,7876010
1110,9,2_abstract_sentence,5,Surgical repair was necessary to obtain relief from pain and to prevent intestinal obstruction. ,7876010
1110,9,2_abstract_sentence,6,"Reduction of the hernia, reinsertion of the diaphragm to  the lumbocostal arch and reinforcement of the repair with a prolene mesh prosthesis was performed through a right thoracophrenolumbotomy incision. ",7876010
1110,10,1_title,0,Malgaigne pelvic ring injury in childhood.  ,1475128
1110,10,2_abstract_sentence,0,Pelvic girdle injuries leading to anterior and posterior disruption are rarely seen in children. ,1475128
1110,10,2_abstract_sentence,1,External fixation is useful to reduce and stabilize the pelvis  in order to control massive blood loss due to severe venous bleeding. ,1475128
1110,10,2_abstract_sentence,2,The anterior tension band element of the external fixator can successfully maintain reduction of the pelvic girdle. ,1475128
1110,10,2_abstract_sentence,3,Dislocation or fracture dislocation of the sacroiliacal joint cannot be reduced with simple traction techniques. ,1475128
1110,10,2_abstract_sentence,4,Leg length  discrepancy is to be expected when the hemipelvis is displaced. ,1475128
1110,10,2_abstract_sentence,5,Seven cases of this rare injury in children are presented together with the late outcome. ,1475128
1110,10,2_abstract_sentence,6,Treatment modalities are discussed. ,1475128
1110,11,1_title,0,Avulsion Fracture and Myositis Ossificans in a Professional Teenage Dancer: A Case Report.  ,26046617
1110,11,2_abstract_sentence,0,"Fractures of the transverse processes in the lumbar vertebrae occur as the result of major forces such as direct blunt trauma, violent lateral flexion-extension forces, avulsion of the psoas muscle, or Malgaigne fractures of the pelvis. ",26046617
1110,11,2_abstract_sentence,1,"Dancers make repeated and forceful hyperextension and flexions of the spine, which may cause fractures of the transverse processes of the lumbar vertebrae. ",26046617
1110,11,2_abstract_sentence,2,Repeated trauma of muscles in dancers may cause avulsion fractures and myositis ossificans. ,26046617
1110,11,2_abstract_sentence,3,"Herein, we report MRI and CT findings of an avulsion from the right transverse process of the L2 and L3 vertebrae in a 16-year-old professional teenage dancer, who responded to conservative treatment. ",26046617
1110,12,1_title,0,Stabilization of sacroiliac joint disruption with threaded compression rods.  ,2766606
1110,12,2_abstract_sentence,0,Eleven cases of sacroiliac dislocation and/or fracture (Malgaigne pattern) were successfully reduced and stabilized using two threaded compression rods. ,2766606
1110,12,2_abstract_sentence,1,"The mean follow-up period was 26.1 months (range, seven to 45 months). ",2766606
1110,12,2_abstract_sentence,2,None of the implants failed and there was no subsequent displacement. ,2766606
1110,12,2_abstract_sentence,3,"Two patients had mild residual lower back pain, and one was treated with implant removal without subsequent relief of pain. ",2766606
1110,12,2_abstract_sentence,4,"One patient, in whom the operation was done 110 days after dislocation, had extension of an incomplete preoperative peroneal nerve palsy. ",2766606
1110,12,2_abstract_sentence,5,"After anterior pelvic ring stabilization has been performed, two threaded  3/16-inch diameter rods are driven from the normal posterior iliac wing superficial to the sacrum and through the reduced opposite iliac wing. ",2766606
1110,12,2_abstract_sentence,6,Compression is obtained with washers and nuts. ,2766606
1110,12,2_abstract_sentence,7,"This procedure can be performed safely and effectively, providing stable fixation and allowing early mobilization to help lessen or prevent the complications associated with prolonged bed rest. ",2766606
1110,13,1_title,0,Abdominal trauma associated with pelvic fracture.  ,7431445
1110,14,1_title,0,Comparative study of the Orthofix and Pittsburgh frames for external fixation of  unstable pelvic ring fractures.  ,3230497
1110,14,2_abstract_sentence,0,We compared the mechanical performance of the Orthofix pelvic external fixator with that of the Pittsburgh triangular frame (PTF) on eight fresh-frozen cadaver  pelves with experimentally created Malgaigne (double-vertical) fracture/dislocations. ,3230497
1110,14,2_abstract_sentence,1,"The pelves were quasi-statically loaded in longitudinal compression and loss of reduction (i.e., failure) was defined as 1.5 cm of diastasis at either of the fracture/dislocation sites. ",3230497
1110,14,2_abstract_sentence,2,"The Orthofix frame-pelvis  complex (four 6-mm half-pins) was comparable to the PTF-pelvis complex (eight 5-mm half-pins) in terms of load to failure and overall stiffness, but was 4-7 times stiffer at lower load levels. ",3230497
1110,14,2_abstract_sentence,3,"Both frame-and-pin complexes deformed moderately at the pin-bone interface, but, while the PTF also showed moderate displacement between frame components, the Orthofix had almost no frame intercomponent motion. ",3230497
1110,15,1_title,0,Malgaigne's fracture: the Larrey variant--a case report.  ,1942182
1110,15,2_abstract_sentence,0,A rare Malgaigne fracture with caudal displacement of the acetabular section is presented. ,1942182
1110,15,2_abstract_sentence,1,This variant has not received significant mention in existing literature. ,1942182
1110,15,2_abstract_sentence,2,It is important because it changes the approach to initial stabilization. ,1942182
1110,15,2_abstract_sentence,3,Treatment is best accomplished with ORIF and placement of a sacral bar. ,1942182
1110,15,2_abstract_sentence,4,Significant complications would occur if this variant were mistaken and treated with traction. ,1942182
1110,16,1_title,0,Surgical treatment of a Malgaigne fracture.  ,25135027
1110,16,2_abstract_sentence,0,Sacral fractures are generally accompanied by pelvic ring fractures. ,25135027
1110,16,2_abstract_sentence,1,They rarely  develop in an isolated form. ,25135027
1110,16,2_abstract_sentence,2,Sacroiliac dislocation without sacral fracture is extremely rare. ,25135027
1110,16,2_abstract_sentence,3,"We report a case with a sacroiliac dislocation without sacral fracture, which was treated surgically. ",25135027
1110,16,2_abstract_sentence,4,Lumbopelvic stabilization was applied using iliac wing plates. ,25135027
1110,16,2_abstract_sentence,5,"The case was evaluated according to his clinical condition and visual analogue score (VAS), American Spinal Injury Association (ASIA) and Oswestry scales. ",25135027
1110,16,2_abstract_sentence,6,"Considering the role of the sacrum, which transmits the load of the entire spine to the pelvis, meticulous care must be given to ensure the mechanic stability of the spine when evaluating patients with sacral and pelvic fractures. ",25135027
1110,16,2_abstract_sentence,7,Very serious spinopelvic instability is present in sacroiliac dislocations even in the absence of sacral fractures. ,25135027
1110,16,2_abstract_sentence,8,Caudal migration of the sacrum together with the cranial migration of the iliac wings can cause serious pelvic imbalance and difficulties in walking and maintaining a standing position. ,25135027
1110,16,2_abstract_sentence,9,"Aggressive stabilization and fusion are required, and these must be performed in the early period. ",25135027
1110,17,1_title,0,Posterior stabilization of pelvic fractures by use of threaded compression rods.  Case reports and mechanical testing.  ,3967429
1110,18,1_title,0,Unstable pelvic fracture with concomitant displacement of the uterus--case report.  ,7555349
1110,18,2_abstract_sentence,0,The paper deals with the displacement of the uterus observed during management of Malgaigne type pelvic fracture in a 33 years old female. ,7555349
1110,18,2_abstract_sentence,1,An intrauterine device seen on the radiographs revealed displacement of the uterus towards contralateral side of the pelvis. ,7555349
1110,18,2_abstract_sentence,2,The reduction of the fracture stabilized with Molski metal clamp reconstituted normal anatomy. ,7555349
1110,19,1_title,0,Two compression rods to treat unstable lesions of the pelvic ring.  ,9269112
1110,19,2_abstract_sentence,0,"The authors report 7 cases involving the surgical treatment of unstable pelvic ring fractures (Malgaigne type) using two compression bars, as described by Tile. ",9269112
1110,19,2_abstract_sentence,1,"The method was used only in cases where x-ray examination and CT scan revealed that the posterior branch of the fracture was located at the very medial aspect of the sacrum (fracture through the sacral foramina or even medial to the sacral  foramina), and therefore could not be stabilized by using other devices. ",9269112
1110,20,1_title,0,The pathological anatomy of Malgaigne fracture-dislocations of the pelvis.  ,7204439
2189,0,1_title,0,Caralluma Fimbriata Supplementation Improves the Appetite Behavior of Children and Adolescents with Prader-Willi Syndrome.  ,26713299
2189,0,2_abstract_sentence,0,BACKGROUND: Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13. ,26713299
2189,0,2_abstract_sentence,1,"PWS develops hyperphagia, which when left unmanaged, leads to an excessive ingestion of food. ",26713299
2189,0,2_abstract_sentence,2,To date there is inadequate pharmacological treatment or supplementation for modification of the PWS hyperphagia and/or the associated behaviors. ,26713299
2189,0,2_abstract_sentence,3,"Therefore, the best practice is  familial supervision and restriction of diet and environment. ",26713299
2189,0,2_abstract_sentence,4,AIM: We aimed to determine if the natural supplement of Caralluma fimbriata extract (CFE) could attenuate hyperphagia or the associated appetite behaviors in children and adolescents with PWS over the 4-week pilot trial period. ,26713299
2189,0,2_abstract_sentence,5,"MATERIALS AND METHODS: We conducted a placebo-controlled, double-blind, randomized crossover trial over a 10-week period to investigate the effects of CFE on hunger control, in a cohort of children and adolescents with confirmed PWS (n =15, mean age 9.27 Â± 3.16 years, body weight 43.98 Â± 23.99 kg). ",26713299
2189,0,2_abstract_sentence,6,"Participants from Australia and New Zealand ingested CFE or a placebo of maltodextrin/cabbage  leaf over a 4-week period, with a 2-week washout before the crossover to the other treatment. ",26713299
2189,0,2_abstract_sentence,7,"Weekly comparisons in appetite behavior, severity, and drive were recorded by parents, as scaled time-point measures on a hyperphagia questionnaire validated for PWS. ",26713299
2189,0,2_abstract_sentence,8,"RESULTS: CFE administration was found to induce a significant accumulative easing of hyperphagia (P = 0.05), with decreases evident in one-third of the participants. ",26713299
2189,0,2_abstract_sentence,9,"Furthermore due to CFE supplementation, a significant decrease (P â¤ 0.05) was recorded in the category of behavior and a decrease in hyperphagia (n = 8, P = 0.009) was observed at the highest dose 1,000 mg/day (recommended adult dose). ",26713299
2189,0,2_abstract_sentence,10,There were no reported adverse effects at any dose. ,26713299
2189,0,2_abstract_sentence,11,CONCLUSION: We demonstrate that an extract of the Indian cactus succulent Caralluma fimbriata eases hyperphagic appetite behavior within a cohort of children and adolescents (n = 15) with PWS without notable adverse effects. ,26713299
2189,0,2_abstract_sentence,12,The outcomes of this study will have a potential positive impact on PWS management. ,26713299
2189,1,1_title,0,Localization of the gene encoding the GABAA receptor beta 3 subunit to the Angelman/Prader-Willi region of human chromosome 15.  ,1714232
2189,1,2_abstract_sentence,0,"Deletions of the proximal long arm of chromosome 15 (bands 15q11q13) are found in the majority of patients with two distinct genetic disorders, Angelman syndrome (AS) and Prader-Willi syndrome (PWS). ",1714232
2189,1,2_abstract_sentence,1,"The deleted regions in the two syndromes, defined cytogenetically and by using cloned DNA probes, are similar. ",1714232
2189,1,2_abstract_sentence,2,"However, deletions in AS occur on the maternally inherited chromosome 15, and deletions in PWS occur on the paternally derived chromosome 15. ",1714232
2189,1,2_abstract_sentence,3,This observation has led to the suggestion that one or more genes in this region show differential expression dependent on parental origin (genetic imprinting). ,1714232
2189,1,2_abstract_sentence,4,No genes of known function have previously been mapped to this region. ,1714232
2189,1,2_abstract_sentence,5,We show here that the gene encoding the GABAA (gamma-aminobutyric acid) receptor beta 3 subunit maps to the AS/PWS region. ,1714232
2189,1,2_abstract_sentence,6,Deletion of this gene (GABRB3) was found in AS and PWS patients with interstitial cytogenetic deletions. ,1714232
2189,1,2_abstract_sentence,7,Evidence of beta 3 gene deletion was also found in an AS patient with an unbalanced 13;15 translocation but not in a PWS patient with an unbalanced 9;15 translocation. ,1714232
2189,1,2_abstract_sentence,8,The localization of this receptor  gene to the AS/PWS region suggests a possible role of the inhibitory neurotransmitter GABA in the pathogenesis of one or both of these syndromes. ,1714232
2189,2,1_title,0,Angelman and Prader-Willi syndromes share a common chromosome 15 deletion but differ in parental origin of the deletion.  ,2564739
2189,2,2_abstract_sentence,0,Many Prader-Willi syndrome (PWS) and Angelman syndrome (AS) patients have a cytogenetic deletion of 15q11q13. ,2564739
2189,2,2_abstract_sentence,1,"While AS and PWS share a similar cytogenetic anomaly, they have very different clinical phenotypes. ",2564739
2189,2,2_abstract_sentence,2,DNAs from 4 AS patients were examined using 5 chromosome 15q11q13-specific cloned DNA segments. ,2564739
2189,2,2_abstract_sentence,3,"With the  present level of resolution, the molecular deletions between AS and those previously reported for PWS did not appear to differ. ",2564739
2189,2,2_abstract_sentence,4,"However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, maternal inheritance of the deleted chromosome 15 was demonstrated in the AS patients by restriction fragment length polymorphisms (RFLPs). ",2564739
2189,3,1_title,0,Chromosome 15 uniparental disomy is not frequent in Angelman syndrome.  ,1985457
2189,3,2_abstract_sentence,0,Genetic imprinting has been implicated in the etiology of two clinically distinct but cytogenetically indistinguishable disorders--Angelman syndrome (AS) and Prader-Willi syndrome (PWS). ,1985457
2189,3,2_abstract_sentence,1,This hypothesis is derived from two lines of evidence. ,1985457
2189,3,2_abstract_sentence,2,"First, while the molecular extents of de novo cytogenetic deletions of  chromosome 15q11q13 in AS and PWS patients are the same, the deletions originate  from different parental chromosomes. ",1985457
2189,3,2_abstract_sentence,3,"In AS, the deletion occurs in the maternally inherited chromosome 15, while in PWS the deletion is found in the paternally inherited chromosome 15. ",1985457
2189,3,2_abstract_sentence,4,The second line of evidence comes from the deletion of an abnormal parental contribution of 15q11q13 in PWS patients without a cytogenetic and molecular deletion. ,1985457
2189,3,2_abstract_sentence,5,These patients have two maternal copies and no paternal copy of 15q11q13 (maternal uniparental disomy) instead of one copy from each parent. ,1985457
2189,3,2_abstract_sentence,6,"By qualitative hybridization with chromosome 15q11q13 specific  DNA markers, we have now examined DNA samples from 10 AS patients (at least seven of which are familial cases) with no cytogenetic or molecular deletion of chromosome 15q11q13. ",1985457
2189,3,2_abstract_sentence,7,"Inheritance of one maternal copy and one paternal copy of 15q11q13 was observed in each family, suggesting that paternal uniparental disomy of 15q11q13 is not responsible for expression of the AS phenotype in these patients. ",1985457
2189,4,1_title,0,Maternal origin of 15q11-13 deletions in Angelman syndrome suggests a role for genomic imprinting.  ,2309781
2189,4,2_abstract_sentence,0,Comment in     Am J Med Genet. ,2309781
2189,4,2_abstract_sentence,1,1991 Jun 15;39(4):495-7. ,2309781
2025,0,1_title,0,Experimental approaches for investigation of aminoacyl tRNA synthetase phosphorylation.  ,27729295
2025,0,2_abstract_sentence,0,"Phosphorylation of many aminoacyl tRNA synthetases (AARSs) has been recognized for decades, but the contribution of post-translational modification to their primary role in tRNA charging and decryption of genetic code remains unclear. ",27729295
2025,0,2_abstract_sentence,1,"In  contrast, phosphorylation is essential for performance of diverse noncanonical functions of AARSs unrelated to protein synthesis. ",27729295
2025,0,2_abstract_sentence,2,"Phosphorylation of glutamyl-prolyl tRNA synthetase (EPRS) has been investigated extensively in our laboratory for more than a decade, and has served as an archetype for studies of  other AARSs. ",27729295
2025,0,2_abstract_sentence,3,EPRS is a constituent of the IFN-Î³-activated inhibitor of translation (GAIT) complex that directs transcript-selective translational control in myeloid cells. ,27729295
2025,0,2_abstract_sentence,4,"Stimulus-dependent phosphorylation of EPRS is essential for its release from the parental multi-aminoacyl tRNA synthetase complex (MSC),  for binding to other GAIT complex proteins, and for regulating the binding to target mRNAs. ",27729295
2025,0,2_abstract_sentence,5,"Importantly, phosphorylation is the common driving force for the context- and stimulus-dependent release, and non-canonical activity, of other AARSs residing in the MSC, for example, lysyl tRNA synthetase (KARS). ",27729295
2025,0,2_abstract_sentence,6,"Here, we describe the concepts and experimental methodologies we have used to investigate  the influence of phosphorylation on the structure and function of EPRS. ",27729295
2025,0,2_abstract_sentence,7,We suggest that application of these approaches will help to identify new functional phosphorylation event(s) in other AARSs and elucidate their possible roles in noncanonical activities. ,27729295
2025,1,1_title,0,Phosphorylation of glutamyl-prolyl tRNA synthetase by cyclin-dependent kinase 5 dictates transcript-selective translational control.  ,21220307
2025,1,2_abstract_sentence,0,"Cyclin-dependent kinase 5 (Cdk5) is an atypical but essential member of the Cdk kinase family, and its dysregulation or deletion has been implicated in inflammation-related disorders by an undefined mechanism. ",21220307
2025,1,2_abstract_sentence,1,"Here we show that Cdk5  is an indispensable activator of the GAIT (IFN-Î³-activated inhibitor of translation) pathway, which suppresses expression of a posttranscriptional regulon of proinflammatory genes in myeloid cells. ",21220307
2025,1,2_abstract_sentence,2,"Through induction of its regulatory protein, Cdk5R1 (p35), IFN-Î³ activates Cdk5 to phosphorylate Ser(886)  in the linker domain of glutamyl-prolyl tRNA synthetase (EPRS), the initial event in assembly of the GAIT complex. ",21220307
2025,1,2_abstract_sentence,3,"Cdk5/p35 also induces, albeit indirectly via a distinct kinase, phosphorylation of Ser(999), the second essential event in GAIT  pathway activation. ",21220307
2025,1,2_abstract_sentence,4,Diphosphorylated EPRS is released from its residence in the tRNA multisynthetase complex for immediate binding to NS1-associated protein and  subsequent binding to ribosomal protein L13a and GAPDH. ,21220307
2025,1,2_abstract_sentence,5,The mature heterotetrameric GAIT complex binds the 3' UTR GAIT element of VEGF-A and other target mRNAs and suppresses their translation in myeloid cells. ,21220307
2025,1,2_abstract_sentence,6,"Inhibition of Cdk5/p35 inhibits both EPRS phosphorylation events, prevents EPRS release from the tRNA multisynthetase complex, and blocks translational suppression of GAIT element-bearing mRNAs, resulting in increased expression of inflammatory proteins. ",21220307
2025,1,2_abstract_sentence,7,"Our study reveals a unique role of Cdk5/p35 in activation of the major  noncanonical function of EPRS, namely translational control of macrophage inflammatory gene expression. ",21220307
2025,2,1_title,0,Two-site phosphorylation of EPRS coordinates multimodal regulation of noncanonical translational control activity.  ,19647514
2025,2,2_abstract_sentence,0,Glutamyl-prolyl tRNA synthetase (EPRS) is a component of the heterotetrameric gamma-interferon-activated inhibitor of translation (GAIT) complex that binds 3'UTR GAIT elements in multiple interferon-gamma (IFN-gamma)-inducible mRNAs and  suppresses their translation. ,19647514
2025,2,2_abstract_sentence,1,"Here, we elucidate the specific EPRS phosphorylation events that regulate GAIT-mediated gene silencing. ",19647514
2025,2,2_abstract_sentence,2,IFN-gamma induces sequential phosphorylation of Ser(886) and Ser(999) in the noncatalytic linker connecting the synthetase cores. ,19647514
2025,2,2_abstract_sentence,3,Phosphorylation of both sites is essential for EPRS release from the parent tRNA multisynthetase complex. ,19647514
2025,2,2_abstract_sentence,4,"Ser(886) phosphorylation is required for the interaction of NSAP1, which blocks EPRS binding to target mRNAs. ",19647514
2025,2,2_abstract_sentence,5,The same phosphorylation event induces subsequent binding of ribosomal protein L13a and GAPDH and restores mRNA binding. ,19647514
2025,2,2_abstract_sentence,6,"Finally, Ser(999) phosphorylation directs the formation of a functional GAIT complex that  binds initiation factor eIF4G and represses translation. ",19647514
2025,2,2_abstract_sentence,7,"Thus, two-site phosphorylation provides structural and functional pliability to EPRS and choreographs the repertoire of activities that regulates inflammatory gene expression. ",19647514
2025,3,1_title,0,Heterotrimeric GAIT complex drives transcript-selective translation inhibition in murine macrophages.  ,23071094
2025,3,2_abstract_sentence,0,"The gamma interferon (IFN-Î³)-activated inhibitor of translation (GAIT) complex in human myeloid cells is heterotetrameric, consisting of glutamyl-prolyl-tRNA synthetase (EPRS), NS1-associated protein 1 (NSAP1), ribosomal protein L13a, and  glyceraldehyde-3-phosphate dehydrogenase (GAPDH). ",23071094
2025,3,2_abstract_sentence,1,The complex binds a structural  GAIT element in the 3' untranslated region of VEGF-A and other inflammation-related transcripts and inhibits their translation. ,23071094
2025,3,2_abstract_sentence,2,EPRS is dually phosphorylated by cyclin-dependent kinase 5 (Cdk5) at Ser(886) and then by a Cdk5-dependent-AGC kinase at Ser(999); L13a is phosphorylated at Ser(77) by death-associated protein kinases DAPK and ZIPK. ,23071094
2025,3,2_abstract_sentence,3,"Because profound differences in inflammatory responses between mice and humans are known, we investigated the GAIT system in mouse macrophages. ",23071094
2025,3,2_abstract_sentence,4,"The murine GAIT complex is heterotrimeric, lacking NSAP1. ",23071094
2025,3,2_abstract_sentence,5,"As in humans, IFN-Î³ activates the mouse macrophage GAIT system via induced phosphorylation of EPRS and L13a. ",23071094
2025,3,2_abstract_sentence,6,"Murine L13a is phosphorylated at Ser(77) by the DAPK-ZIPK cascade, but EPRS is phosphorylated only at Ser(999). ",23071094
2025,3,2_abstract_sentence,7,Loss of EPRS Ser(886) phosphorylation prevents NSAP1 incorporation into the GAIT  complex. ,23071094
2025,3,2_abstract_sentence,8,"However, the triad of Ser(999)-phosphorylated EPRS, Ser(77)-phosphorylated L13a, and GAPDH forms a functional GAIT complex that inhibits translation of GAIT target mRNAs. ",23071094
2025,3,2_abstract_sentence,9,"Thus, translational control by the heterotrimeric GAIT complex in mice exemplifies the distinctive species-specific  responses of myeloid cells to inflammatory stimuli. ",23071094
